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Summary
Insulin and insulin like growth factor (IGF)-1 mediate their metabolic and mi-
togenic effects on target tissues through activation of the insulin and IGF-1
receptor. Insulin receptor substrate (IRS) proteins function as intermediate
docking platforms to transduce the insulin/IGF-1 signal to intracellular effector
molecules that regulate glucose homoeostasis, lipid metabolism, cell prolifera-
tion and β-cell survival. The activated receptors function as tyrosine kinases
that phosphorylate IRS proteins on tyrosine residues, thereby generating in-
teraction motifs for Src homology (SH) 2 domain containing proteins. Signal
transduction via IRS proteins is furthermore regulated by their serine/threonine
phosphorylation by several kinases and this can result in inhibitory or stimu-
latory consequences for downstream signalling. Hyperphosphorylation of IRS1
has been shown to be involved in the desensitization process that can result
in insulin resistance. Both IRS1 and IRS2 undergo proteasomal degradation
while particularly IRS2 levels are additionally regulated by cAMP-dependent
gene activation.
14-3-3 proteins are versatile regulators of a variety of intracellular processes
like control of cell cycle, cell growth, gene transcription and apoptosis. Ser-
ine/threonine phosphorylation within distinct motifs on the interaction partner
is a prerequisite for 14-3-3 binding. IRS1 and IRS2 have been described as
14-3-3 interaction proteins and interaction of IRS2 with 14-3-3 proteins was
specifically characterized in this thesis.
Insulin/IGF-1-dependent PI 3-kinase stimulation as well as elevated cAMP
levels were identified to modulate 14-3-3 binding to IRS2. IGF-1 stimulation led
to increased binding of 14-3-3 to IRS2 in transfected HEK293 cells and this bind-
ing was prevented by inhibition of the PI 3-kinase pathway and an Akt/PKB
inhibitor. Insulin-stimulated interaction between endogenous IRS2 and 14-3-3
was observed in rat hepatoma cells and in mice liver after an acute insulin stimu-
lus or refeeding. Application of different IRS2 fragments enabled localization of
the IGF-1-dependent 14-3-3 binding region spanning amino acids 300-600. Mass
spectrometric analysis produced a total of 24 phosphorylated serine/threonine
residues on IRS2 after IGF-1 stimulation with 12 sites unique for IRS2 while
the other residues are conserved in IRS1 and IRS2. The 24 identified phos-
phorylated residues on IRS2 included several 14-3-3 binding candidates in the
region 300-600 and single alanine mutants of these candidates led to the identi-
fication of Ser573 as 14-3-3 binding site by overlay assays. A phosphosite specific
antibody was generated to further characterize Ser573. IGF-1-dependent phos-
phorylation of Ser573 was reduced by inhibition of PI 3-kinase and Akt/PKB.
The alanine mutant of Ser573 showed enhanced phosphorylation of Akt/PKB in
vii
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an IGF-1 time course experiment. In summary, the data presented in this thesis
indicate a negative impact of Ser573 phosphorylation on downstream signalling.
Binding of 14-3-3 to IRS2 upon stimulation with forskolin and the cAMP
analogue CPT-cAMP (8-(4-chlorophenylthio) adenosine 3’,5’-cyclic monophos-
phate) was demonstrated in HEK293 cells, that was prevented with the PKA
inhibitor H89. The amino acid region behind position 952 on IRS2 was identified
as cAMP/PKA-dependent 14-3-3 binding region by GST-14-3-3 pulldown as-
says. Mass spectrometric analyses revealed Ser1137/Ser1138 as cAMP-dependent,
potential PKA phosphorylation sites. Inhibition of Akt/PKB or ERK did
not prevent the cAMP-dependent phosphorylation of IRS2 on PKA consensus
motifs. Mutation of Ser1137/Ser1138 to alanine strongly reduced the cAMP-
dependent 14-3-3 binding as shown by GST-14-3-3 pulldown experiments and
co-immunoprecipitation assays. IRS2 protein degradation was demonstrated by
the application of cycloheximide and an increased IRS2 protein stability was
observed when HEK293 cells stably expressing IRS2 or primary hepatocytes
were incubated with forskolin. This reduced IRS2 protein degradation was de-
pendent on the presence of Ser1137/Ser1138, since stimulation with forskolin
did not increase protein stability of the double Ala1137/Ala1138 mutant. To
conclude, Ser1137/Ser1138 are presented as novel cAMP-dependent phosphory-
lation sites on IRS2 and their importance in 14-3-3 binding and IRS2 protein
stability is demonstrated. This represents a novel mechanism for the cAMP-
dependent upregulation of IRS2 protein levels that can be of importance for
hepatic metabolism and β-cell survival.
Zusammenfassung
Insulin und Insulin like growth factor (IGF)-1 vermitteln ihre metabolischen
und mitogenen Effekte in Zielgeweben durch die Aktivierung des Insulin- und
des IGF-1-Rezeptors. Die Insulin Rezeptor Substrat (IRS) Proteine fungieren
als intermedia¨re Bindungsstationen, u¨ber die das Insulin/IGF-1 Signal an in-
trazellula¨re Effektormoleku¨le, welche die Glukosehomo¨ostase, den Fettstoffwech-
sel, das Zellwachstum und das U¨berleben der β-Zelle regulieren, weitergeleitet
wird. Die Bindung von Insulin/IGF-1 aktiviert die Tyrosinkinaseaktivita¨t des
Rezeptors und fu¨hrt zur Phosphorylierung der IRS Proteine an Tyrosinresten,
wodurch Bindungsstellen fu¨r Proteine mit einer Src homology (SH) 2 Doma¨ne
generiert werden. Phosphorylierung von IRS Proteinen durch zahlreiche Serin/
Threoninkinasen kann stimulatorische oder hemmende Auswirkungen auf die
nachfolgende Signalkaskade zur Folge haben. Es konnte gezeigt werden dass die
Hyperphosphorylierung von IRS1 zur Abschaltung des Insulinsignals beitra¨gt,
was zur Insulinresistenz fu¨hren kann. Sowohl IRS1 als auch IRS2 werden pro-
teasomal degradiert, wobei vor allem IRS2 zusa¨tzlich durch cAMP-abha¨ngige
Genaktivierung reguliert wird.
14-3-3 Proteine regulieren so unterschiedliche intrazellula¨re Prozesse wie den
Zellzyklus, das Zellwachstums, die Gentranskription und die Apoptose. Die
Serin/Threoninphosphorylierung in konservierten Motiven des Interaktionspart-
ners ist eine Voraussetzung fu¨r die Bindung von 14-3-3 Proteinen. IRS1 und
IRS2 wurden bereits als 14-3-3 Bindungspartner beschrieben und die Interaktion
von IRS2 und 14-3-3 Proteinen wurde in der vorliegenden Dissertation genauer
untersucht.
Sowohl Insulin/IGF-1 Stimulation als auch erho¨hte cAMP-Spiegel konnten
als Modulatoren der 14-3-3 Bindung an IRS2 identifiziert werden. IGF-1 Stim-
ulation in transfizierten HEK293 Zellen fu¨hrte zur Bindung von 14-3-3 an IRS2
wobei diese Bindung durch Inhibierung des PI 3-Kinase Signalweges und einen
Akt/PKB-Kinase Inhibitor gehemmt werden konnte. Die Insulin-vermittelte
Interaktion von 14-3-3 und endogenem IRS2 konnte in Ratten Hepatomzellen
und in Ma¨uselebern nach akuter Insulinstimulation oder Nahrungsaufnahme
beobachtet werden. Durch die Anwendung von verschiedenen Fragmenten des
IRS2 Proteins konnte die IGF-1-abha¨ngige 14-3-3 Bindungsregion im IRS2 in
den Bereich der Aminosa¨uren 300 – 600 lokalisiert werden. Eine massenspek-
trometrische Analyse ergab 24 phosphorylierte Serin-/Threoninreste im IRS2
Protein nach IGF-1 Stimulation, wovon 12 Stellen nur im IRS2 Protein ge-
funden wurden, wa¨hrend die anderen auch im IRS1 Protein konserviert sind.
Unter den 24 identifizierten Phosphorylierungsstellen im IRS2 Protein befan-
den sich auch einige Kandidaten in der 14-3-3 Bindungsregion. Die Mutationen
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xdieser Bindungskandidaten zu Alanin fu¨hrte zur Identifizierung von Ser573 als
14-3-3 Bindungsstelle und es wurde ein phosphospezifischer Antiko¨rper zur weit-
eren Charakterisierung der Stelle Ser573 hergestellt. Die Phosphorylierung von
Ser573 durch IGF-1 Stimulation war nach Hemmung der PI 3-Kinase und der
Akt/PKB-Kinase reduziert. Die Alaninmutante von Ser573 zeigte eine versta¨rkte
Phosphorylierung der Akt/PKB-Kinase in einer IGF-1 Zeitreihe. Zusammen-
fassend deuten die Daten, welche in dieser Dissertation vorgestellt werden, auf
einen negativen Einfluss der Phosphorylierung von Ser573 auf die nachfolgende
Signalkaskade hin.
Bindung von 14-3-3 an IRS2 durch Stimulation mit Forskolin oder dem
cAMP Analogon CPT-cAMP (8-(4-chlorophenylthio) adenosin 3’,5’-zyklisches
monophosphat) konnte in HEK293 Zellen gezeigt werden. Diese Bindung konn-
te mit dem PKA Inhibitor H89 gehemmt werden. Mittels GST pulldown Ex-
perimenten wurde die cAMP/PKA-abha¨ngige 14-3-3 Bindungsregion in den
Bereich der Aminosa¨uren 952 − 1321 im IRS2 lokalisiert. Eine massenspek-
trometrische Analyse identifizierte Ser1137/Ser1138 als cAMP-abha¨ngige und po-
tentielle PKA Phosphorylierungsstellen. Eine Hemmung der Akt/PKB-Kinase
oder der ERK-Kinase konnte die cAMP-abha¨ngige Phosphorylierung von IRS2
an PKA-Konsensusstellen nicht verhindern. Die Mutation von Ser1137/Ser1138
zu Alanin fu¨hrte zu einer starken Reduzierung der cAMP-abha¨ngigen 14-3-3
Bindung in GST pulldown Experimenten und Ko-Immunpra¨zipitationen. Die
Degradation des IRS2 Proteins wurde durch die Anwendung von Cyclohex-
imid sichtbar gemacht und eine erho¨hte Stabilita¨t konnte beobachtet werden,
wenn HEK293 Zellen die stabil IRS2 exprimierten, oder prima¨re Hepatozyten
mit Forskolin stimuliert wurden. Die reduzierte Proteindegradation war auf die
Stellen Ser1137/Ser1138 zuru¨ckzufu¨hren, da die Proteinstabilita¨t der entsprechen-
den Ala1137/Ala1138-Mutante nicht durch Forskolinstimulation erho¨ht werden
konnte.
Ser1137/Ser1138 werden in dieser Dissertation als neue cAMP-abha¨ngige IRS2
Phosphorylierungsstellen vorgestellt. Sowohl ihre Bedeutung bei der Interaktion
von 14-3-3 und IRS2 als auch bei der IRS2 Proteinstabilita¨t werden dargestellt.
Die Ergebnisse deuten auf einen neuen Mechanismus fu¨r die cAMP-abha¨ngige
Erho¨hung der IRS2 Proteinlevel hin, welche fu¨r den Metabolismus der Leber
und das U¨berleben der β-Zelle von Wichtigkeit sein ko¨nnte.
Chapter 1
Introduction
Already in the nineteenth century scientists speculated that there must be a
connection between the pancreas and diabetes. In 1921/22 material extracted
from the islets of Langerhans of a healthy dog lowered high blood glucose levels
from a diabetic dog and after treating a diabetic boy with that purified extract
and the resulting reduction of blood glucose Frederick Banting and John Mcleod
received the Nobel Prize for medicine in 1923 for their discovery of insulin [168].
Insulin administration is one of the standard treatments for insulin-dependent
diabetes and today we now a lot more about the molecular mechanisms that are
responsible for the blood glucose lowering effects of insulin. However, they are
still not completely understood. In this thesis the interaction of insulin receptor
substrate protein (IRS) 2 and 14-3-3 proteins was investigated. IRS proteins
have been established as important adapter proteins in the early steps of insulin
signal transduction. 14-3-3 proteins also function as adapter proteins and are
part of numerous intracellular processes.
1.1 Diabetes
There are two major types of diabetes. Type I diabetes (T1D) is a chronic
disease characterized by an autoimmune destruction of the pancreatic β-cells
resulting in an absolute insulin deficiency with indispensable dependence on ex-
ogenous administration of insulin. Type II diabetes (T2D) is characterized as
a metabolic disorder with disturbed carbohydrate, fat and protein metabolism
due to overweight, obesity and physical inactivity. These characteristic lifestyle
features can be found mostly in industrialized countries with a western lifestyle.
Since this kind of living is also desired by people in developing countries, dia-
betes has become a global epidemic. According to the World Health Organi-
zation more than 346 million people worldwide suffer from diabetes and 80 %
occurs in low- and middle income countries1. The metabolic syndrome with adi-
positas, hypertension, dyslipidaemia and insulin resistance often precedes T2D.
The term “insulin resistance” denominates a status, where the body becomes
incapable to react metabolically adequate to an insulin stimulus. Pathologic
long-term effects of diabetes include diabetic nephropathy and retinopathy with
1http://www.who.int/features/factfiles/diabetes/facts/en/index9.html
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neuronal and peripheral vascular complications. In the early stages of insulin re-
sistance the β-cell reacts with increased insulin secretion and β-cell hyperplasia.
Life-style intervention with a modest reduction in body weight, moderate phys-
ical activity and sensible food-intake at this stage can improve insulin resistance
and T2D patients might not obligatory need to administer exogenous insulin. If
T2D is left disregarded by the patient the β-cells of the pancreas will undergo
apoptosis and the exogenous administration of insulin becomes inevitable.
The genetic influence for the susceptibility to develop T2D is not clear yet.
No disease-causing mutations have been discovered to date, but there are at
least 17 genetic loci associated with T2D [45]. Jin and Patti state in their review
that in addition to genetic factors, pre- and postnatal factors like suboptimal
intrauterine environment, obesity, inactivity, gestational diabetes and advancing
age can lead to insulin resistance and β-cell dysfunction [78]. Taken together,
type II diabetes is a complex disorder arising from genetic as well as epigenetic
factors.
The exact molecular mechanisms of the aforementioned risk factors for the
development of T2D are still not completely understood, but there is emerging
knowledge from tissue culture, animal and human studies. Several physiological
defects could be identified which account for the development of insulin resis-
tance and T2D. The largest insulin-responsive tissue in humans is the skeletal
muscle and a reduced rate of glucose disposal is the first step to insulin re-
sistance. A decreased glucose uptake leads to hyperglycemia, whereupon the
β-cells secrete more insulin to counteract the increased blood glucose levels,
thereby creating hyperinsulinaemia. This deleterious circle eventually leads to
β-cell hyperplasia and later to apoptosis of the β-cells. Adipose tissue was re-
garded only as fat depot for a long time but in recent years it became clear
that adipose tissue depending on the location in the body secretes important
hormones and cytokines like TNFα and IL-6 [116, 157] and this secretion is
altered in insulin resistance. Of note, adipocytes release free fatty acids into
the circulation due to absent inhibition of lipolysis by insulin. In concert with
increased glucose levels glucolipotoxicity further impairs insulin signalling and
worsens insulin resistance.
The liver as central organ for carbohydrate, fat and protein metabolism has
a special role in insulin resistance and T2D. Insulin usually suppresses hepatic
glucose production by reducing the expression of gluconeogenic enzymes and a
lack of inhibition is a key feature in T2D [86], thereby the already increased
systemic blood glucose levels are further increased by glucose molecules from
the liver. Of note, the expression of SREBP-1c (sterol response element binding
protein 1c) protein, which acts as a transcription factor for fatty acid synthesis
is still stimulated by insulin [73]. In addition, hyperinsulinaemia and insulin re-
sistance are discussed as pathogenic factors for the development of nonalcoholic
fatty liver disease (NAFLD) [160, 32].
In the following sections the insulin signalling cascade with two of the most
important signalling pathways activated by insulin and the intermediate sig-
nalling proteins IRS1 and IRS2 are introduced. Furthermore, an overview about
14-3-3 proteins is given.
1.2. INSULIN SIGNAL TRANSDUCTION 3
1.2 Insulin signal transduction
1.2.1 Insulin and insulin like growth factor (IGF)-1
Insulin is synthesized in the β-cells of the islets of Langerhans in the pancreas.
Initially, preproinsulin which consists of 107 amino acids is synthesized at the
endoplasmic reticulum (ER). Two disulfide bonds between the A and the B-
peptide and an internal disulfide bond within the A-peptide enable folding and
when preproinsulin enters the ER 24 amino acids are removed and the generated
molecule is named proinsulin. The A (21 amino acids) and B-peptide (30 amino
acids) are connected through the 31 amino acid comprising C-peptide. Proin-
sulin is stored as hexamer, stabilized by a zinc ion in vesicles of the Golgi appara-
tus and upon demand the C-peptide is proteolytically cleaved and active insulin
is secreted into the blood stream. It is released into the blood stream in response
to elevated blood glucose concentrations. Fatty acids, amino acids and in-
cretins like glucagon like peptide (GLP)-1 and glucose-dependent insulinotropic
polypeptide (GIP) also lead to insulin secretion, whereas glucagon functions as
the major physiological antagonist. Insulin acts on insulin-sensitive tissues such
as liver, skeletal muscle, adipose tissue and brain and exerts metabolic and mito-
genic effects like increased glucose uptake, synthesis of glycogen, protein, lipids
and proliferation. The phosphatidylinositol 3-kinase (PI 3-kinase) and Rat sar-
coma/mitogen activated protein kinase (Ras/MAPK) pathways represent the
major signalling pathways initiated by insulin and are depicted in Figure 1.4.
Insulin signalling via the insulin receptor (IR) is a very complex process. To
add another level of complexity, insulin can also signal via the IGF-1 receptor
and IGF-1 and -2 can also signal through the IR and IR/IGF hybrid recep-
tors. IGF-2 for example can bind to the IR with an affinity of approximately
1 % of insulin [137]. IGF-1 and -2 are peptides that show a high homology to
insulin and are thought to function as growth factors in most tissues whereas
insulin regulates glucose and cellular metabolism. Insulin binds with 100-fold
higher affinity to the IR than the IGF receptor and vice versa. Due to the high
homology hybrid receptors can be formed when IR and IGF-1 receptors are
co-expressed and they are often the most abundant receptor type and differ in
their ligand binding affinity [173, 155, 13].
Exon 11 of the IR gene encodes for a 12 amino acid region at the C-terminal
end of the β-subunit, therefore two isoforms either lacking (IR-A) or possessing
the 12 amino acids (IR-B) are transcribed. Both transcripts show a tissue-
specific distribution with IR-A being expressed mainly in the central nervous
system and hematopoietic cells and IR-B being found in adipose tissue and
skeletal muscle [156, 110, 112]. The affinity of insulin for IR-A is 2-fold higher
than for IR-B and the ligand-induced internalization rate for IR-A is about 25 %
higher than for IR-B [215].
1.2.2 Insulin receptor and IGF-1 receptor
The IR and the IGF receptor belong to the family of receptor tyrosine kinases
and are structurally similar. They show 50 % overall amino acid sequence ho-
mology, their kinase domains share 84 % sequence homology and many common
steps in their signalling pathways. As mentioned in subsection 1.2.1 insulin and
IGF-1 can bind to both receptors and hybrid receptors with differing affinities.
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The insulin receptor consists of two α-subunits that build the extracellular
part of the receptor and two β-subunits spanning the membrane with an in-
tracellular extension. The α- and β-subunits are covalently connected to each
other via disulfide bonds and binding of an insulin molecule to the α-subunits
leads to a conformational change that brings the β-subunits in close proximity,
thus enabling autophosphorylation on distinct tyrosine residues. Autophospho-
rylation of the IR on Tyr1146, Tyr1150 and Tyr1151 (human insulin receptor
numbering) in the regulatory loop is indispensable for the full activation of the
tyrosine kinase activity [70]. The activated IR phosphorylates further tyrosine
residues on the β-subunits, namely Tyr953, Tyr960, Tyr1316 and Tyr1322. These
phosphorylated tyrosine residues represent binding sites for intracellular Src
homology 2 (SH2) domain containing proteins that serve as substrates for the
IR like Shc (Src homology s/α-collagen-related protein) [170], Grb associated
binder (Gab)-1 [68], APS (adapter protein with a PH and SH2 domain) [4] and
the IRS (insulin receptor substrate) proteins [209]. The adapter proteins show
preferences concerning the amino acid composition surrounding the phospho-
rylated tyrosine residues. Recruited substrates get phosphorylated on tyrosine
residues themselves and a subset of signalling proteins with SH2-domains can
bind. Of note, the IR and the IGF-1 receptor phosphorylate IRS proteins on
the same tyrosine residues [138, 125, 89]. Insulin stimulation also leads to the
activation of signalling events that terminate the signalling cascade after an
appropriate time. Lipid and protein phosphatases and serine/threonine kinases
uncouple and dephosphorylate signalling elements and the IR itself. In addition,
the IR is rapidly internalized upon ligand binding. The ligand-receptor complex
is internalized into endosomes, thereby other substrates that are not located at
the outer plasma membrane of the cell can be phosphorylated by the IR. Upon
acidification of the endosome due to proton pumps, insulin is removed from
the IR and signalling events are attenuated. Protein tyrosine phosphatases in
addition dephosphorylate the IR and it can be either degraded or relocated to
the cell surface to start a new signalling cycle [19]. Despite their high homology,
IR and IGF-1 receptors are not completely functionally redundant. IR-deficient
mice are slightly smaller than wild type littermates but die a few days after
birth from diabetic ketoacidosis [80, 1]. IGF-1 receptor-deficient mice on the
other hand show severe growth retardation and die shortly after birth from
respiratory complications [99, 207].
Taken together, the tissue-specific expression of IR-A, IR-B and hybrid re-
ceptors with their differing affinities for insulin, IGF-1 and IGF-2 account for
the diverse actions of insulin, IGF-1 and IGF-2.
1.2.3 General characteristics of IRS proteins
The IRS proteins are involved in the signalling process at a very early stage.
They function as multiadapter proteins providing interfaces between activated
receptors for insulin/IGF-1, growth hormones, several interferons and inter-
leukins to various intracellular signalling proteins. In addition, extracellular
stimuli like glucose and amino acids can also modulate IRS serine/threonine
phosphorylation. The IRS family comprises 6 isoforms varying in their tissue
expression pattern, their biological function and the degree of sequence homol-
ogy [181]. They all share the same configuration of the N-terminus: a pleckstrin
homology (PH) domain, followed by a phosphotyrosine binding (PTB) domain
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what accounts for the high affinity for the insulin receptor. The C-terminal part
contains several tyrosine residues within distinct motifs that allow interaction
with SH2 domain containing proteins upon phosphorylation. The IRS proteins
feature unique tyrosine phosphorylation sites but also three well conserved mo-
tifs that are responsible for interaction with the p85 regulatory subunit of PI
3-kinase (YMXM, multiple motifs are present), with Grb2 (YXNX) and with
the protein tyrosine phosphatase SHP-2 (YIDL and YASI) [115].
IRS1 and IRS2 are widely expressed, whereas IRS3 is mainly limited to the
brain and adipocytes. IRS3 knock-out mice demonstrated that the deletion
of IRS3 did not result in a different phenotype compared to wild type mice,
probably due to compensatory IRS1 and IRS2 expression [101]. IRS4 expression
can be seen in embryonic tissues and could be detected in mice in skeletal muscle,
liver, heart, brain and kidney [40]. The characterization of IRS4 knock-out mice
showed a relatively mild phenotype of knock-outs compared to their wild type
littermates, they showed growth reduction of about 10 %, produced less well
and had decreased blood glucose levels [41]. Wauman et al. could show that
IRS4 couples the leptin receptor to multiple signalling pathways, indicating a
potential role of IRS4 in the brain [40]. Tsuruzoe et al. suggested that IRS3 and
IRS4 could act as negative regulators of IGF-1 signalling due to the suppression
of IRS1 and IRS2 [187]. Sequence comparisons from IRS5/DOK4 (downstream
of kinase) and IRS6/DOK5 revealed that they are more related to one another
than to other IRS proteins, they are both phosphorylated on tyrosine residues
upon IGF-1 or insulin stimulation and could potentially play roles in IGF-1 or
insulin action [23], but so far no important function has been reported yet.
Tyrosine phosphorylation of IRS proteins is the crucial step in the activation
of the PI 3-kinase pathway and the Ras/MAPK pathway, since only tyrosine
phosphorylation enables the regulatory p85 subunit of PI 3-kinase or Grb2 to
bind to IRS proteins [12, 170]. That is why tyrosine phosphatases have an im-
portant influence on the regulation of the PI 3-kinase and Ras/MAPK pathway
[190]. Reduced tyrosine phosphorylation of IRS proteins in pathologies like obe-
sity impairs activation of the aforementioned signalling pathways. Goodyear et
al. showed reduced IRS1 tyrosine phosphorylation with decreased PI 3-kinase
activity in skeletal muscle biopsies from obese subjects compared to samples
from lean subjects [56]. Kanety et al. provided data where they showed dimin-
ished IRS1 tyrosine phosphorylation by TNFα [81].
A remarkable feature of the IRS proteins in general is the presence of nu-
merous serine/threonine residues on the C-terminus that serve to modulate the
adapter function of IRS proteins and to integrate different intra- and extracel-
lular signals. The different IRS isoforms with varying protein length and the
common PH and PTB domain are depicted in Figure 1.1. Of note, the kinase
regulatory loop binding domain (KRLB) is unique to IRS2.
Taken together, phosphorylation of tyrosine residues is crucial to activate
the signalling pathways and serine/threonine phosphorylation integrates and
modulates the signalling pathways initiated by the activated receptors.
1.2.4 Physiological importance of IRS1 and IRS2
The most important representatives of the IRS family are IRS1 and IRS2 and
their biological significance has been demonstrated by knock-out mice mod-
els. IRS1 knock-out mice have a metabolic syndrome-like phenotype and show
1.2. INSULIN SIGNAL TRANSDUCTION 6
PH PTB N C KRLB 
1 1321 
PH PTB 
PH PTB 
PH PTB 
PH PTB 
N 
N 
N 
N C 
C 
C 
C 
1 
1 
1 
1 
1233 
495 
326 
306 
IRS-1 
IRS-2 
IRS-3 
IRS-5/DOK4 
IRS-6/DOK5 
PH PTB N C 
1 1216 
IRS-4 
Figure 1.1: Schematic presentation of IRS isoforms. The individual protein length with
regard to the amino acids is shown (PH, pleckstrin homology domain; PTB, phosphotyrosine
binding domain; KRLB, kinase regulatory loop binding domain). Sequences according to
UniProt accession numbers for Mus musculus IRS1 (P35569), Mus musculus IRS2 (P81122),
Mus musculus IRS3 (O54718), Mus musculus IRS4 (Q9Z0Y7), Homo sapiens IRS5/DOK4
(Q8TEW6) and Homo sapiens IRS6/DOK5 (Q9P104).
growth retardation, impaired glucose tolerance and decreased glucose uptake
but do not develop diabetes due to compensatory hepatic IRS2 expression, β-
cell hyperplasia and increased insulin secretion [10, 180]. IRS2 knock-out mice
in contrast display hepatic and skeletal muscle insulin resistance and the β-cell
mass continuously decreases with the inevitable development of diabetes [208,
88]. Of note, IRS2 knock-out mice do not show compensatory upregulation of
IRS1 and if the diabetes of IRS2 knock-out mice is left untreated these mice die
at 16 weeks of age from diabetic coma. A central role of IRS2 expression in the
β-cell is emphasized by studies from Hennige et al. who showed that reexpres-
sion of IRS2 in β-cells in IRS2−/− mice resulted in β-cell growth, survival and
insulin secretion that prevented diabetes in these mice [65]. The involvement of
IRS1 and IRS2 in hepatic metabolism is controversially discussed. The whole
body knock-out models for IRS1 and IRS2 implicate a prominent role for IRS2
in the liver [134, 164, 207], but liver-specific knock-out models imply a rather
complementary role for IRS1 and IRS2 [33, 182, 167]. IRS1 and IRS2 share a
high sequence identity, resulting in overlapping but also distinct functions and
will be described in more detail in the following sections.
1.2.5 IRS1
IRS1 is the predominant isoform in adipose tissue and skeletal muscle. IRS1
was cloned for the first time in 1991 and Sun et al. demonstrated that IRS1
gets phosphorylated on tyrosine residues upon insulin stimulation in CHO cells
stably expressing IRS1 and IR and that IRS1 binds PI 3-kinase, thereby acting
itself as a docking molecule [177]. Phosphorylation of Tyr960 within the motif
NPEY on the IR is essential for the binding of IRS1 to the IR [203].
IRS1 abundance is regulated on the protein level and on the transcriptional
level, but differing results depending on cell type and tissue are published. IRS1
mRNA expression in 3T3-L1 and 3T3-F442A adipocytes can be reduced by dex-
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amethasone treatment [188, 142] whereas it increased IRS1 protein expression
in rat hepatoma cells [143]. IRS1 was found to be expressed in β-cells of the
pancreas [61] and high fat feeding decreased IRS1 protein levels in epididymal
adipocytes [9]. Short-term insulin stimulation in rat hepatoma cells as well as
refeeding in mice increases hepatic IRS1 levels [141], whereas fasting of mice
does not change hepatic IRS1 protein levels [87]. The short-term administration
of insulin in humans results in increased IRS1 levels in muscle [141].
Regulatory subunits of PI 3-kinase interact with tyrosine phosphorylated
IRS1 and this interaction can be modulated negatively by the SH2 domain con-
taining protein tyrosine phosphatase SHP-2 [115]. Phosphorylation of Tyr895 of
IRS1 couples insulin signalling to Ras signalling via binding of Grb2 to IRS1
[170]. The regulatory subunits of PI 3-kinase also interact with tyrosine phos-
phorylated IRS1, as well as Nck [91] and c-fyn [176].
Multiple serine/threonine sites on IRS1 have been described in the litera-
ture whose phosphorylation mainly seems to negatively regulate signalling, but
also positive regulation has been observed. For example, Giraud et al. showed
that Ser302 phosphorylation is inducible by stimulation with IGF-1 or insulin
and treatment of cells with glucose or amino acids and stimulation of this site
promoted mitogenesis and cell growth [54]. An inhibitory effect on tyrosine phos-
phorylation by JNK phosphorylation of Ser307 has been established by Aguirre
et al. [3]. Nevertheless, one should always keep in mind that the aforementioned
sites cannot be looked at in an isolated manner, the overall phosphorylation pat-
tern instead is important for the signalling process. Single alanine mutants are
used to investigate the influence of single sites on the signalling cascade, but
in vivo the entity of serine/threonine residues work in concert to regulate sig-
nalling – they can depend on each other and can be phosphorylated be several
kinases at different time points. Werner et al. established phosphorylation of
Ser302 and Ser307 by JNK1 is necessary to disrupt IR/IRS1 interaction [202].
The phosphorylation of Ser302 is a prerequisite for phosphorylation of Ser318 by
PKCζ as has been shown by Weigert et al. [201]. Further, they could show that
phosphorylation events occur at different time points of the signalling process.
Ser302 and Ser318 were involved in the first 10 min of signalling, whereas Ser307
and Ser318 were maximally phosphorylated at 30 and 60 min of insulin stimu-
lation. Ser612, Ser622, Ser632 and Ser731 modulate the tyrosine phosphorylation
of IRS1 and its association with p85 of PI 3-kinase [113]. S6K1 phosphorylates
Ser270 on IRS1 upon TNFα stimulation and this is the prerequisite for further
phosphorylation of IRS1 by S6K1 on residues Ser307, Ser636 and Ser1101 [222].
In Figure 1.2 the IRS1 protein structure is displayed in a simplified way.
Serine and tyrosine phosphorylation sites that were experimentally tested with
for example loss-of-function mutants are indicated. If the responsible kinase is
known this is indicated by an arrow above the IRS1 protein scheme and binding
partners are shown below. For a further overview of IRS1 phosphorylation sites
see the review from Taniguchi et al. [181].
Serine/threonine phosphorylation not only modulates signalling, but can also
be used to mark the IRS proteins for degradation. When 3T3-L1 adipocytes are
exposed to insulin for several hours the IRS1 protein content decreases and this is
not due to changed protein synthesis but increased degradation [135]. Pederson
and co-workers showed insulin-mediated IRS1 protein degradation in adipocytes
through a rapamycin-sensitive pathway [127]. However, a partial participation
of the PI 3-kinase pathway in insulin-induced IRS1 degradation in adipocytes
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Figure 1.2: Collection of reported phosphorylated serine and tyrosine residues on IRS1.
Kinases are shown above the IRS1 protein scheme whereas binding partners are shown below.
was shown by Haruta et al. although they also showed a rapamycin-sensitive
pathway to be involved in IRS1 degradation [62]. Insulin-independent IRS1 pro-
tein degradation can be mediated by glycogen synthase kinase 3β (GSK3β). It
phosphorylates IRS1 at Ser332 and thereby induces ubiquitinylation with sub-
sequent proteasomal degradation without the participation of IR signalling and
PI 3-kinase in CHO cells treated with high glucose concentrations [93]. GSK3β
activity is increased in type II diabetes in basal and insulin-stimulated muscle
and thereby could play a causative role in the development of insulin resistance
[117].
1.2.6 IRS2
In 1995 Tobe et al. and Patti et al. discovered IRS2 when they investigated IRS1
knock-out mice [184, 125]. Since these mice displayed only mild insulin resistance
both groups figured that there must be an alternate substrate for the IR to
mediate insulin signalling, resulting in the identification of IRS2. Similar to
IRS1, IRS2 contains numerous serine/threonine residues that potentially could
be phosphorylated by a variety of kinases like Akt/PKB, S6K, JNK, GSK3,
PKA, PKC, IKKβ, MAPK and AMPK [158, 20]. Both proteins display a high
homology and show overlapping yet also distinct functions, but the molecular
mechanisms that distinguish IRS1 from IRS2 function are not fully understood.
In their C-terminus IRS1 and IRS2 only share 35 % of sequence identity with
similar tyrosine phosphorylation motifs that are surrounded by variable amino
acid sequences [178].
The most important structural feature that distinguishes IRS2 from IRS1
and all other IRS proteins is the presence of a domain reaching from amino
acids 591-733 (according to IRS2 mouse numbering) what was named the ki-
nase regulatory loop binding (KRLB) domain [153, 152, 210]. It was defined
by yeast two-hybrid studies and serves as negative regulatory element to con-
trol the extent of IRS2 tyrosine phosphorylation. IRS2 can bind to the IR via
phosphorylated Tyr960 in the NPEY motif, but it is not essential for the inter-
action with the IR [152]. The two tyrosine residues Tyr624 and Tyr628 within
the motif PYPEDY in the KRLB domain mediate binding to the IR. Although
the corresponding region in IRS1 shows quite sequence similarity, mutations to
constitute the PYPEDY motif in IRS1 does not lead to stable interaction with
the IR.
IRS2 is expressed in skeletal muscle, liver, brain, β-cells of the pancreas
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and to a lesser extent in testis and adipocytes. IRS2 expression and function
is especially important in the liver and β-cells of the pancreas. Hepatic IRS2
expression is tightly regulated by fasting and refeeding [24, 48]. Fasting induces
IRS2 mRNA expression through activation of the transcription factor CREB.
In addition, TORC2 (transducer of regulated CREB activity 2) is an impor-
tant co-activator for CREB-dependent IRS2 expression in hepatocytes [149].
IRS2 expression is suppressed by sterol regulatory element binding proteins
(SREBPs) that control lipid synthesis. They directly repress IRS2 expression
by replacing forkhead transcription factors on the IRS2 promotor. Repressed
IRS2 expression by SREBPs serves as a switch to lipogenesis from glycogen
synthesis. This could contribute to hepatic insulin resistance which is associ-
ated with hepatosteatosis [73]. Insulin also suppresses IRS2 protein expression
by reducing the transcription rate of the IRS2 gene [73]. Simpson et al. could
show that the phosphatase and tensin homolog (PTEN) apparently can regulate
IRS2 expression in a positive manner and suggest the PTEN substrate PIP3 can
regulate the amount of IRS2 available for insulin signalling [169]. In pancreatic
β-cells IRS2 expression is crucial for survival and function [154]. β-cell specific
expression of IRS2 in IRS2 knock-out, obese and streptozotocin-treated mice
prevents diabetes in these mice [65]. IRS2 turnover is rapid, mainly regulated
at the transcriptional level, predominantly by FoxO3a (forkhead box class O)
and can be augmented by elevated glucose and cAMP levels [76, 97, 185].
Similar to IRS1, IRS2 can also be degraded via the proteasome. Prolonged
insulin stimulation and refeeding leads to proteasomal degradation of IRS2 [87,
48, 164]. Rui et al. showed that prolonged insulin/IGF-1 stimulation led to
degradation of IRS2 via the proteasome in a PI 3-kinase and mTOR-dependent
manner in 3T3 cells, rat hepatoma cells and mouse embryo fibroblasts [139].
Compared to IRS1 less is known about individual IRS2 serine/threonine
phosphorylation sites and their potential inhibitory or stimulatory effects. Ser-
ine/threonine phosphorylation of IRS2 has been found to exert negative effects
on hepatic insulin signalling. An example is the phosphorylation of IRS2 on
Ser488 by JNK and Ser484 by GSK3 [159]. Phosphorylation by JNK as the
priming kinase with subsequent phosphorylation by GSK3 reduced IRS2 tyro-
sine phosphorylation and the association with p85 in H4IIE cells overexpressing
JNK and GSK3.
Gurevitch et al. mutated five serine residues on IRS2 simultaneously (Ser303,
Ser343, Ser362, Ser381 and Ser480) to alanine. This alanine mutant showed pro-
longed tyrosine phosphorylation compared to wild type IRS2 and increased
binding to the IR in CHO cells. Murine islets adenovirally infected with this
alanine mutant showed reduced apoptosis when treated with pro-inflammatory
cytokines [60]. Our laboratory could show that Ser675 and Ser907 of IRS2 are
phosphorylation sites for mTOR and ERK respectively and mutation of Ser675
to alanine increased the IRS2 protein half-life [48].
In Figure 1.3 the IRS2 protein scheme is displayed in a simplified way. Ex-
perimentally reported serine and tyrosine phosphorylation sites are indicated. If
the responsible kinase is known this is indicated by an arrow above the protein
scheme and binding partners are shown below.
Due to the fact that several serine/threonine residues present in IRS1 can
also be found in IRS2 and the overlapping but also distinct functions of IRS1
and IRS2 it is a major challenge to dissect the IRS2 serine/threonine phosphory-
lation sites. The knowledge about the precise mechanisms that regulate IRS2
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Figure 1.3: Collection of reported phosphorylated serine and tyrosine residues on IRS2.
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function could open up novel possibilities for drug development and treatment
of pathologies like type 2 diabetes.
1.2.7 PI 3-kinase pathway
Other growth factors and hormones can activate PI 3-kinase, but only insulin
has the ability to effectively induce glucose metabolism. There are three differ-
ent functional classes of PI-kinases that differ in their protein domain structure,
lipid substrate specificity and the associated regulatory subunits. The class I
PI 3-kinases transduce signals from receptor tyrosine kinases and G-protein cou-
pled receptors [46]. Class IA PI 3-kinase catalyzes the formation of PI-3,4,5-P3
(PIP3) from PI-4,5-P2. Five regulatory isoforms (p85α, p85β, p55α, p55γ and
p50α) and two catalytic isoforms (p110α and p110β) have been discovered to
date [124, 130, 75, 74]. All regulatory subunits have the ability to recruit p110
with subsequent PI 3-kinase activation [162]. The p85 regulatory subunit inter-
acts via its two SH2 domains with YXXM or YMXM motifs on IRS proteins
[12]. For full activation of PI 3-kinase it is important that both SH2 domains
of the regulatory subunit bind to IRS [11]. PIP3 acts as a membrane tether for
example for PDK (phosphoinositide-dependent kinase) 1 and Akt/PKB. By in-
teraction of Akt/PKB with PIP3 via its PH domain it translocates to the plasma
membrane where it gets phosphorylated, and thereby activated, on Thr308 and
Ser473 through PDK1 and mTOR respectively [150]. Activation of the PI 3-
kinase pathway leads to GLUT4 translocation to the plasma membrane with
subsequently increased glucose uptake, glycogen synthesis, induction of triglyc-
eride synthesis, suppression of gluconeogenesis by inhibition of gluconeogenic
enzyme gene expression and DNA synthesis [145, 147, 16]. For a schematic
overview see Figure 1.4.
1.2.8 Ras/MAPK pathway
Via activation of the Ras/MAPK pathway insulin mediates its mitogenic effects.
The Ras/MAPK pathway can be initiated by the recruitment of Grb2 (Growth
factor receptor-bound 2) and Sos (son of sevenless). This can be achieved by
phosphorylation of tyrosine residues within YVNI motifs on IRS1 resulting in a
recognition motif for SH2-domain containing protein Grb2 that associates with
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IRS1. Grb2 contains a SH3-domain which can interact with the guanine nu-
cleotide exchange factor Sos. Grb2 and Sos can be alternatively recruited to an
activated receptor by Shc which interacts with the receptor via its PTB domain.
Sos exchanges GDP for GTP on Ras, whereupon Ras can bind and thereby ac-
tivate Raf (MAPKKK). Raf activates MEK (MAPKK) by phosphorylation of a
serine residue within its activation loop. MEK1/2 then activates ERK (MAPK
or extracellular regulated kinase) by phosphorylation. ERK itself phosphory-
lates cellular proteins [219], but also translocates into the nucleus where it ac-
tivates various transcription factors. Taken together, the Ras/MAPK pathway
controls cellular processes like proliferation, migration and differentiation (re-
viewed in [82]. In Figure 1.4 the PI 3-kinase and the Ras/MAPK kinase pathway
are depicted.
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Figure 1.4: Schematic illustration of the PI 3-kinase and Ras/MAPK pathway. Abbrevia-
tions: ERK, extracellular signal regulated kinase; FOXO, forkhead box O; Grb2, growth recep-
tor bound protein-2; GSK3, glycogen synthase kinase-3; IRS, insulin receptor substrate; MEK,
MAP kinase ERK kinase; mTORC, mammalian target of rapamycin; PDK1, phosphoinositide-
dependent kinase 1; PI 3-kinase, phosphatidylinositol 3-kinase; Akt/PKB, protein kinase B;
Sos, son of sevenless.
1.3 14-3-3 proteins
Posttranslational modification of serine and threonine residues by phosphory-
lation is regarded as mechanism to regulate catalytic activity, but these modifi-
cations also allow the formation of multimolecular signalling complexes. This is
achieved by a multitude of proteins that can recognize modified serine/threonine
residues. These recognition elements are domains in proteins like WW domains,
forkhead-associated (FHA) domains and WD40 repeats/LRR modules in F-box
proteins. 14-3-3 proteins represent a protein family also capable of recognizing
phosphorylated serine/threonine residues. Over the past two decades it became
clear that 14-3-3 proteins are part of virtual all important cellular processes.
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Figure 1.5: The two 14-3-3 monomers β and τ build a heterodimer. All seven 14-3-3 isoforms
are superimposed and the other isoforms beside β and τ are shaded in grey [217].
They are versatile regulators of numerous cellular processes with no intrinsic
enzymatic activity, highly conserved and expressed in all eukaryotes [49]. The
high level of sequence homology and functional conservation is emphasized by
the fact that 14-3-3 isoforms from yeast, plants and mammals are functionally
interchangeable [161]. Expression of various 14-3-3 isoforms in different numbers
can be found in different species. The mammalian family of 14-3-3 proteins com-
prises seven isoforms encoded by seven genes. The nomenclature was based on
14-3-3 isolated from bovine brain and separated by reversed phase chromatog-
raphy. These analysis revealed a complex mixture consisting of 7 polypeptides
which were assigned seven greek letters, namely α, β, γ, δ, , ζ and η [72]. A
few years later Aitken et al. discovered that α and δ are the phosphorylated β
and ζ isoforms [8]. Two other isoforms, τ and σ, were found to be expressed in
T cells and epithelial cells [5]. Drosophila and yeast express two genes whereas
Arabidopsis plants contain 15 genes for 14-3-3 proteins [171, 195, 44].
1.3.1 Structure
A special feature of the 14-3-3 proteins is their high sequence conservation.
Maximal isotype diversification can only be found in the acidic stretch of the
C-terminus [213].
14-3-3 proteins are synthesized as ∼ 30 kDa proteins and built-up from 9 an-
tiparallel α-helices (αA-αI) with a 40 A˚ channel in the center of the cup shaped
protein, where the first four are crucial for the dimer formation and helices αC,
αE, αG and αI form the conserved peptide binding groove [212, 100]. Two 14-
3-3 proteins contact each other with their N termini, thereby forming a central
groove while the C-terminal helices form a wall around the central groove as
shown in Figure 1.5 [98, 212]. The central groove is also named dimer interface
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Figure 1.6: 14-3-3 cladogram. Shown are 14-3-3 isoforms from fission yeast (spRad25p and
spRad24p), budding yeast (scBMH1 and scBMH2) and the human isoforms [205].
and the amino acid residues located within are strictly conserved throughout
yeast and mammalian species. Liu et al. and Silhan et al. established that
the C-terminal residues are acidic and therefore can interact with the basic
residues in the dimer interface. This interaction is mainly based on two glu-
tamate residues that are negatively charged, thereby mimicking the negative
charge of a phosphate group. This brings the C-terminus on top of the central
groove thereby masking it and upon ligand binding the C-terminus adopts a
new conformation and is ejected from the central groove [98, 166]. In Figure 1.5
a 14-3-3 heterodimer consisting of the β and τ isoforms are shown to illustrate
the cup shape. In addition, the high similarity between the different isoforms
is expressed by the superimposition of all isoforms which conform to nearly the
same structure.
14-3-3 proteins form homo- and heterodimers depending on steric compati-
bility [25]. 14-3-3σ preferentially forms homodimers [205], whereas 14-3-3 seems
to preferentially form heterodimers [25, 217]. From an evolutionary point of view
14-3-3σ is the most divergent isoform in comparison to the other six family mem-
bers, shown in the cladogram from Wilker et al. in Figure 1.6 [205]. This is in
line with distinct functions in vivo. Of note, the key residues that coordinate the
phosphate group of the binding protein are the same as in other 14-3-3 isoforms.
There are four stabilizing interactions in the σ homodimer that cannot occur in
heterodimers. In addition, three amino acids (Met202, Asp204 and His206) are
unique to 14-3-3σ and enable 14-3-3σ to specifically bind its substrates [205].
1.3.2 Binding to phosphorylated serine/threonine residues
Studies with dimerization-deficient 14-3-3 mutants revealed a significant role
of dimerization for phosphorylation-dependent target binding [161]. Muslin et
al. discovered that the recognition of a target protein by 14-3-3 proteins is
dependent on a phosphoserine and identified a putative motif for 14-3-3 binding
(RSXpSXP, p indicates phosphorylated serine, X denotes any amino acid) and
showed that phosphorylated serine is crucial for recognition by 14-3-3 [114].
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They established the importance of the arginine in position -3 relative to the
phosphorylated serine on the target protein, since it is required for recognition
by kinases for phosphorylation. Further studies led to the nomination of two 14-
3-3 binding motifs, namely mode I (RSXpSXP) and mode II (RX(Y/F)pSXP)
[214, 136]. Additionally, Yaffe et al. showed binding of a 14-3-3 dimer with a
30-fold increase in affinity for a peptide containing two phosphoserine motifs
[214].
The phosphopeptide bonds are built with the three absolutely conserved re-
sidues Lys49, Arg56 and Arg127 along with Tyr128, by formation of a basic pocket
whereas the surrounding amino acids are negatively charged [213, 114]. 14-3-3
binding to a phosphorylated target is a two-step process where in the first step
the binding of the phosphorylated peptide to the central groove is dependent
on general protein-protein interaction motifs and the second step involves inter-
action of the globular domain of the target protein with the remaining sections
of the 14-3-3 dimer [217]. Both mode I and mode II binding motifs include a
proline at position +2 relative to the phosphorylated serine/threonine. Yaffe et
al. hypothesized that the proline allows the remainder of the peptide/protein
to exit the binding cleft [214], but an extensive analysis of > 200 reported 14-
3-3 binding targets by Johnson et al. revealed that a proline in position +2
is only found in about 50 % of the target proteins thus raising the question if
this is always essential for 14-3-3 binding [79]. In addition, Aitken states that
the defined binding sequences surrounding the phosphorylated serine/threonine
residues do often not correspond to the 14-3-3 binding motifs defined by peptide
library studies [6]. This could be due to affinity, because if they would exactly
match the binding motif, the strength of the binding would be too strong to
carry out a regulatory role.
It is now well established that phosphorylation of serine/threonine is a pre-
requisite for recognition by 14-3-3 proteins, but there is one report where phos-
phorylation of the target protein is not required for 14-3-3 binding [108]. Of
note, a report from Waterman and co-workers shows that dephosphorylation of
a serine residue on the tumor suppressor p53 creates a 14-3-3 binding motif [198].
Some studies report 14-3-3 binding to only one phosphorylated serine/threonine
residue [17, 27, 128], whereas binding to two simultaneously phosphorylated ser-
ine/threonine residues is often reported [133, 51, 29, 118]. The question arises
how the 14-3-3 isoforms can exert different binding specificities, when they are
so similar? Yaffe et al. propose that the binding specificity is not derived from
differences in phosphopeptide binding motifs, but from variable contacts from
the surface of 14-3-3 proteins outside the binding cleft [214]. Noteworthy, Yang
et al. propose a certain conformational flexibility in the peptide binding site
and the dimer interface that allows binding of peptides and proteins of varying
size and sequence [217]. Another important fact concerning 14-3-3 specificity
is the tissue [129, 197, 174] and temporal distribution [183, 196] as well as the
subcellular localization [50, 163] of 14-3-3 proteins.
1.3.3 Regulation of 14-3-3 proteins
14-3-3 proteins are regulated by phosphorylation and isoform-specific regula-
tion is possible because the phosphorylation sites are not conserved among the
isoforms [120]. Phosphorylation can influence the dimer and monomer status
as well as target specificity. For example does phosphorylation of Ser184 and
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Ser/Thr232, which are in close proximity of the ligand binding groove, reduce lig-
and binding [220, 186, 179, 36, 7]. Ser58 is located within the dimer interface and
its phosphorylation promotes monomer formation [58, 131]. These data imply
that phosphorylation of 14-3-3 proteins serves as a rather negative regulatory
mechanism, since the outcome is reduced interaction with target proteins.
Beside serine phosphorylation of 14-3-3 proteins to regulate their function
tyrosine phosphorylation has also been described. Phosphorylation of 14-3-3ζ
on Tyr179 leads to a scaffolding complex where via Tyr179 Shc bound with its
SH2 domain and this complex is indispensaple for formation of a PI 3-kinase sig-
nalling complex [15]. There are other studies where tyrosine phosphorylation of
14-3-3 proteins were reported, but the exact sites were not determined [52, 102].
Also acylation, acetylation, polyglycation, oxidation and proteolytic processing
has been described and is reviewed by Aitken [6].
1.3.4 Function
14-3-3 interactome studies show the involvement of 14-3-3 proteins in cell migra-
tion and shape change and the participation of 14-3-3σ in cell cycle regulation
[77, 18, 132, 109]. Yaffe proposed that by the rigid structure of the 14-3-3 pro-
teins with only minor possible movement between free and peptide bound forms,
14-3-3 dimers can provide themselves as a molecular anvil whereupon the tar-
get protein can be reshaped [213]. It is suggested by Yaffe et al. that 14-3-3
proteins and the family of AGC kinases coevolved, since basic residues 3 or 4
positions N-terminal to the phosphoserine are the consensus motif required for
phosphorylation by these kinases [214] and the basic residue arginine is crucial
in both 14-3-3 binding motifs.
The precise role of 14-3-3 proteins is hard to define, since the number of
binding partners increases constantly and involves very divergent proteins like
kinases, phosphatases, receptors, transcription factors and regulatory proteins.
According to Kjarland et al. do 14-3-3 proteins provide a mechanism to simulta-
neously influence several intracellular processes [84]. Binding of 14-3-3 proteins
to target proteins can result in several possible outcomes: conformational change
of the target protein that influences the activity of the target protein; acting
as scaffold to connect proteins; obscuring a nearby binding/interaction motif
thus modulating interaction of the target protein with other binding partners;
regulation of translocation upon binding.
The serotonin N-acetyltransferase (AANAT) is a good example for confor-
mational change of the target protein with subsequently altered activity. Upon
binding of 14-3-3 the affinity and activity of AANAT for its substrates is in-
creased [119].
Braselman and McCormick presented an example for 14-3-3 proteins acting
as a scaffold where Bcr and Raf form a complex in vivo via 14-3-3 proteins [22].
Another example for a scaffold function was presented by Agarwal-Mawal and
co-workers who showed 14-3-3ζ simultaneously bound GSK3β and τ , thereby
bringing them into close proximity resulting in phosphorylation of tau by GSK3β
[2].
14-3-3 binding to the cytoplasmic adapter 3BP2 (c-Abl Src homology 3
domain-binding protein-2, also SH3BP2) upon phosphorylation of two serine
residues modulates NFAT (nuclear factor of activated T-cells)/AP (activator
protein)-1 transcriptional activities in T cells [47]. A 3BP2 mutant incapable of
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14-3-3 binding showed an increased capacity to stimulate transcriptional activ-
ities, thus 14-3-3 binding modulates 3BP2 function.
The regulation of cellular localization by 14-3-3 proteins has been shown
for example for forward transport from proteins from the endoplasmic reticu-
lum (ER). Usually the proteins contain a β-COP (coatomer protein) binding
site that functions as retention signal for the ER. Upon phosphorylation in
the “release site” 14-3-3 proteins bind and suppress β-COP binding, thereby
overcoming the retention signal and proteins are transported forward [122]. Nu-
clear/cytoplasmic shuttling from FOXO proteins and carbohydrate response
element-binding protein (ChREBP) is also mediated by 14-3-3 proteins [223,
146].
Since 14-3-3 proteins are part of various cellular processes it is not surprising
that they are involved in the pathogenesis of many diseases. Isotype-specific
involvement in diseases includes the σ isoform that acts as a negative regulator
of cell cycle and has been associated with breast cancer [192] and is reported
to be down-regulated or completely lost in breast and prostate cancer cells [42,
69]. The ζ isoform has been found to be elevated in the cerebrospinal fluid of
neuroleptic patients [221]. Umahara et al. investigated the localization of 14-3-3
isoforms in atherosclerotic lesions from human cerebral and carotid arteries and
show that the different isoforms differed in their expression levels in the diverse
cell types that are found in atherosclerotic lesions [191].
Over the past few years 14-3-3 proteins and their expression levels seem to
be investigated as potential biomarkers for cancer or as predictors for tumor
response. Hodgkinson et al. for example report 14-3-3 proteins to be differen-
tially expressed in chemotherapy-resistant and chemotherapy-sensitive oestro-
gen receptor-positive breast cancer [67]. The analysis of 14-3-3 protein expres-
sion therefore could function to predict beneficial chemotherapy in oestrogen
receptor-positive breast cancer patients. Another example is the reduced 14-
3-3 expression in gastric cancer samples that was associated with diffuse-type
gastric cancer and an early onset of this cancer type [90].
1.4 Aims of the thesis
The importance of the IRS proteins in the insulin/IGF-1 signalling cascade and
the manifoldness of 14-3-3 protein function are well established. The multiple
serine/threonine residues that can modulate signalling positively or negatively
and the still incomplete understanding of the signalling processes make it in-
evitable to further investigate the IRS proteins and IRS2 in particular. Dys-
regulated serine/threonine phosphorylation patterns of IRS proteins can lead to
pathophysiological changes. Additional information about inhibitory or stimula-
tory serine/threonine residues on IRS2 could potentially lead to the development
of new pharmaceuticals to treat insulin resistance and T2D.
IRS1 and IRS2 have been shown to interact with 14-3-3 proteins. A clear role
for 14-3-3 binding to IRS1 could not be established yet, although data indicate
a rather negative regulatory role.
The aim of this thesis was to characterize the interaction between 14-3-3
proteins and IRS2. This included identification of stimuli that led to interac-
tion between 14-3-3 and IRS2. With fragments of IRS2 that encompass different
regions of the IRS2 protein the 14-3-3 binding regions were localized. Mass spec-
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trometry was applied to identify residues that were phosphorylated by stimuli
that also enabled 14-3-3 binding to IRS2. These candidate residues were tested
for their importance in 14-3-3 binding and their potential kinases were identi-
fied. A physiological occurrence and importance for the interaction of 14-3-3
and IRS2 was also investigated.
Chapter 2
Materials and Methods
2.1 Chemicals
Table 2.1: Chemicals
Substance Company
12-O-tetradecanoylphorbol
13-acetate (TPA)
Merck
Darmstadt, Germany
14-3-3ζ-HRP, human recombinant R&D Systems
Wiesbaden-Nordenstadt, Germany
2-[bis(2-hydroxyethyl)ammonio]
ethanesulfonate (BES)
Sigma-Aldrich
Munich, Germany
3-aminophthalhydrazide (luminol) Sigma-Aldrich
Munich, Germany
4− 12 % Bis-tris mini gel Invitrogen,
Karlsruhe, Germany
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid
(HEPES)
Roth
Karlsruhe, Germany
8-(4-chlorophenylthio) adenosine
3′, 5′-cyclic monophosphate
(CPT-cAMP)
Sigma-Aldrich
Munich, Germany
A23187 Calbiochem
Schwabach, Germany
A-769662 Division of Signal Transduction and
Therapy, University of Dundee
Dundee, UK
acetic acid, 100 %, waterfree Sigma-Aldrich
Munich, Germany
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Substance Company
acrylamide 30 (37.5:1) Roth
Karlsruhe, Germany
agarose, peqgold universal Peqlab
Erlangen, Germany
Akt inhibitor Akti-1/2 Calbiochem
Schwabach, Germany
ammonium persulfate (APS) Sigma-Aldrich
Munich, Germany
ampicillin Sigma-Aldrich
Munich, Germany
BID 1870 Division of Signal Transduction
and Therapy, University of
Dundee
Dundee, UK
bovine serum albumin (BSA) Roche
Mannheim, Germany
bromophenol blue Sigma-Aldrich
Munich, Germany
calcium chloride (CaCl2) Sigma-Aldrich
Munich, Germany
Calyculin A Cell Signaling Technology
Frankfurt, Germany
complete tablet Roche
Mannheim, Germany
Coomassie Brilliant Blue G-250 Merck
Darmstadt, Germany
disodium hydrogen phosphate (Na2HPO4) Merck
Darmstadt, Germany
DMEM high glucose (4.5g/l) Lonza
Cologne, Germany
dimethylsulfoxide (DMSO) Roth
Karlsruhe, Germany
DPBS Lonza
Cologne, Germany
E. coli (DH5α) New England Biolabs
Schwalbach, Germany
epidermal growth factor (EGF) Sigma-Aldrich
Munich, Germany
ethanol p.A. Merck
Darmstadt, Germany
ethidium bromide Sigma-Aldrich
Munich, Germany
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Substance Company
ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich
Munich, Germany
ethylenglycol tetraacetic acid (EGTA) Sigma-Aldrich
Munich, Germany
fetal calve serum (FCS) HyClone Thermo Fisher Scientific
Schwerte, Germany
forskolin Applichem
Darmstadt, Germany
gelatine Merck
Darmstadt, Germany
GFP Trap R© Chromotek
Martinsried, Germany
glutathione sepharose 4B (suspension) GE Healthcare
Munich, Germany
glycerol Merck
Darmstadt, Germany
glycine Merck
Darmstadt, Germany
H2O, HPLC-grade Merck
Darmstadt, Germany
H89 Calbiochem
Schwabach, Germany
hepatocyte maintenance medium with
supplements
Provitro
Berlin, Germany
Hind III (10 U/µl) Roche
Mannheim, Germany
hydrochloric acid (HCl) Applichem
Darmstadt, Germany
hydrogen peroxide (H2O2) Merck
Darmstadt, Germany
hygromycin B solution PA
Co¨lbe, Germany
insulin like growth factor 1 (IGF-1) Sigma-Aldrich
Munich, Germany
insulin, human recombinant Sigma-Aldrich
Munich, Germany
Insuman rapid (insulin for mice studies) Sanovi Aventis
Frankfurt, Germany
isopropyl-β-D-
thiogalactopyranoside (IPTG)
Roth
Karlsruhe, Germany
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Substance Company
LB agar Sigma-Aldrich
Munich, Germany
LB broth Sigma-Aldrich
Munich, Germany
L-glutamine (200mM in 0.85 % NaCl) Lonza
Cologne, Germany
magnesium chloride (MgCl2) Sigma-Aldrich
Munich, Germany
magnesium sulfate (MgSO4) Merck
Darmstadt, Germany
methanol Normapur VWR
Darmstadt, Germany
N,N,N′,N′-tetramethyl-
ethylenediamine (TEMED)
Roth
Karlsruhe, Germany
nonfat dried milk powder Applichem
Darmstadt, Germany
NuPAGE R© MOPS SDS running
buffer
Invitrogen
Karlsruhe, Germany
PEG 3350 Sigma-Aldrich
Munich, Germany
penicillin/streptomycin Lonza
Cologne, Germany
PI-103 Division of Signal Transduction
and Therapy, University of
Dundee
Dundee, UK
p-iodophenole Sigma-Aldrich
Munich, Germany
polyethylenimine (MW 40000) Polysciences Inc.
Eppelheim, Germany
Ponceau S Sigma-Aldrich
Munich, Germany
potassium chloride (KCl) Sigma-Aldrich
Munich, Germany
protein A sepharose (suspension) GE Healthcare
Munich, Germany
protein G sepharose (suspension) GE Healthcare
Munich, Germany
quickload 1 kb DNA ladder New England Biolabs
Beverly, USA
RPMI 1640 PAA
Co¨lbe, Germany
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Substance Company
Sephadex G-50 superfine GE Healthcare
Munich, Germany
sequencing buffer 5× Applied Biosystems
Foster City, CA, USA
sodium chloride (NaCl) Merck
Darmstadt, Germany
sodium dihydrogen phosphate (NaH2PO4) Merck
Darmstadt, Germany
sodium dodecyl sulfate (SDS) Biorad
Munich, Germany
sodium fluoride (NaF) Sigma-Aldrich
Munich, Germany
sodium hydrogen carbonate (NaHCO3) Merck
Darmstadt, Germany
sodium-ortho-vanadate (Na3VO4) Sigma-Aldrich
Munich, Germany
sodium-pyrophosphate (Na4P2O7) Sigma-Aldrich
Munich, Germany
tris(hydroxymethyl)aminomethane (TRIS)
ultrapure for ECL
MP Biomedicals Inc.
Solon, OH, USA
Triton X-100 Sigma-Aldrich
Munich, Germany
Trizma base (TRIS) Sigma-Aldrich
Munich, Germany
trypsin gold, mass spectrometry grade Promega
Madison, USA
trypsin/EDTA Lonza
Cologne, Germany
Tween 20 Sigma-Aldrich
Munich, Germany
wortmannin Calbiochem
Schwabach, Germany
Xba I (10 U/µl) Roche
Mannheim, Germany
xylene cyanole Sigma-Aldrich
Munich, Germany
β-glycerophosphate Sigma-Aldrich
Munich, Germany
β-mercaptoethanol Sigma-Aldrich
Munich, Germany
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2.2 Consumables/Kits
Table 2.2: Consumables/Kits
Consumable/Kit Company
0.1− 10µl, 2− 100µl, 100− 1000µl ep
T.I.P.S. Reloads
Eppendorf
Hamburg, Germany
0.5ml, 1.5ml, 2.0ml safe-lock reaction
tubes
Eppendorf
Hamburg, Germany
0.22µm filter unit (sterile) Millipore
Schwalbach, Germany
5ml, 10ml, 25ml, 50ml polystyrene,
sterile pipettes (Stripette)
Corning B. V. Life Sciences
Amsterdam Netherlands
15 and 50ml polypropylene conical tube BD Biosciences
Erembodegem, Belgium
96-well ELISA microplate, PS, flat
bottom
Greiner Bio One
Frickenhausen, Germany
Amersham Hyperfilm ECL GE Healthcare
Munich, Germany
Biorad Protein Assay Biorad
Munich, Germany
blotting membrane Protran BA85
(nitrocellulose)
Whatman
Dassel, Germany
C57Bl/6 mice Charles River Laboratories
Sulzfeld, Germany
cell scraper Corning B. V. Life Sciences
Amsterdam, Netherlands
Centri Sep Spin Column Princeton Separations
Adelphia, USA
Costar 150mm, tissue culture treated Corning B. V. Life Sciences
Amsterdam, Netherlands
Costar 6-well plates, tissue culture treated Corning B. V. Life Sciences
Amsterdam, Netherlands
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Consumable/Kit Company
dounce homogenizer (2ml) Sartorius
Gttingen, Germany
drigalski applicator Neolab
Heidelberg, Germany
Flp-In System Invitrogen
Karlsruhe, Germany
gel blotting paper GB005 Whatman
Dassel, Germany
Immobilon Western HRP Substrate
Luminol Reagent
Millipore
Schwalbach, Germany
inoculation loop Sarstedt
Nmbrecht, Germany
Plasmid Maxi Kit Qiagen
Hilden, Germany
plunger for dounce homogenizer, size S Sartorius
Gttingen, Germany
Precision Plus Protein Dual Color Standard
(1610374)
Biorad
Munich, Germany
Qiaprep Spin Miniprep Kit Qiagen
Hilden, Germany
QIAquick PCR Purification Kit
100bp − 10kb
Qiagen
Hilden, Germany
Quikchange II XL mutagenesis kit Stratagene/Agilent
Waldbronn, Germany
quickload 1kb DNA ladder New England BioLabs
Beverly, USA
tissue culture dishes 10cm and 15cm TPP
Trasadingen, Switzerland
tissue culture plates 6-well, 12-well TPP
Trasadingen, Switzerland
2.3. LABORATORY DEVICES 25
2.3 Laboratory devices
Table 2.3: Laboratory devices
Laboratory device Company
agarose gel chamber bsb11 blue
Schauenburg, Germany
Agfa Curix 60 Developer
machine
Agfa Healthcare GmbH
Berlin, Germany
centrifuge Biofuge Fresco Heraeus
Hanau, Germany
centrifuge Heraeus Pico 17 Thermo Fisher Scientific
Schwerte, Germany
centrifuge Hettich Rotanta RPC Andreas Hettich GmbH & Co KG
Tuttlingen, Germany
electrophoresis chamber for
SDS-PAGE
bsb11 blue
Schauenburg, Germany
CO2-incubator Binder GmbH
Tuttlingen, Germany
ELISA reader Model 680 Biorad
Munich, Germany
gradient gel maker Pharmacia LKB Biotechnology AB
Bromma, Sweden
Hera Safe Biological Safety Hood Thermo Fisher Scientific
Schwerte, Germany
HP scanjet 4670 Hewlett Packard GmbH
Berlin, Germany
incubator for bacteria Heraeus
Hanau, Germany
laboratoy scale Sartorius
Gttingen, Germany
magnetic stirrer IKA Labortechnik,
Staufen, Germany
Mastercycler Gradient Eppendorf
Hamburg, Germany
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Laboratory device Company
microscope Axiovert 40 Zeiss
Oberkochen, Germany
Neubauer chamber for cell counting Marienfeld GmbH & Co. KG
Lauda-Ko¨nigshofen, Germany
power supply consort E 802 Consort nv
Turnhout, Belgium
Powershot camera A710IS Canon
Krefeld, Germany
precision scale ALJI60-4NM Gottl. Kern & Sohn GmbH
Balingen, Germany
Printer Selphy CP 510 Canon
Krefeld, Germany
rotator wheel Gru¨newald GmbH & Co KG
PSI Medizintechnik
Laudenbach, Germany
Scepter Cell Counter Millipore
Schwalbach, Germany
semi-dry western blotting chambers Hoelzel
Wo¨rth/Ho¨rlkofen, Germany
Systec DX-65 autoclave Systec
Wettenberg, Germany
table shaker Hecht Assistent
Sondheim, Germany
ThermoStat Plus Hot/Cold Incubator Eppendorf
Hamburg, Germany
UV-Transilluminator 254nm LTF Labortechnik, GmbH & Co KG
Wasserburg, Germany
Vortex Genie 2 Scientific industries
New York, USA
waterbath Memmert
Schwabach, Germany
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2.4 Software
Table 2.4: Software
Software Company
JMP 10.0.0 SAS Institute Inc.
NC, USA
Gelscan Professional V5.1 BioSciTec GmbH
Frankfurt, Germany
2.5 Antibodies
2.5.1 Primary antibodies
Table 2.5: Primary antibodies
Primary antibody Dilution Company
p-Thr308 Akt/PKB 1:500 − 1:1000 Cell Signaling Technology
Frankfurt, Germany
p-Ser473 Akt/PKB 1:1000 Cell Signaling Technology
Frankfurt, Germany
p-Ser9/p-Ser21 GSK3α/β 1:1000 Cell Signaling Technology
Frankfurt, Germany
p-Thr202/p-Tyr204 ERK 1:1000 Cell Signaling Technology
Frankfurt, Germany
p-Ser157 VASP 1:500 in 5 % milk
in TBS-T
Abcam
Cambridge, UK
p-Ser573 IRS2 1:2000 − 1:5000 University of Dundee
Dundee, UK
Akt/PKB 1:1000 BD
Heidelberg Germany
GST 1:20000 GE Healthcare
Munich, Germany
IRS2 (polyclonal) 1:1000 − 1:5000 Millipore,
Schwalbach, Germany
IRS2 (monoclonal) 1:500 − 1:5000 Millipore,
Schwalbach, Germany
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Primary antibody Dilution Company
IRS1 1:1000 Millipore,
Schwalbach, Germany
PKA substrate antibody 1:1000 Cell Signaling Technology
Frankfurt, Germany
GSK3β 1:1000 Cell Signaling Technology
Frankfurt, Germany
GFP 1:1000 − 1:5000 Santa Cruz
Santa Cruz, CA, USA
β-actin 1:1000 Cell Signaling Technology
Frankfurt, Germany
insulin receptor (β-chain) 1:1000 Santa Cruz
Santa Cruz, CA, USA
ERK 1:1000 Cell Signaling Technology
Frankfurt, Germany
myc 1:500 Rainer Lammers, UKT
Tu¨bingen, Germany
14-3-3ζ (C-17) 1:1000 Santa Cruz
Santa Cruz, CA, USA
pan 14-3-3 (K-19) 1:1000 Santa Cruz
Santa Cruz, CA, USA
2.5.2 Secondary antibodies
Table 2.6: Secondary antibodies
Secondary antibody Dilution Company
goat anti-rabbit-HRP 1:3000 − 1:5000 Santa Cruz Biotechnology
Santa Cruz, CA, USA
goat anti-mouse-HRP 1:1000 − 1:3000 Santa Cruz Biotechnology
Santa Cruz, CA, USA
donkey anti-goat-HRP 1:3000 − 1:5000 Santa Cruz Biotechnology
Santa Cruz, CA, USA
rabbit anti-sheep-HRP 1:3000 − 1:5000 Thermo Fisher Scientific
Bonn, Germany
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2.5.3 Generation of a phospho-specific antibody at the
University of Dundee
Sequence of the peptide used to generate a phospho-specific antibody against
phosphorylated residue Ser573 of mouse IRS2:
CLRKRTYS*LTTPAR (residues 567− 579, * indicates phosphorylated serine)
The phosphopeptide was conjugated to keyhole limpet haemocyanin (KLH)
and BSA using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) accord-
ing to the method of Harlow and Lane [48]. Five aliquots containing 0.5mg of
each peptide conjugate were sent to the Scottish Blood Transfusion Service,
Penicuik, Scotland, where they were injected into sheep at monthly intervals.
Serum was collected from the sheep at monthly intervals and purified by affinity
chromatography with the appropriate phospho-peptide.
2.6 Tissue culture
2.6.1 Cell lines used in this work
Fao and HEK293 cells were purchased from The European Collection of Cell
Cultures (Salisbury, UK) and Flp-In HEK293 cells from Invitrogen (Karlsruhe,
Germany). Fao cells were cultivated on tissue culture plates from Corning and
HEK293, Flp-In HEK293 and primary hepatocytes were cultivated on tissue
culture plates from TPP.
2.6.2 Media and conditions of cultivation
All cell lines were cultivated in an incubator with 5 % CO2-atmosphere and 95 %
humidity at 37◦C. HEK293 and Flp-In HEK293 cells were maintained in the
following growth medium: DMEM high glucose (4.5g/l), supplemented with
10 % FCS, 100 U/ml penicillin, 100µg/ml streptomycin and 2mM glutamine.
Fao cells were cultivated in RPMI 1640 containing 10 % FCS, 100 U/ml peni-
cillin and 100µg/ml streptomycin. Regular change of growth medium took
place every 2 − 4 days, depending on the cell line. For stimulation experi-
ments cells were starved in their respective medium without any supplements
for at least three hours. Primary hepatocytes were cultured in hepatocyte main-
tenance medium with supplements (albumin, 50nM dexamethason, 5mg/l in-
sulin, 2.75mg/l transferrin, 3.35µg/l selen, 10µg/l hepatocyte growth factor,
20µg/l EGF). Hepatocytes were starved for serum overnight before stimulation
experiments.
For long term propagation cells were maintained in 15 cm dishes with 20ml
of growth medium. If not otherwise indicated, cells were seeded in 6-well plates
in 2ml of growth medium or on 10cm plates with 10ml of growth medium.
For long-term storage cells were resuspended in 1ml 10 % DMSO in FCS,
transferred into cyrotubes and stored at either −140◦C or in liquid nitrogen.
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2.6.3 Cell splitting and seeding
When cells reached confluency they were split and seeded onto new tissue culture
dishes. This required detachment of the cells from the tissue culture plates. Cells
were washed once with PBS and incubated with trypsin/EDTA for 5 − 10min
at 37◦C to detach cells. Trypsin activity was blocked by adding growth medium,
cells were pelleted at 900rpm for 4min at room temperature and medium was
aspirated. The cell pellet was resuspended in fresh growth medium and appro-
priate dilutions onto fresh plates were prepared.
For transfection purposes and stimulation experiments cells were counted
before seeding to guarantee equal cell numbers in each well. After centrifugation
the cell pellet was resuspended in 1ml growth medium, filled up to 10ml with
growth medium and cells were counted using the Scepter Cell Counter from
Millipore.
2.6.4 Transient transfection of HEK293 cells
Plasmid DNA was introduced into the cells by using polyethylenimine (PEI).
A PEI stock was prepared as follows: PEI was dissolved in 25mM HEPES,
the solution was sterile filtered (0.22µm filter unit) and 1mg/ml aliquots were
stored at -80◦C. The day before transfection 0.4×106 cells were seeded per well
of a 6-well plate.
The transfection mix was prepared in medium without any supplements.
2µg DNA and 8µg PEI per well were mixed with 1ml medium, the solution was
slightly mixed and pipetted drop-wise onto the cells in addition to the 2ml of
growth medium. In cases of co-transfection of two plasmids, 1µg DNA of each
plasmid was used respectively. After 45h cells were starved for serum for at
least 3h before stimulation experiments were conducted.
2.6.5 Stable transfection of Flp-In HEK293 cells
For stable expression of proteins the Flp-In System from Invitrogen was used.
The DNA of the desired protein was cloned into the pcDNA5/FRT/TO vector.
Flp-In HEK293 cells, which possess a Flp Recombination Target (FRT) site in
their genome were transfected with the vector containing the desired DNA and
in addition with the vector pOG44, encoding for the Flp recombinase, arranging
the homologous recombination event between the FRT sites (one FRT site in
the host cell line, one in the pcDNA5/FRT/TO vector). This system allowed
generation of stable cell lines with equal expression levels, since the vector DNA
was always inserted at the same site of the genome, allowing reproducibility. To
ensure sufficient levels of Flp recombinase, the pOG44:pcDNA5/FRT/TO ratio
was 9:1. The day before transfection 0.4×106 Flp-In HEK293 cells were seeded
in a well of a 6-well plate. On the day of transfection the growth medium was
exchanged against medium without antibiotics. For transfection the calcium
phosphate method was used. For one well of a 6-well plate the transfection mix
was prepared as shown in Table 2.7 and 2.8.
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Table 2.7: Components of stable transfection mix
1µl pcDNA5/FRT or pcDNA5/FRT/TO containing
DNA for desired protein (c = 1µg/µl)
9µl pOG44 (c = 1µg/µl)
90µl 0.25 M CaCl2
100µl 2×BBS
Table 2.8: BBS solution (pH 6.96)
50mM BES
280mM NaCl
1.5mM Na2HPO4
The solution was prepared as 2× BBS and stored at -20◦C. After adding the
DNA to the calcium chloride solution, the reaction tubes were slightly vortexed.
Addition of 2× BBS followed flipping of the reaction tube for 20 seconds and
further incubation for 20min at room temperature, before the transfection mix
was pipetted drop-wise onto the cells. 24h after transfection the cells from
one well were splitted in equal amounts onto a 12-well plate. One day later
the antibiotic hygromycin B was added to the medium at a concentration of
50µg/ml to select for positive clones. After several days expanding colonies
were picked and propagated. Cells were checked for expression of the desired
protein by western blot. For experiments cells were seeded at a density of 106
cells/well in a 6-well plate for two days and starved for serum at least 3h.
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2.7 Protein Biochemistry
2.7.1 Cell lysis
Cells were washed once with ice cold PBS, followed by adding 175µl lysis buffer
with phosphatase inhibitors for one well of a 6-well plate, 400µl for a 10cm dish
or 900µl for a 15cm dish. HEK293 and Flp-In HEK293 cells were incubated
with lysis buffer on a shaker at 4◦C for 15min, whereas Fao cells were incubated
for 20−30min. Cells were scraped off the well on ice by using a cell scraper and
transferred into 1.5ml reaction tubes. Lysates were cleared by centrifugation
with 13000rpm for 5min at 4◦C. The supernatant was transferred into fresh
tubes and stored at −80◦C. If not otherwise indicated the following lysis buffer
and phosphatase inhibitors were used:
Table 2.9: Lysis buffer
50mM HEPES
150mM NaCl
1.5mM MgCl2
1mM EGTA
10 % glycerol
1 % Triton X-100
100mM NaF
10mM Na4P2O7
Lysis buffer was freshly prepared with phosphatase inhibitors. The phos-
phatase inhibitors were stored as 10× solution at −20◦C and diluted 1:10 in
lysis buffer.
Table 2.10: Phosphatase Inhibitors
10 mM NaF
5 mM sodium pyrophosphate
10 mM sodium-ortho-vanadate
10 mM β-glycerophosphate
Phosphatase inhibitors were diluted in bidest water, stored at −20◦C and
thawed shortly before use.
2.7.2 Protein determination and sample preparation for
SDS-PAGE
The protein determination according to Bradford is based on the dye Coomassie
Brilliant Blue G-250 that can form a complex with proteins in acidic solutions.
Upon complex formation the dye is stabilized in its unprotonated form and the
absorbance maximum is shifted from 470nm to 595nm. This shift in absorption
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can be measured with a spectrophotometer and comparison with a standard
curve allows calculation of the relative protein concentration in a sample. Bovine
serum albumin (BSA) standards and samples were diluted in HPLC-grade H2O.
Table 2.11: BSA concentrations used for standard curve
Standard BSA [µg/µl]
1 0
2 0.05
3 0.1
4 0.2
5 0.3
6 0.4
7 0.5
Samples and standards were measured in triplicate. In case of cell lysates
samples were diluted 1:20 and lysates from mice liver were diluted 1:100 in
HPLC-grade H2O. 40µl of samples and standards were prepared and 3×10µl
were pipetted in a 96-well microtiter plate. 200µl of 1:5 in water diluted and
filtered dye reagent was added and absorbance was measured at 595 nm using
a Biorad Microplate Reader, Model 680.
After protein determination varying amounts of protein were mixed with
5×La¨mmli buffer and denaturated at 95◦C for 5min before loading onto SDS
gels. The exact amount of protein used in the different experiments is indicated
in the Figure legends.
Table 2.12: 5×La¨mmli
1M Tris-HCl, pH 6.8
50 % glycerol
10 % SDS
5.5 % β-mercaptoethanol
1 % bromphenol blue
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2.7.3 SDS-PAGE (sodium dodecyl sulfate polyacrylamide
gel electrophoresis)
By applying a negative charge to proteins with sodium dodecyl sulfate, proteins
can be separated in an electric field according to their molecular weight. In
addition, the density of the polyacrylamide gel can be varied and influences
the migration behaviour of the protein as well. Proteins with a high molecular
weight migrate slower, whereas proteins with a low molecular weight migrate
faster through the gel.
Two glass plates were separated by a spacer of 1mm thickness and sealed
with a rubber band. The separating gel was mixed and poured between the
glass plates, filled up with water to avoid drying-out and left to polymerize for
20min at room temperature. After removing the water, the stacking gel was
prepared and poured on top of the separation gel and a comb with an appropri-
ate number of pockets was plugged into the stacking gel. After polymerization
of the stacking gel, the comb was removed and the pockets were rinsed with
water. The rubber band was removed and the glass plates with the polymer-
ized separation and stacking gel in between were placed in an electrophoresis
apparatus. Samples and a molecular weight marker were loaded and gels were
run overnight with 50V. The next day the voltage was increased to 200V until
the separation process was completed.
Table 2.13: Electrophoresis buffer
25mM Tris
200mM glycine
0.1 % SDS
Table 2.14: Stacking gel and separating gel buffer
Separating gel buffer
(pH 8.8)
Stacking gel buffer
(pH 6.8)
Component
1.5M 0.5M Tris
2 % 2 % SDS
Table 2.15: Pipetting scheme for separation and stacking gels
7.5 % Separating gel 5 % Stacking gel Component
20ml 7.05ml H2O
10ml 2.55ml separating gel buffer
10ml 1.35ml acrylamide 30 (37.5 : 1)
66µl 15µl TEMED
270µl 112.5µl 10 % APS
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For a 5− 15 % gradient gel, 5 % separation gel and 15 % separation gel were
mixed in a gradient gel maker simultaneously while pouring between the glass
plates, therefore the 15 % “heavy” gel forms the bottom part of the gel, while
the 5 % “light” gel forms the upper part of the gel. As stacking gel, the recipe
for the 5 % stacking gel was used.
Table 2.16: Pipetting scheme for gradient gel
5 % gel 15 % gel Component
10ml 2.2ml H2O
5ml 5ml separating gel buffer
3.3ml 9ml acrylamide 30 (37.5 : 1)
33µl 33µl TEMED
135µl 135µl 10 % APS
- 2ml glycerol
2.7.4 Western blotting
As with SDS-PAGE, the characteristic that proteins migrate in an electric field
is used by the western blotting technique. The polyacrylamide gel is placed
between wet filter papers and an electric field is applied. The still negatively
charged proteins are transferred onto a nitrocellulose or polyvinylidene fluoride
membrane.
In this thesis the semi-dry western blotting technique was used. Gel blotting
paper and a nitrocellulose membrane with a size of 14×16cm were soaked in
blotting buffer. The blot was assembled carefully to avoid enclosure of air
bubbles and proteins were transferred for 2h with 0.8 mA/cm2. The membrane
was reversibly stained with Ponceau S (0.1 % Ponceau S in 5 % acetic acid) to
control the quality of the protein transfer and to mark the bands of the molecular
weight marker.
Table 2.17: 10× western blot buffer
480mM Tris
390mM glycine
0.4 % SDS
The blot buffer was set up as 10× solution and diluted to a 1× solution with
water and 20 % methanol.
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2.7.5 Immunodetection
To block unspecific binding sites membranes were incubated 3×15min in NET-G
at room temperature. Blocking in 5 % milk in TBS-T for 1h at room tempera-
ture was necessary for detection of GST.
Table 2.18: NET-G (pH 7.4)
10× NET-G 1× NET-G
500mM Tris 50mM Tris
50mM EDTA 5mM ETDA
1.5 NaCl 150mM NaCl
2.5 % gelatine 0.25 % gelatine
0.5 % Triton X-100 0.05 % Triton X-100
Mebranes were incubated overnight at 4◦C with primary antibody diluted
in NET-G. The next day membranes were washed 3× 15min with NET-G and
incubated with the appropiate secondary antibody diluted in NET-G for 45min
at room temperature followed by three final washes with NET-G for 15min.
Visualization of proteins was carried out using the enhanced chemiluminescence
system (ECL). For this, solution A and B were mixed in equal volumes and
membranes were incubated in the mixture for approximately 1min. Hyperfilm
ECL films were exposed for various time points and developed using an Agfa
Curix 60 machine.
Table 2.19: Solution A for ECL
0.1M Tris-HCl ultrapure, pH 9.35
0.44mM p-iodphenol
0.43mM luminol
Table 2.20: Solution B for ECL
0.1M Tris-HCl ultrapure, pH 9.35
0.0075 % H2O2
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2.7.6 Overlay assay
The overlay assay, sometimes referred to as far western blotting technique can be
used to visualize protein-protein interactions. After separation of the proteins
on SDS-PAGE and transfer onto nitrocellulose membranes, membranes were
blocked for 1h at room temperature in 5 % milk in TBS-T. Incubation with
14-3-3ζ-HRP diluted 1:1000 in 5 % milk in TBS-T was carried out overnight at
4◦C. The following day the membrane was washed 5× 5min with TBS-T and
interaction of 14-3-3 with proteins on the membrane was visualized using ECL.
Table 2.21: TBS-T buffer
25mM Tris-HCl, pH 7.4
150mM NaCl
0.1 % Tween 20
2.7.7 Stripping
After detection of phospho-antibody signals on the membrane or performing
overlay assay, the corresponding proteins had to be detected to check for ex-
pression and equal loading. Therefore, membranes were shortly washed with
NET-G to remove residual ECL solution. The antibodies were removed by in-
cubating the membranes in stripping buffer in a water bath at 56◦C for 30min.
Afterwards, the membrane was blocked with NET-G and immunodetection with
protein antibodies took place.
Table 2.22: Stripping buffer (pH 6.8)
66mM Tris
0.5 % β-mercaptoethanol
2 % SDS
2.7.8 Immunoprecipitation
Protein lysates were incubated with the appropriate antibody and protein A or
G sepharose (depending on the antibody) for 3−4 hours at 4◦C in reaction tubes
on an end-over-end wheel. To ensure homogenous incubation of the samples
HNTG buffer was used to fill up the reaction tubes to at least 500µl of total
volume. The beads were washed 2 − 3 times with 200µl HNTG buffer with
centrifugation steps in between at 4◦C with 5000rpm for 1min. After aspiration
of the washing buffer after the last wash, beads were denaturated in 20µl of
5× La¨mmli buffer at 95◦C for 5min before loading onto SDS gels.
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Table 2.23: HNTG buffer (pH 7.5)
20mM HEPES
10mM NaF
150mM NaCl
0.1 % Triton X-100
10 % glycerol
2.7.9 GFP pulldown
All centrifugation steps were carried out at 4◦C for 5000rpm for 1min. Lysates
were precleared with 50 % slurry of protein A sepharose for 30min at 4◦C and
after centrifugation the supernatant was transferred into fresh tubes containing
50 % slurry of a mixture of protein A sepharose and GFP binder. Up to 500µg
protein was pulled down with 2.5µl GFP binder, 5-10mg of protein was pulled
down with 15µl GFP binder without protein A sepharose. Samples were mixed
for 2h at 4◦C, followed by washing twice with 500µl high salt buffer and twice
with 500µl no salt buffer. 20µl 5× La¨mmli was added to the beads, samples
were denaturated for 5min at 95◦C and separated by SDS-PAGE.
Table 2.24: High salt washing buffer
50mM Tris-HCl, pH 7.5
150mM NaCl
Table 2.25: No salt washing buffer
50mM Tris-HCl, pH 7.5
1mM EGTA
0.1 β-mercaptoethanol
2.7.10 GST pulldown
Varying amounts of protein were used as indicated in the Figure legends. Protein
lysates were incubated with 2µg of GST-14-3-3 protein and 500µl of HNTG
buffer to ensure adequate mixing for 2h on a rotating wheel at 4◦C. This was
followed by 3 times washing with 200µl HNTG buffer with centrifugation steps
in between with 5000rpm for 1min at 4◦C. 20µl 5× La¨mmli was added after the
last wash and samples were denaturated at 95◦C for 5min before SDS-PAGE.
As a control for efficient and comparable pulldown of GST fusion protein, the
membrane was incubated with GST antibody.
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2.8 Molecular Biology
2.8.1 Plasmid generation at the University of Dundee
The following expressions plasmids were generated at the University of Dundee:
• pcDNA5/FRT/TO-GFP-IRS2
• pcDNA5/FRT/TO-GFP-IRS2-1-R300
• pcDNA5/FRT/TO-GFP-IRS2-1-T600
• pcDNA5/FRT/TO-GFP-IRS2-S301-E1321
• pcDNA5/FRT/TO-GFP-IRS2-F601-E1321
• pcDNA5/FRT/TO-GFP-IRS2-S303A
• pcDNA5/FRT/TO-GFP-IRS2-T401A
• pcDNA5/FRT/TO-GFP-IRS2-T517A
• pcDNA5/FRT/TO-GFP-IRS2-S556A
• pcDNA5/FRT/TO-GFP-IRS2-S573A
Recombinant DNA procedures, restriction digests and ligations were per-
formed using standard protocols. All PCR and mutagenesis reactions were
carried out using KOD Hot Start DNA polymerase (Novagen). The coding re-
gion for mouse IRS2 (NM 001081212.1) was amplified from a pRK5-IRS2 vector
(originally from Morris White, Boston, USA) using primers 5’-gaggatccatggct
agcgcgcccctgcctg-3’ and 5’-ctgcggccgctcgagtcactctttcacgactgtggcttcc
ttc-3’, cloned into vector pSC-B (Stratagene) and sequenced. IRS2 was sub-
cloned from this plasmid into pcDNA5/FRT/TO-GFP as a BamH1/Not1 in-
sert to give vector pcDNA5/FRT/TO-GFP-IRS2 in which IRS2 is tagged with
GFP at the N-terminus. This vector was used to generate various mutants
by PCR mutagenesis. All clones were fully sequenced. DNA sequencing was
performed by The Sequencing Service, College of Life Sciences, University of
Dundee (www.dnaseq.co.uk).
Truncated IRS2 versions coding for IRS2 residues 1-R300 and 1-T600 were
made by introducing a stop codon behind position 300 or 600 respectively by
PCR mutagenesis. The following mutagenesis primers were used:
Table 2.26: Mutagenesis primers for fragments 1-300 and 1-600
Mutation Primer pair
R300 Stop 5’-gagttccggcctcgctgaaagagtcagtcgtcc-3’
3’-ggacgactgactctttcagcgaggccggaactc-5’
T600 Stop 5’-ctcatgagggccacctgatctggtagttcaggtc-3’
3’-gacctgaactaccagatcaggtggccctcatgag-5’
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Constructs coding for residues S301-E1321 and F601-E1321 were made by
amplifying the appropriate fragment from the full length pSC-B IRS2 vector,
cloning into pSC-B and sequencing. S301-E1321 and F601-E1321 fragments
were sub-cloned into pcDNA5/FRT/TO-GFP as a BamH1/Not1 or BamH1/
BamH1 insert respectively.
For point mutations the following primers were used:
Table 2.27: Mutagenesis primers for single point mutations
Mutation Primer pair
S303A 5’-cggcctcgcagcaaggctcagtcgtccgggtcg-3’
3’-cgacccggacgactgagccttgctgcgaggccg-5’
T401A 5’-cttagccgctcgcacgccctgagcgccggctg-3’
3’-cagccggcgctcagggcgtgcgagcggctaag-5’
T517A 5’-gtagccacaggagcaacgcacccgagtcaatagc-3’
3’-gctattgactcgggtgcgttgctcctgtggctac-5’
S556A 5’-ccttaccgtagggtcgcaggggatggggccc-3’
3’-gggccccatcccctgcgaccctacggtaagg-5’
S573A 5’-gaggaagaggacttatgccctaaccacgcctg-3’
3’-caggcgtggttagggcataagtcctcttcctc-5’
In addition to the generated plasmids at the University of Dundee a vector
coding for the human IRS2 sequence used in this work was a kind gift from
Calum Sutherland (Ninewells Hospital, Dundee, UK).
2.8.2 Additional plasmids used in this thesis
The myc-14-3-3γ expression vector was provided by Prof. Reiner Lammers
(University Hospital Tuebingen).
Mutagenesis primers were synthesized at TIB Molbiol (Berlin, Germany).
Based on the pcDNA5/FRT/TO-GFP-IRS2 expression vector additional mu-
tants were generated during this thesis. For the S556A/S573A double mu-
tant pcDNA5/FRT/TO-GFP-IRS2-S573A was used as template. The frag-
ment F601-S952 was generated by mutating S952 into a stop codon and the
pcDNA5/FRT/TO-GFP-IRS2-F601-E1321 construct served as template.
Table 2.28: Mutagenesis primers for generation of a double and a truncated mutant
Mutation Primer pair
S556A 5’-ccttaccgtagggtcgcaggggatggggcc-3’
3’-ggccccatcccctgcgaccctacggtaagg-5’
S952 stop 5’-cttcatccctgggttgaggaaccccagg-3’
3’-cctggggttcctcaacccagggatgaag-5’
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For single point mutations expression vector pcDNA5/FRT/TO-GFP-IRS2
served as template with the used mutagenesis primers as follows:
Table 2.29: Mutagenesis primers for generation of single point mutations
Mutation Primer pair
S1137A 5’-ggacgtcgtcgccacgcttcagagacc-3’
3’-ggtctctgaagcgtggcgacgacgtcc-5’
S1138A 5’-gtcgtcgccacagtgcagagaccttttcc-3’
3’-ggaaaaggtctctgcactgtggcgacg-5’
S1163A 5’-ccagcgccacaatgcggcctctgtg-3’
5’-cacagaggccgcattgtggcgcttg-3’
S1137A/S1138A 5’-gtcgtcgccacgctgcagagaccttttc-3’
5’-gaaaaggtctctgcagcgtggcgacgac-3’
2.8.3 PCR mutagenesis
Mutagenesis was performed with the Quickchange II XL site-directed Mutage-
nesis Kit from Stratagene. All components were pipetted in a 0.5ml reaction
tube as shown in Table 2.30. All components were kept on ice.
Table 2.30: Pipetting scheme for site-directed mutagenesis
2.5µl 10× reaction buffer
0.5µl template plasmid (c = 10 ng/µl)
3.6µl mutagenesis primer up (c = 1 pmol/µl)
3.6µl mutagenesis primer down (c = 1 pmol/ml)
0.5µl dNTP mix
1.5µl Quicksolution
0.5µl Pfu Ultra Polymerase
12.3µl PCR-grade H2O
Depending on the G/C content of the mutagenesis primers different tempera-
tures were chosen in the gradient cycler (58.1◦C, 58.4◦C, 59◦C, 59.8◦C, 60.8◦C,
61.8◦C, 63◦C, 64◦C, 65◦C, 65.7◦C or 66.2◦C). The reaction tubes were placed
in a gradient cycler and the program depicted in Table 2.31 was carried out.
To remove the template DNA a DpnI digest was performed. DpnI only cuts
methylated and hemimethylated, thus parental DNA and leaves only the mu-
tated, unmethylated DNA. 20µl of the sample were incubated with 0.5µl DpnI
(10 U/µl) for 1h at 37◦C. Afterwards, the residual 5µl were filled up with 15µl
HPLC-grade H2O to get an equal volume of 20µl. The DpnI-treated and the
DpnI-untreated samples were purified with the QIAquick PCR Purification Kit
from Qiagen according to the manufacturer’s instructions and purified DNA was
eluted with 30µl HPLC-grade H2O.
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Table 2.31: Gradient cycler protocol for site-directed mutagenesis
Temperature [◦C ] Duration Repeats
95 1min 1
95 50 sec 18
58.1-66.2 50 sec 18
68 10min 18
68 7min 1
DNA was transformed into DH5α E. coli using the KCM method as described
in subsection 2.8.4.
2.8.4 Transformation
5×KCM solution was stored at −20◦C. 30µl of the purified DNA were mixed
with 20µl 5×KCM and 50µl HPLC-grade H2O in a reaction tube, vortexed and
placed on ice for 5min. 100µl competent DH5α E. coli were added, the reaction
tube was vortexed again and incubated on ice for 15min, followed by a tempera-
ture shock at 42◦C for 2min in a water bath with subsequent addition of 1ml LB
medium without ampicillin and incubation at 37◦C for 30min. Bacteria were
pelleted by centrifugation for 2min with 6500rpm at room temperature. The
supernatant was removed and the bacterial pellet resuspended in the residual
LB medium (∼ 50µl) and plated onto LB agar plates with 0.1mg/ml ampicillin.
After overnight incubation at 37◦C colonies were picked for MiniPrep isolation
of DNA. In case of a MaxiPrep preparation 1µg DNA was mixed with 20µl 5×
KCM and filled up with HPLC-grade H2O to 100µl of total volume.
Table 2.32: KCM solution
5×KCM 1×KCM
2M KCl 0.4M KCl
1M MgCl2 0.25M MgCl2
1M CaCl2 0.25M CaCl2
2.8.5 MiniPrep/MaxiPrep for isolation of DNA
For MiniPrep isolation of DNA several colonies were picked from the LB agar
plates. Each colony was mixed with 2ml LB medium containing 0.1mg/ml
ampicillin. For MaxiPrep isolation a single colony was mixed with 100ml LB
medium containing 0.1mg/ml ampicillin. All cultures were incubated at 37◦C
overnight in a bacteria shaker. The next day DNA was isolated by using the
QIAprep Spin Miniprep Kit or the Plasmid Maxi Kit from Qiagen according
the to manufacturer’s instructions.
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2.8.6 Sequencing
Mutagenesis was verified by sequencing MiniPrep DNA to confirm successful
mutagenesis. MaxiPrep preparations were also sequenced to ensure that the
desired mutation was still present. The sequencing primers listed in Table 2.33
were synthesized at TIB Molbiol (Berlin, Germany).
Table 2.33: Sequencing primers
Construct Sequencing primer
pcDNA5/FRT/TO-GFP-IRS2-F601-S952 cctctacccacagagcccaagagc
pcDNA5/FRT/TO-GFP-IRS2-S556A gcgacctgagagccttcagtagccaca
pcDNA5/FRT/TO-GFP-IRS2-S573A ggagaccccgccagccagagatg
pcDNA5/FRT/TO-GFP-IRS2-S1137A gctaagtctcatggatcaggtatctgg
pcDNA5/FRT/TO-GFP-IRS2-S1138A gctaagtctcatggatcaggtatctgg
pcDNA5/FRT/TO-GFP-IRS2-S1163A gctaagtctcatggatcaggtatctgg
Sequencing Mix was prepared in a 0.5ml reaction tube on ice as shown in
Table 2.34.
Table 2.34: Pipetting scheme for sequencing PCR
0.5µl plasmid (c = 1µg/µl)
1µl sequencing primer (c = 100pmol/µl)
2µl sequencing mix
1µl 5×buffer
5.5µl HPLC-grade H2O
The reaction was carried out in a Mastercycler from Eppendorf with the
following program:
Table 2.35: Cycler programme for sequencing
Step Temperature [◦C ] Time Repeats
denaturation 96 1min 1
denaturation 96 10 sec 24
annealing 50 10 sec 24
elongation 60 4min 24
cool 4 overnight -
10µl of HPLC-H20 was added to the PCR product and purifed by using
sephadex columns. The Centri-Sep Spin Columns already contained sephadex,
which was discarded and replaced by 650µl of 5 % pre-swelled sephadex at room
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temperature. Columns were centrifuged at 5000rpm for 4min at room temper-
ature. The columns were placed in a 1.5ml reaction tube and 20µl of the PCR
product were pipetted onto the sephadex column. Centrifugation at 5000rpm
for 4min at room temperature led to elution of the purified PCR product. Se-
quencing was carried out by the Genotyping Facility Tu¨bingen (Department of
Internal Medicine IV, University Hospital Tu¨bingen).
2.8.7 Restriction Digest
Restriction digests were routinely performed after MaxiPrep preparation to en-
sure amplification of the right construct. 1µg of DNA was incubated with the
appropriate restriction enzyme and buffer for 1h at 37◦C.
Table 2.36: Pipetting scheme for restriction digest
1µl DNA (c = 1µg/µl)
0.5µl XhoI
0.5µl BamHI
1µl buffer B
7µl HPLC-grade H2O
After the digest fragments were mixed with gel loading buffer and loaded on
a 1 % agarose gel which contained 0.01 % ethidium bromide. For gel preparation,
agarose was dissolved in 1× TAE buffer by heating the mixture in a microwave,
after cooling down the agarose to approximately 60◦C ethidium bromide was
added, the solution was poured into an agarose gel chamber and a comb to form
pockets for sample loading was added. Samples were run at 80mA and DNA
bands were visualized with a UV lamp.
Table 2.37: 50× TAE buffer
1.25M Tris
625mM acetic acid
50mM EDTA
Table 2.38: 10× gel loading buffer
0.1 % bromphenolblue
0.1 % xylene cyanole
60 % glycerol
20 % 50× TAE
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2.8.8 Propagation of E. coli
2ml of LB medium were inoculated with E. coli and incubated overnight at
37◦C. The next day 150ml LB medium were inoculated with 1ml of the overnight
culture and incubated at 37◦C until an optical density of 0.6 at 600nm. Bacteria
were harvested with 4000rpm for 10min at room temperature. The pellet was
resuspended in 15ml TSB for 10min on ice. TSB medium was freshly prepared
and DMSO was added in a final concentration of 5 % shortly before the E. coli
were aliquoted and stored at -80◦C.
Table 2.39: TSB medium
50 % LB medium
10mM MgCl2
10mM MgSO4
2.5 % PEG 3350
40 % H2O
2.8.9 Propagation of GST-14-3-3 expression vectors
GST-14-3-3β and GST-14-3-3 constructs in pGEX vectors were a kind gift from
Angelika Hausser (University of Stuttgart). The GST-14-3-3 plasmids were
transformed into DH5α E. coli and 100ml LB medium containing 0.1mg/ml
ampicillin was inoculated with one colony, followed by overnight incubation at
37◦C. The next day the bacterial culture was diluted 1:10 in fresh LB medium
with ampicillin and cultured for 1h at 37◦C. Induction of protein expression
was achieved by adding 1mM IPTG (isopropyl β-D-thiogalactopyranoside) for
5h. Bacterial cells were harvested at 4◦C by centrifugation with 5000rpm for
15min. The supernatant was aspirated and the pellet resuspended in 10ml PBS.
Bacterial cells were disrupted by applying 40 strokes with a probe-type sonica-
tor. After adding Triton X-100 to a final concentration of 1 % the suspension
was centrifuged at 5000rpm for 20min at 4◦C. The supernatant was transferred
into a fresh 15ml tube and prewashed 50 % slurry of glutathione sepharose 4B
was added. After incubation for 1.5h on a rotating wheel at 4◦C, beads were
washed 3 times with PBS and stored as 50 % slurry at 4◦C for further use.
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To determine the amount of GST-14-3-3 protein which was purified from the
bacteria a 5− 15 % gradient SDS gel was prepared. The gel was loaded with a
standard curve prepared from a BSA stock solution ranging from 1µg to 10µg
of BSA and with different amounts of purified GST-14-3-3. Coomassie staining
visualized the protein bands. BSA has a molecular weight of approximately
66 kDa and the GST fusion proteins run at 50 kDa. A representative gel is
shown in Figure 2.1.
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Figure 2.1: SDS gel stained with Coomassie G-250 to visualize the amount of prepared
GST-14-3-3 proteins. On the left side next to the gel the molecular weights in kDa of the
marker is shown. Lanes 1-6 show the BSA concentrations in µg used as standard, lanes 7 and
12 show the molecular weight marker bands, lanes 8-11 show the different amounts loaded of
GST-14-3-3 in µl and lanes 13-16 show the different amounts loaded of GST-14-3-3β in µl.
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2.9 Mass spectrometry performed at the Uni-
versity of Dundee (Scotland, UK)
2.9.1 Sample preparation for mass spectrometry
HEK293 cells were seeded onto 10cm tissue culture plates, transfected with
10µg DNA of GFP empty vector or GFP-IRS2 and 30µg polyethylenimine in
25mM HEPES/plate. 45h later cells were starved 3h for serum and stimulated
with 50ng/ml IGF-1 and after preincubation with 1µM PI-103 for 30min. After
lysis with buffer consisting of 50mM Tris, 1mM EGTA, 1mM EDTA, 1 % Triton
X-100, 1mM sodium-ortho-vanadate, 50mM sodium fluoride, 5mM sodium py-
rophospate and one Protease Inhibitor Cocktail tablet (complete, Mini, EDTA-
free, Roche, West Sussex, UK), the protein concentration was determined using
Coomassie Protein Assay Kit (Pierce, Rockford, USA). 10mg of total protein
were pulled down using 15µl pure GFP binder and separated on a precast 4-12 %
Bis-tris mini gel (Invitrogen, Paisley, UK). The gel was stained overnight us-
ing the Colloidal Blue Staining Kit (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions. IRS2 bands were cut and transferred into 1.5ml
reaction tubes. For washing steps 0.5ml per gel band was used for 10min and
all liquid was discarded between the washes if not otherwise indicated. Gel
pieces were washed with ultrapure H2O, 50 % methanol/H2O, 0.1M NH4HCO3,
methanol/50mM NH4HCO3. Proteins were incubated with 10mM DTT/0.1M
NH4HCO3 on a hot block at 65
◦C for 45min. After removal of the liquid samples
were alkylated by adding 50mM iodacetamide/0.1M NH4HCO3 and incubation
in the dark for 20min at room temperature. Two times washing with 50mM
NH4HCO3 and 50mM NH4HCO3/50 % methanol was followed by shrinking the
gel pieces with methanol for 15min. Liquid was removed and samples were dried
with a Speed-Vac. Gel pieces were soaked in 20mM triethylammonium bicar-
bonate containing 5µg/ml trypsin and shaken at 30◦C overnight. An equivalent
volume of methanol was added the next day and samples were shaken for 15min,
before the supernatant was removed and the samples were dried in a Speed-Vac.
Residual peptides were extracted from the gel pieces with 50 % methanol/2.5 %
formic acid and the supernatant was combined with the dried first extract and
dried completely.
2.9.2 Mass spectrometric analysis of IRS2 tryptic digests
IRS2 tryptic digests were analysed by LC-MS (liquid chromatography mass
spectrometry) on a LTQ-orbitrap classic mass spectrometer system (Thermo
Fisher Scientific, Schwerte, Germany) coupled to a Proxeon Easy-LC HPLC
system. The peptide mixtures were loaded onto a nanoseparations C18 guard
column (0.1 × 20mm) equilibrated in 0.1 % formic acid/water at 5µl/min and
then separated on a 0.075×150mm PepMap C18 column, equilibrated in 0.1 %
formic acid/water (LC Packings, Amsterdam, Netherlands). Peptides were
eluted with a 100min discontinuous gradient of acetonitrile/0.1 % formic acid at
a flow rate of 300nL/min. The column outlet was connected to a ThermoFisher
Nanospray 1 source fitted with a New Objective FS360 20-10 uncoated emitter
and a voltage of 1.3kV was applied to the emitter. The orbitrap was set to anal-
yse the survey scans (m/z 350-2000) at 60.000 resolution and top 5 ions in each
duty cycle (minimum ion intensity of 50000cps), were selected for MS/MS in
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the LTQ linear ion trap with multistage activation. Ions were excluded for 30s
after 2 occurrences. The raw files were converted into mascot generic files using
Raw2msm (a gift from M. Mann, Martinsried, Germany). The MSMS spectra
(mgf file) were searched against SwissProt database using the Mascot search
engine (Matrix Science) run on an in-house server using the following criteria:
peptide tolerance = 10 ppm; trypsin as the enzyme; carboxyamidomethylation
of cysteine as a fixed modification with oxidation of methionine and phosphory-
lation of serine, threonine and tyrosine as a variable modification. Any MS/MS
spectra that could be assigned to a phosphopeptide were inspected manually
using QualBrowser software. IRS2 tryptic digests were also analysed by LC-MS
with precursor of 79 scanning on a 4000 Q-Trap system (Applied Biosystems,
Carlsbad, USA) as described by [206]. Extracted ion chromatograms for all
detected phosphopeptides were generated using Analyst 1.4.1 software.
2.10 Mass spectrometry performed at the Insti-
tute for Ophtalmology at the University of
Tu¨bingen
2.10.1 Sample preparation for mass spectrometry
1× 107 HEK293 cells were seeded 24h prior transfection onto 15cm tissue cul-
ture plates. 10µg DNA and 80µg PEI were used to transfect HEK293 cells and
45h later cells were serum starved for 3h. Cells were left unstimulated, stimu-
lated with 20µM forskolin for 30min or after preincubation with 30µM H89 for
30min. Cells were lysed with 900µl lysis buffer and precleared with 30µl of a
50 % protein A sepharose slurry. GFP and GFP-IRS2 was purified from 5mg
total protein by using 15µl GFP binder and samples were separated on 4-12 %
Bis-tris mini gels. Protein bands were visualized by staining gels as follows: fix-
ing of protein bands by washing 3× 10min with fixer/destainer solution (50 %
methanol, 6 % acetic acid), staining with 0.4 % Coomassie G-250 in H2O for
20-30min and destaining with fixer solution 3× 10min. Bands corresponding to
IRS2 were cut and subjected to tryptic proteolysis as described by Gloeckner
et al. [55] prior to LC-MS/MS analysis.
2.10.2 Mass spectrometric analysis of IRS2 tryptic digests
Peptides were separated using the UltiMate 3000 nano HPLC system. They
were eluted from the trap column onto the analytical column (Acclaim PepMap
RSLC 75µl x 25cm C18, 2µm, 100A˚) applying an acetonitrile gradient of 2 %
to 35 % of eluent (80 % acetonitrile; 0.08 % formic acid) in 33min. The eluted
peptides were analyzed by mass spectrometry (LTQ Orbitrap Velos, Thermo
Fisher Scientific, Waltham, USA). Mass spectra were extracted by Mascot Dae-
mon without charge state deconvolution and deisotoping and results were an-
alyzed using Mascot (Matrix Science version 2.3.0, Boston, USA). Mascot was
set up to search the Mus musculus subset of the SwissProt database (Release
2011 12, 533657 entries) assuming trypsin as the digestion enzyme. Mascot was
searched with a fragment ion mass tolerance of 1Da and a parent ion tolerance
of 10ppm. Oxidation of methionine, deamidation of asparagines and glutamine
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and phosphorylation of serine, threonine and tyrosine were specified in Mascot
as variable modifications. Carboxyamidomethylation of cysteine was specified
as fixed modification. The Mascot result files were loaded into Scaffold soft-
ware (version 3.3.1, Proteome Software Inc., Portland, USA) to validate MS/MS
based peptide identifications. Peptide identifications were accepted if they could
be established at greater than 80 % probability as specified by the Mascot Dae-
mon. Further analysis of the MS/MS data with regard to posttranslational
modifications was performed using the Proteome Discoverer software (version
1.3, Thermo Fisher Scientific, San Jose, USA) and Skyline (version 1.2) [106].
2.11 Animal studies
All procedures were approved by the local Animal Care and Use committee.
Male C57Bl/6 mice were obtained from Charles River Laboratories and main-
tained on a normal 12h dark-light cycle with standard chow.
2.11.1 Isolation of mice liver protein
For the experiments shown in Figure 3.4 mice were fasted overnight and injected
intraperitoneally with 2 IU (international units) insulin for 10min. For the ex-
periments shown in Figure 3.5 mice were also fasted overnight, refed ad libitum
for 5h or injected intravenously with 0.75U/kg insulin for 30min before liver
was taken. Liver tissue was homogenized on ice with a dounce homogenizer
and 2ml lysis buffer containing phosphatase inhibitors and protease inhibitors
(Complete tablet from Roche). After incubation on ice for 30min lysates were
cleared by centrifugation for 3× 10min at 4◦C with 13000rpm. Cleared lysates
were transferred to a fresh reaction tube and stored at -80◦C.
Table 2.40: Lysis buffer for protein isolation of mouse liver (pH 7.6)
50mM Tris
150mM NaCl
1 % Triton X-100
Phosphatase and protease inhibitors were added directly before use.
2.11.2 Isolation of primary hepatocytes
14 week old male C57Bl/6 mice were anaesthetized and the portal vein was
catheterized. Liver was perfused with Krebs-Henseleit buffer I (Table 2.41) and
subsequently with Krebs-Henseleit buffer II (Table 2.42) containing 1mg/ml
collagenase II (Biochrom, Berlin, Germany). Isolated hepatocytes were washed
with Krebs-Henseleit buffer II without collagenase and counted with Trypan
Blue. 5×105 cells were seeded in hepatocyte maintenance medium with supple-
ments on 6-well plates precoated with Collagen R (Serva, Heidelberg, Germany).
24h after isolation cells were starved for serum overnight and stimulated as in-
dicated in the Results/Figure legends.
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Table 2.41: Krebs Henseleit buffer I (pH 7.4), sterile filtered
20 mM HEPES
115 mM NaCl
25 mM NaHCO3
5.9 mM KCl
1.18 mM MgCl2
1.23 mM NaH2PO4
1.195 mM Na2SO4
0.5 mM EGTA
Table 2.42: Krebs Henseleit buffer II (pH 7.2), sterile filtered
20 mM HEPES
115 mM NaCl
25 mM NaHCO3
5.9 mM KCl
1.18 mM MgCl2
1.23 mM NaH2PO4
1.195 mM Na2SO4
2.5 mM CaCl2
2.12 Statistical analysis
If not otherwise indicated, 3 independent biological replicates were made.
Western blots were digitalized with a HP Scanjet 4670 to enable quantifi-
cation of signal intensities. Phosphorylation intensities were normalized to the
corresponding protein intensity. For the degradation experiments the IRS2 pro-
tein signal was related to β-actin. In co-immunoprecipitation and GST pull-
down experiments the protein that was used for immunoprecipitation or GST
respectively was used to normalize signal intensities.
Data are presented as mean ± SEM, unpaired student’s t-test was used to
test for significant differences and p values < 0.05 were considered significant.
Chapter 3
Results
3.1 Identification of signalling pathways that in-
creased 14-3-3 binding to IRS2
To identify conditions for increased 14-3-3 interaction with IRS2, HEK293 cells
were transfected transiently with GFP-IRS2 and incubated with different sub-
stances, which activate or inhibit major intracellular signal transduction path-
ways: IGF-1 leads to activation of the PI 3-kinase pathway; PI-103 is an ATP-
competitive compound targeting the catalytic subunit p110 of PI 3-kinase; EGF
(epidermal growth factor) leads to activation of the Ras/MAPK signalling path-
way; TPA (phorbol-12-myristate-13-acetate), also called PMA, activates PKC
isoforms and other kinases; BID 1870 is an inhibitor against the RSK (90 kDa
ribosomal S6 kinase) family of kinases which are downstream effectors of the
Ras/MAPK signalling cascade; forskolin, a diterpene derived from the plant
Coleus forskohlii, acts as an activator of adenylylcylase, thus leading to in-
creased intracellular cAMP levels which result in activation of PKA (protein
kinase A); H89 is an inhibitor of PKA, but can also inhibit other kinases such
as MSK1, S6K1 and ROCK-II (153); A23187 is also known as Calmycin and is
a calcium ionophore increasing intracellular calcium concentrations; A-769662
is an AMPK (AMP-activated protein kinase) activator; Calyculin A is a potent
serine/threonine phosphatase inhibitor. After cell lysis, purification of GFP-
IRS2, SDS-PAGE and western blot the membrane was incubated with human
recombinant HRP-labelled 14-3-3ζ, in the latter named overlay assay, to visu-
alize direct interaction of IRS2 and 14-3-3. The upper part of Figure 3.1 shows
the 14-3-3 overlay, the lower part the corresponding GFP reblot to ensure equal
expression and loading of GFP-IRS2.
In the serum starved condition a 14-3-3 interaction with IRS2 could be ob-
served. A strong increase in the 14-3-3 interaction with IRS2 was observed in
the Calyculin A-treated sample. There was a slight increase observable when
cells were treated with IGF-1 or forskolin, but marked decreases were detectable
when the PI 3-kinase pathway was inhibited by PI-103 or PKA activity was in-
hibited by H89. The reblot showed an augmented GFP signal for the Calyculin
A-treated sample which would implicate unequal loading, unequal expression
or incomplete stripping of the overlay membrane. From this experiment it was
concluded that two pathways could trigger 14-3-3 binding to IRS2: IGF-1 with
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PI-103 (PI 3-kinase inhibitor) 
EGF (Ras/MAPK pathway activator) 
TPA (PKC activator) 
BID 1870 (RSK inhibitor) 
forskolin (adenylycyclase activator) 
H89 (PKA inhibitor) 
A23187 (calcium ionophore) 
A-769662 (AMPK activator) 
Calyculin A (Ser/Thr phosphatase inhibitor) 
Figure 3.1: Kinase panel assay. HEK293 cells were transfected transiently with GFP-IRS2,
starved for serum 48h later and incubated with the following agents: 50ng/ml IGF-1 for
30min, 1µM PI-103 for 30min, 100ng/ml EGF for 15min, 100ng/ml TPA for 30min, 10µM
BID 1870 for 30min, 20µM forskolin for 30min, 30µM H89 for 30min, 10µM A23187 for
15min, 50µM A-769662 for 60min, 50nM Calyculin A for 10min. GFP-IRS2 was purified
using the GFP-TrapR© from 250µg of total protein, separated on 4-12 % Bis-tris mini gel and
overlay assay was performed. Membrane was stripped afterwards and reprobed with GFP
antibody to ensure equal expression and loading.
involvement of the PI 3-kinase pathway and elevated cAMP levels with subse-
quent PKA activation.
Based on these findings and the subsequent experiments the results are par-
titioned in two sections, the first section shows the results of the characterization
of IGF-1-mediated 14-3-3 interaction with IRS2 and the second section shows
the results of the characterization of PKA-mediated interaction of IRS2 and
14-3-3.
3.2 IGF-1-mediated 14-3-3 interaction with IRS2
3.2.1 Interaction of 14-3-3 with IRS2 upon IGF-1 or in-
sulin stimulation in different cell systems
To verify the results of the kinase panel assay HEK293 cells were transfected
with GFP-IRS2, stimulated with IGF-1 and PI 3-kinase activity was inhibited
by pretreating cells with PI-103. In addition, Fao rat hepatoma cells as a cell
system that expresses IRS2 endogenously were tested if interaction of 14-3-3
with IRS2 could be observed.
Since HEK293 cells express adequate amounts of IGF-1 receptor but not
insulin receptor [37] IGF-1 was used to stimulate HEK293 cells. The overlay
assay showed that upon stimulation with IGF-1 for 30min the 14-3-3 binding
to GFP-IRS2 was increased, whereas it was decreased by treating cells 30min
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Figure 3.2: 14-3-3 can bind to transiently and endogenously expressed IRS2. a) HEK293 cells
were transfected transiently with GFP-IRS2 and incubated with 50ng/ml IGF-1 for 30 min
or with 1µM PI-103 for 30min prior IGF-1 stimulation. GFP-IRS2 was purified from 250µg
total lysate using GFP-TrapR©, samples were separated on 4-12 % Bis-tris mini gels and overlay
assay was performed. GFP reblot is shown as loading control. b) Fao cells were incubated with
either 10nM insulin or 50ng/ml IGF-1 for 30min. IRS2 was immunoprecipitated (IP) from
250µg total lysate, separated on 5-15 % gradient SDS gel and overlay assay was performed
with subsequent IRS2 reblot as loading control. Lysates containing 80µg total protein were
checked for p-Thr308 phosphorylation and Akt/PKB reblot is shown as loading control.
prior IGF-1 stimulation with PI-103 as shown in Figure 3.2a. Figure 3.2b shows
that insulin stimulation led to a strong interaction of 14-3-3 with IRS2 and
increased Akt/PKB phosphorylation in Fao cells. Stimulation with IGF-1 did
not result in activation of the PI 3-kinase pathway, shown as missing Akt/PKB
phosphorylation, and did not increase 14-3-3 binding. The finding that IGF-1
stimulation in Fao cells does not lead to activation of the PI 3-kinase pathway
is similar to previous data from Fritsche et al. [48], probably due to low IGF-1
receptor expression levels. Therefore, insulin stimulation was used to investigate
IRS2 and 14-3-3 interaction in Fao cells. The data from Figure 3.2 suggest that
insulin/IGF-1 stimulation induced phosphorylation on the IRS2 molecule on
serine or threonine residues within one or more 14-3-3 binding motif(s) with
involvement of the PI 3-kinase pathway.
3.2.2 Co-immunoprecipitation of endogenous 14-3-3
Since the overlay assay shows binding of 14-3-3 to denaturated IRS2 on a nitro-
cellulose membrane after SDS-PAGE, a co-immunoprecipitation experiment was
conducted to confirm interaction of 14-3-3 and IRS2 in situ. HEK293 cells were
transfected transiently with GFP or GFP-IRS2, starved for serum and either
incubated with IGF-1 alone or after preincubation with wortmannin. Endoge-
nously expressed 14-3-3 was immunoprecipitated and IRS2 was detected.
Figure 3.3 shows the results for the co-immunoprecipitation experiment. Im-
munoprecipitation of endogenous 14-3-3 revealed interaction with IRS2 already
at basal levels, but IGF-1 stimulation increased that amount. Incubation with
the covalent PI 3-kinase inhibitor wortmannin decreased binding of 14-3-3 and
IRS2. Of note, the two different PI 3-kinase inhibitors used in this work, namely
PI-103 and wortmannin, led to similar results.
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Figure 3.3: Co-immunoprecipitation of 14-3-3 and IRS2. HEK293 cells were transiently
transfected with GFP or GFP-IRS2 and starved for serum 48h after transfection. Cells were
either left untreated, incubated with 50ng/ml IGF-1 for 30min alone or after preincubation
with 100nM wortmannin for 30min. 400µg protein were used for immunoprecipitation with
2µg 14-3-3 C-17 antibody, samples were separated on 5-15 % SDS gel and after western blotting
upper membrane was incubated with IRS2 antibody, whereas the membrane in the middle
was incubated with 14-3-3 K-19 antibody. 40µg protein was separated by 7.5 % SDS-PAGE
and membrane was incubated with GFP antibody as expression control. Experiment was
performed once.
3.2.3 14-3-3 interacts with IRS2 from mouse liver
To evaluate the physiological importance of 14-3-3 binding to IRS2 it was tested
if the overlay assay could show 14-3-3 binding to IRS2 in mouse liver after an
acute insulin stimulus. Mice were fasted overnight, injected intravenously with
insulin and after 10min liver was taken and IRS2 was immunoprecipitated.
Figure 3.4 shows the overlay assay and the corresponding densitometric analysis
thereof.
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Figure 3.4: Interaction of 14-3-3 with IRS2 upon insulin stimulation in mice liver. a) 14 week
old male C57Bl/6 mice were fasted overnight and injected intravenously with 2 IU insulin.
After 10min liver was taken and 500µg of total protein was immunoprecipitated with 2µg IRS2
antibody. Separation of proteins was carried out on a 5−15 % gradient gel and membrane
was incubated overnight with 14-3-3-HRP. As loading control membrane was stripped and
reprobed with IRS2 antibody. Two mice of each group are shown. b) Densitometric analysis
of 14-3-3 interaction with IRS2. Overlay signal was normalized for total IRS2 protein content
(mean ± SEM; n = 4; * p < 0.05 fasted vs. insulin).
Intravenous application of insulin for 10min led to a markedly increased
14-3-3 binding to IRS2. The overlay assay showed a possible interaction of
14-3-3 and IRS2 after an acute insulin stimulus and the next question was if the
acute insulin-stimulated interaction could be compared to a physiological refed
condition.
For this experiment, male C57Bl/6 mice were fasted overnight, refed for 4h
or injected intraperitoneally with insulin for 30min before liver was taken.
Figure 3.5 shows the increased binding of 14-3-3 to IRS2 after the acute
insulin stimulus in the overlay assay, but also the refeeding condition led to
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Figure 3.5: 14-3-3 binds to IRS2 after refeeding and insulin stimulation in mice. a) Male
C57Bl/6 mice were fasted overnight, refed for 5h or injected i.p. with insulin for 30min.
1mg of total protein was immunoprecipitated with 2µg IRS2 antibody, samples were loaded
twice on a 5-15 % gradient gel and one membrane was incubated overnight with 14-3-3-HRP,
whereas the other membrane was directly incubated with IRS2 antibody. Four mice of each
group are shown. b) 14-3-3 interaction with IRS2 was quantified by scanning densitometry of
immunoblots and normalization for IRS2 protein (mean ± SEM; n = 4; * p < 0.05 fasted vs.
refed and insulin stimulation).
an increased binding of 14-3-3 to IRS2 when the overlay signal was normalized
against total protein content. In conclusion, an acute insulin stimulus as well
as refeeding could lead to increased interaction between IRS2 and 14-3-3, thus
implicating a physiological importance of this interaction.
3.2.4 Mass spectrometry for identification of phosphory-
lated serine/threonine residues on IRS2 after IGF-1
stimulation
To identify serine/threonine residues on IRS2 that are involved in the insulin/
IGF-1 signalling cascade GFP or GFP-IRS2 encoding mouse IRS2 was ex-
pressed transiently in HEK293 cells and stimulated with IGF-1 alone or after
pre-treatment with PI-103. GFP and GFP-IRS2 was purified from cell lysates
and after SDS-PAGE and Coomassie staining, bands corresponding to IRS2
were cut and prepared for mass spectrometry according to section 2.9. The
complete experiment including data analysis was performed at the University
of Dundee.
Figure 3.6 shows the Coomassie stained SDS gel where the bands for mass
spectrometric analysis were cut out from. A vector containing solely GFP was
transfected as a control for evaluation of the pulldown. This would be of major
importance when the lanes with the different conditions used for stimulation
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Figure 3.6: Coomassie stained SDS gel. HEK293 cells were transfected transiently with
expression vectors coding for GFP or GFP-IRS2. Cells were left untreated or stimulated
with 50ng/ml IGF-1 for 30min or incubated prior IGF-1 stimulation for 30min with 1µM
PI-103. GFP and GFP-IRS2 were purified from 10mg protein by GFP-TrapR© and samples
were separated on 4-12 % Bis-tris mini gels. The SDS gel was stained with the Colloidal Blue
Staining Kit overnight. The first lane shows the molecular weight marker, the numbers on
the left side depict the individual molecular weights in kDa.
would be analyzed for interaction partners. A prominent band between 150 and
250kDa could be assigned to IRS2 in every GFP-IRS2 lane, since at the corre-
sponding height in the GFP control lane no such prominent band was visible.
In this thesis only the bands corresponding to IRS2 were cut and analyzed for
phosphorylated residues. Tryptic digests of IRS2 protein bands followed liq-
uid chromatography mass spectrometry (LC-MS). The sequence coverage was
92 % and a total of 24 phosphorylated serine/threonine residues were identified.
According to IRS2 mouse numbering phosphorylations were detected at resi-
dues Ser66, Ser303, Ser305, Ser347, Ser385, Ser388, Thr401, Thr517, Ser556, Ser573,
Ser675, Ser722, Ser727, Ser728, Ser762, Ser907, Ser968, Ser977, Ser999, Ser1089,
Ser1151, Ser1165, Ser1190 and Ser1266 (see Figure A.1 and Figure A.2 for the
identified phosphopeptides). In Figure 3.7 the sections of the IRS2 mouse se-
quence are shown that contain the 24 phosphorylated residues (labeled in bold
red). Corresponding residues found in human IRS2 and mouse/human IRS1 are
also shown. A complete alignment of mouse and human IRS1 and IRS2 can be
found in Figure A.5.
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IRS species numbering sequence 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
42 
42 
24 
24 
HGHKRFFVLRGPGTGGDEASAAGGSPPQPPRLEYYESEKKWR 
HGHKRFFVLRGPGAGGDEATAGGGSAPQPPRLEYYESEKKWR 
SMHKRFFVLRAASEAG-----------GPARLEYYENEKKWR 
SMHKRFFVLRAASEAG-----------GPARLEYYENEKKWR 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
291 
294 
255 
260 
LKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQ 
LKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQ 
MSDE--FRPRSKSQSSS-SCSNPISVPL--RRHHLNNPPPSQ 
MSDE--FRPRSKSQSSS-NCSNPISVPL--RRHHLNNPPPSQ 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
333 
336 
292 
297 
TGLVRRSRTDSLAATPPAAKC----TSCRVRTASEGDGGAAG 
TGLVRRSRTDSLAATPPAAKC----SSCRVRTASEGDGGAAA 
VGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGT--- 
VGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGT--- 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
371 
374 
331 
336 
GAGTAGGRPMSVAGSPLSPGPVRAPLSRSHTLSAGCGGRPSK 
GAAAAGARPVSVAGSPLSPGPVRAPLSRSHTLSGGCGGRGSK 
-----MSRPASVDGSPVSPSTNRTHAHRHR---------G-- 
-----MSRPASVDGSPVSPSTNRTHAHRHR---------G-- 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
497 
500 
423 
428 
LDEYGSSPGDLRAFSSHRSNTPESIAETPPARDGS-GGELYG 
LDEYGSSPGDLRAFCSHRSNTPESIAETPPARDGGGGGEFYG 
SDEYGSSPCDFRS--SFRSVTPDSLGHTPPARGEE---ELSN 
SDEYGSSPCDFRS--SFRSVTPDSLGHTPPARGEE---ELSN 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
554 
558 
502 
507 
-RVSGDGAQDLDRGLRKRTYSLTTPA---RQRQVPQPSSASL 
-RVSGDAAQDLDRGLRKRTYSLTTPA---RQRPVPQPSSASL 
PGDEAAGAADLDNRFRKRTHSAGTSPTISHQKTPSQSSVASI 
AGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASI 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
667 
671 
624 
628 
KSDDYMPMSPTSVSAPKQILQPRLAA----ALPPSGAAVPAP 
RSDDYMPMSPASVSAPKQILQPRAAAAAAAAVPSAGPAGPAP 
GNGDYMPMSPKSVSAPQQIINPIRRHPQR--VDPNGYMMM-- 
GSGDYMPMSPKSVSAPQQIINPIRRHPQR--VDPNGYMMM-- 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
705 
713 
662 
666 
PSGVGRTFPVNGGG-YKASSPAESSPEDSGYMRMWCGSK--- 
TSAAGRTFPASGGG-YKASSPAESSPEDSGYMRMWCGSK--- 
-SPSGSCSPDIGGGSSSSS-SISAAPSGSSYGKPWTNGVGGH 
-SPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGH 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
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---------LSMENPDPKLLP-NGDYLNMSPSEAGTAGTPPD 
---------LSMEHADGKLLP-NGDYLNVSPSDAVTTGTPPD 
HTHALPHAKPPVESGGGKLLPCTGDYMNMSPVGDSNTSSPSE 
HSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSD 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
889 
897 
860 
865 
GLQ--TL-----------PSMQEYPLPTEPKSPGEYINIDFG 
GLP--SL-----------PSMHEYPLPPEPKSPGEYINIDFG 
DPKASTLPRVREQQQ----QQQSSLHPPEPKSPGEYVNIEFG 
DPKASTLPRAREQQQ----QQQPLLHPPEPKSPGEYVNIEFG 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
960 
968 
926 
931 
DSRQRSPLSDYMNLDFSSPKSPKPSTRSGDTVGSMDGLLSPE 
DSRQRSPLSDYMNLDFSSPKSPKPGAPSGHPVGSLDGLLSPE 
PRE-ETGSEEYMNMDLGPGRRATWQESGGVELGRIGPA-PPG 
PREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPA-PPG 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
1079 
1090 
1028 
1034 
PPKPEGARV---ASPTSGL-------KRLSLMDQVSGVEAFL 
PPKPEAARV---ASPTSGV-------KRLSLMEQVSGVEAFL 
PPPSSTASSSASVTPQGATAEQATHSSLLGGPQGPGGMSAFT 
ASSSSAASAS-PTGPQ-GAAELAAHSSLLGGPQGPGGMSAFT 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
1111 
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1070 
1074 
QVSQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSP 
QVSQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSP 
RVNLSPNHNQSAKVIRADTQGCRRRHSSETFSA---PTRAGN 
RVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGN 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
1153 
1164 
1109 
1116 
SFAHNSKRHNSASVENVSLRKSSEGSSTL--GGGDEPPTSPG 
SFAHNPKRHNSASVENVSLRKSSEGGVGVGPGGGDEPPTSPR 
TVPFG-------------------AGAAVGGSGGGGGGGSED 
TVPFG-------------------AGAAVGGG-GGSSSSSED 
mouse IRS-2 
human IRS-2 
mouse IRS-1 
human IRS-1 
1264 
1281 
1205 
1214 
KNSWSRTRSLGGLLGTVGGSGASGVCGGPGTGALPSASTYAS 
KSSWGRTRSLGGLISAVGVGSTGGGCGGPGPGALPPANTYAS 
NEGNSPRR------------------------SSEDLSNYAS 
GESSSTRR------------------------SSEDLSAYAS 
Figure 3.7: Sequence alignments of IRS1 and IRS2. Protein sequences from mouse IRS2
(NP 001074681.1), human IRS2 (NP 003740.2), mouse IRS1 (NP 034700.2) and human IRS1
(NP 005535.1) were aligned. The sequences were searched for homologue residues of mouse
IRS2 that were identified by mass spectrometry and marked in bold red. Shown are only parts
of the sequences that contain an identified phosphorylated serine/threonine residue. The term
“numbering” indicates the amino acid position of the first amino acid in every line.
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Of note, Ser305 and Ser1266 were the only sites that were unique to the
IGF-1-treated sample. However, the mass spectrometric approach was suitable
to identify phosphorylation sites, but did not allow evaluation of changes in
the phosphorylation levels due to IGF-1 treatment. Interestingly, some resi-
dues are unique for IRS2 (Ser66, Thr401, Ser556, Ser727, Ser728, Ser968, Ser977,
Ser999, Ser1089, Ser1151, Ser1165 and Ser1266), whereas some are conserved in
IRS1 and IRS2 (Ser303, Ser305, Thr347, Ser385, Ser388, Thr517, Ser573, Ser675,
Ser722, Ser762, Ser907 and Ser1190).
3.2.5 Generation of IRS2 fragments to identify the insu-
lin/IGF-1-dependent 14-3-3 binding region
Having identified at least 24 potential candidate residues to be phosphorylated
by IGF-1, the next step was to choose sensible candidates for further testing. By
comparing the 14-3-3 binding motifs RSXpS/pTXP and RX(F/Y)XpS/pTXP
with the sequences surrounding the identified phosphorylated residues it became
apparent that potential 14-3-3 binding motifs frequently appeared in an amino
acid area between the PTB (phosphotyrosine binding) and the KRLB (kinase
regulatory loop binding) domain on IRS2 stretching from amino acid position
300-600. To prove that region 300-600 was important for 14-3-3 binding and to
exclude possible other regions IRS2 fragments spanning different sections of the
protein were generated. A schematic illustration of the generated fragments is
displayed in Figure 3.8. Two fragments from position 1-300 and 1-600 encom-
passed the N-terminal part of the IRS2 molecule including the PH and the PTB
domain. The C-terminal part was also divided into two fragments spanning
amino acids 301-1321 and 601-1321, both containing the KRLB domain. The
5th construct comprised amino acids 301-600. All fragments were GFP-tagged
at the N-terminus to allow purification with the GFP-Trap R©.
PH PTB KRLB N C 
31 140 191 294 591 735 
1-300 GFP 
601-1321 GFP 
1-600 GFP 
301-1321 GFP 
GFP 301-600 
Figure 3.8: Schematic illustration of truncated IRS2 constructs to identify the 14-3-3 binding
region. Shown are the five fragments of IRS2 and full length IRS2 with amino acid numbering
according to mouse IRS2.
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3.2.6 The area between amino acids 301 and 600 on IRS2
is important for 14-3-3 binding
HEK293 cells were transfected transiently with GFP-IRS2 full length or with
IRS2 fragments and stimulated with IGF-1 or after preincubation with PI-103.
While equal amounts of DNA were used to transfect the cells, the protein ex-
pression levels differed between IRS2 wild type and truncated IRS2 forms as
shown in Figure 3.9.
GFP-IRS2- 
1-300 
GFP-IRS2-
301-600 
GFP 
GFP-IRS2 GFP-IRS2- 
1-600 
GFP-IRS2-
301-1321 
GFP-IRS2-
601-1321 
250 
150 
100 
75 
50 
Figure 3.9: Cell lysates of IRS2 wild type and fragments separated by SDS-PAGE. HEK293
cells were transiently transfected with GFP-IRS2, GFP-IRS2-1-300, GFP-IRS2-1-600, GFP-
IRS2-301-1321, GFP-IRS2-601-1321 or GFP-IRS2-301-600. Cells were either left unstimu-
lated, stimulated with 50ng/ml IGF-1 for 30min or with 1µM PI-103 for 30min prior IGF-1
stimulation. 20µg of total protein was separated on a 5-15 % SDS gel and after western blot-
ting the membrane was incubated with GFP antibody. The arrow indicates a longer exposure
time and the numbers on the left side denote the molecular weight marker (molecular weights
in kDa).
Figure 3.10 shows the results for the transiently transfected fragments that
were tested for residual 14-3-3 binding. GFP-IRS2 and fragments were purified
from the cell lysate and tested for residual 14-3-3 binding.
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- 
- 
+ + 
+ - 
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301-600 
Figure 3.10: Overlay assay of IRS2 wild type and truncated versions of IRS2 to check for
residual 14-3-3 binding. Lysates were prepared as described in Figure 3.9. 250µg of total
protein was incubated with GFP-TrapR©, samples were separated on 4-12 % Bis-tris mini gels
and overlay assay was performed. Stripping of the membranes followed reprobing with GFP
antibody as loading control.
The overlay assay showed regulated binding of 14-3-3 to wild type IRS2, but
no interaction between 14-3-3 and the constructs GFP-IRS2-1-300 and GFP-
IRS2-601-1321. A strong and almost unregulated interaction was observed with
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the construct GFP-IRS2-1-600. On the contrary, the construct GFP-IRS2-
301-1321 showed regulated 14-3-3 binding upon IGF-1 stimulation and reduced
binding by PI-103 treatment. These data showed the importance of the region
301-600 for 14-3-3 binding. To test if this region alone was capable of binding
to 14-3-3 the fragment 301-600 was tested. This fragment also showed almost
unregulated binding to 14-3-3 similar to GFP-IRS2-1-600.
3.2.7 Identification of Ser573 as IGF-1-dependent 14-3-3
binding site on IRS2
Having localized the 14-3-3 binding region to amino acids 301-600, the phospho-
rylated serine/threonine residues that were identified by mass spectrometry and
corresponded to a 14-3-3 binding motif as shown in Table 3.1 were investigated.
Table 3.1: With mass spectrometry identified residues with surrounding amino acids that
correspond to a 14-3-3 binding motif. Shown are the identified residues indicated in bold with
pS or pT and the surrounding six amino acids.
Residue Peptide
303 RSKRSKpSQSSGSS
401 PLSRSHpTLSAGCG
517 SSHRSNpTPESIAE
556 RPYRRVpSGDGAQD
573 LRKRTYpSLTTPAR
After single mutation of each serine/threonine to alanine residual 14-3-3
binding upon IGF-1 stimulation was tested in transiently transfected HEK293
cells by overlay assay. The mutation of Ser573 to alanine blocked the basal
and IGF-1-dependent 14-3-3 interaction completely, while the other mutants
showed similar interaction with 14-3-3 when compared with IRS2 wild type.
An exemplary MS/MS spectrum for a phosphorylated peptide corresponding to
Ser573 is shown in Figure A.3.
- + + - + + - + + 
- - + - - + - - + 
- + + - + + - + + 
- - + - - + - - + 
GFP-IRS2 GFP-IRS2-
S573A 
GFP-IRS2-
T401A 
GFP-IRS2-
T517A 
GFP-IRS2-
S556A 
GFP-IRS2-
S303A 
14-3-3-HRP 
GFP 
PI-103 
IGF-1 
Figure 3.11: Identification of Ser573 as 14-3-3 binding site by overlay assay. HEK293 cells
were transiently transfected with GFP-IRS2, GFP-IRS2-S303A, GFP-IRS2-T401A, GFP-
IRS2-T517A, GFP-IRS2-S556A or GFP-IRS2-S573A and stimulated with 50ng/ml IGF-1
for 30min or after preincubation with 1µM PI-103 30min prior IGF-1 stimulation. 250µg
of total protein were used for GFP pulldown and overlay assay was performed. Stripping
followed reprobing of the membrane with GFP antibody as loading and expression control.
Experiment was performed once.
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Ser573 as 14-3-3 binding site was again confirmed in HEK293 cells transiently
expressing GFP-IRS2-S573A and also Flp-In HEK293 cells stably expressing
GFP-IRS2-S573A showed similar results. No difference in the ability of the two
PI 3-kinase inhibitors used (wortmannin or PI-103) to decrease IGF-1-mediated
14-3-3 binding to IRS2 was detected.
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Figure 3.12: Confirmation of Ser573 of IRS2 as an IGF-1-dependent 14-3-3 binding site. a)
Transiently with GFP-IRS2 or GFP-IRS2-S573A transfected HEK293 cells were stimulated
with 50ng/ml IGF-1 alone for 30min or after preincubation with 100nM wortmannin for
30min. 100µg of total protein was used for GFP pulldown, separated on 5-15 % SDS gels and
overlay assay was performed. Corresponding GFP reblot as expression and loading control
is shown. b) Flp-In HEK293 cells stably expressing GFP-IRS2 or GFP-IRS2-S573A were
stimulated as in a) and cell lysis was followed by pulldown of 400µg total protein. Samples
were divided into two equal volumes and separated on SDS-PAGE. One membrane was used
for overlay assay, the other one was directly incubated with GFP antibody. c) 100µg protein
from lysates in b) were separated on 7.5 % SDS gel and membranes were incubated with GFP
antibody as expression control, with p-Thr308 Akt/PKB antibody as stimulation control and
β-actin antibody as loading control. d) Interaction of 14-3-3 with IRS2 from b) was quantified
scanning densitometry of western blots (mean ± SEM; n = 3; * p < 0.05 IRS2 wild type
IGF-1 vs. IRS2 wild type wortmannin/IGF-1).
Noteworthy, the Flp-In HEK293 cells showed phosphorylation of Thr308
Akt/PKB in the serum starved condition, which may influence basal phosphory-
lation of Ser573. Since Ser573 was crucial for insulin/IGF-1-mediated binding of
14-3-3 to IRS2, sequence alignments were performed and these are shown in
Table 3.2 and Table 3.3.
3.2.8 Characterization of p-Ser573 antibody
To characterize a phosphorylation site the use of a phospho-specific antibody is
indispensable. For this reason an antibody was raised against a phosphorylated
peptide that corresponded to phosphorylated Ser573 of IRS2. Before the anti-
body was used to monitor Ser573 phosphorylation, the antibody itself had to be
characterized and tested for its suitability.
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Table 3.2: Sequence alignments concerning the surrounding amino acids of Ser573. Sequence
alignment of the amino acids adjacent to the 14-3-3 binding site Ser573 of IRS2 in differ-
ent species. Shown are IRS2 sequences from Homo sapiens (NP 003740.2), Mus musculus
(NP 001074681.1), Rattus norvegicus (NP 001162104.1) and Xenopus laevis (AAH72768.1).
Homo sapiens 571LRKRTYSLTTPAR584
Mus musculus 567LRKRTYSLTTPAR579
Rattus norvegicus 568LRKRTYSLTTPAR580
Xenopus laevis 519LRKRTYSLTKHTN531
Table 3.3: Shown is the amino acid sequence surrounding Ser573 in mouse IRS2 and the
sequence surrounding the homologue position Ser522 in mouse/rat IRS1.
mouse IRS2 567LRKRTYSLTTPAR579
mouse IRS1 516FRKRTHSAGTSPT528
Sequence specificity of p-Ser573 antibody
To test the specificity of the antibody Flp-In HEK293 cells stably expressing
GFP-IRS2 or GFP-IRS2-S573A were incubated with IGF-1 or TPA alone or
with wortmannin before the IGF-1 stimulation. A representative blot is shown
in Figure 3.13.
TPA 
GFP-IRS2 GFP-IRS2-    
S573A 
p-Ser573 
GFP 
- + + - - + + - 
- - + - - - + - 
- - - + - - - + 
wortmannin 
IGF-1 
Figure 3.13: Specificity test of the p-Ser573 antibody. Flp-In HEK293 cells stably expressing
GFP-IRS2 or GFP-IRS2-S573A were stimulated with 50ng/ml IGF-1 for 30min, 0.5µM TPA
for 30min and 100nM wortmannin for 30min. 200µg lysate was separated by SDS-PAGE,
membrane was incubated with p-Ser573 antibody (diluted 1:5000 in NET-G) and reprobed
with GFP antibody as loading control. Shown is a representative blot from two independent
experiments.
While the antibody did not detect any phosphorylation signal in the 573 ala-
nine mutant, it detected IGF-1 and TPA-stimulated phosphorylation of Ser573
in wild type IRS2. Wortmannin blocked the IGF-1-mediated phosphorylation of
Ser573. The antibody recognized different bands, which all corresponded to the
IRS2 protein according to the reblot. This recognition of different sub-species
of the IRS2 protein by immunoblotting is well in line with data from Fritsche
et al. [48].
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p-Ser573 antibody does recognize its homologue position Ser577 in hu-
man IRS2
Sequence alignments showed Ser522 of rat/mouse IRS1 (same numbering in rat
and mouse IRS1 sequence) and Ser577 of human IRS2 to be homologue posi-
tions of Ser573 of mouse IRS2. To test if the antibody against phosphorylated
Ser573 of IRS2 recognizes the homologue positions, HEK293 cells were trans-
fected transiently with either rat IRS1 or human IRS2. In addition, the insulin
receptor was co-transfected to enable stimulation of HEK293 cells with insulin.
p-Ser573 
IRS2 
IRS1 
IR 
mIRS2 hIRS2 rIRS1 
- + - + - + insulin 
Figure 3.14: p-Ser573 antibody is specific for IRS2. HEK293 cells were co-transfected
transiently with mouse IRS2 / IR (insulin receptor), human IRS2 / IR and rat IRS1 / IR
and stimulated with 10nM insulin for 30min. Membranes were incubated with p-Ser573
antibody (diluted 1:5000 in NET-G) and reprobed with the corresponding protein antibodies.
IR expression was also checked. Experiment was performed once.
Mouse IRS2 was transfected as a positive control. The antibody detected
phosphorylation of mouse IRS2 Ser573 and human IRS2 Ser577, but not IRS1
Ser522. The p-Ser573 signal for human IRS2 seemed to be stronger than the
corresponding signal for mouse IRS2, but the IRS2 reblot showed that the
human IRS2 construct was expressed at a higher level than the mouse IRS2
construct. From this result it could be concluded that the antibody is spe-
cific for the sequence LRKRTYpS573/577LTTPAR, while the IRS1 sequence
FRKRTHpS522AGTSPT is not recognized.
Determination of antibody dilution to detect phosphorylation of Ser573
on IRS2 in Fao cells
Since the p-Ser573 antibody recognized the fusion protein GFP-IRS2 in HEK293
cells, it was further investigated, if the antibody detected Ser573 phosphorylation
of endogenous expressed IRS2. Fao cells were starved for serum and incubated
with insulin or TPA to induce phosphorylation of Ser573. Since the expression
levels of endogenous and transiently overexpressed proteins differ very much,
several dilutions of the p-Ser573 antibody were tested to establish the optimal
dilution factor for the antibody to detect IRS2 in Fao cells.
Figure 3.15 shows that a strong signal intensity in every condition was ob-
servable on the membrane piece that was incubated with an antibody dilution
of 1:1000, wheras with higher dilutions of the antibody the signal got more dis-
tinct. It was decided to use the antibody within a dilution range from 1:2000
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1:1000 1:2000 1:5000 1:10000 
p-Ser573 
IRS2 
- - + - - + - - + - - + 
- + - - + - - + - - + - insulin 
TPA 
Figure 3.15: p-Ser573 antibody test in Fao cells. Fao cells were starved for serum and
incubated with 10nM insulin or 0.5µM TPA for 30min. 35µl cell lysate was separated on
SDS-PAGE and the membrane was cut in 4 parts. Membrane pieces were incubated with
different antibody dilutions (1:1000, 1:2000, 1:5000, 1:10000). Stripping and reprobing of the
membrane with IRS2 antibody was performed as loading control. Experiment was performed
once.
to 1:5000, because these dilutions allowed a clear differentiation to the serum
starved condition and insulin as well as TPA stimulation was observable.
Immunoprecipitation of IRS2 with p-Ser573 antibody
The antibody was used to immunoprecipitate IRS2 species that were specifi-
cally phosphorylated on Ser573. Two different cell systems were used for this
approach, Flp-In HEK293 cells stably expressing either GFP or GFP-IRS2 and
Fao cells.
-      5      60       -     5    60 IGF-1 
GFP 
GFP GFP-IRS2 
-      5      60  240 insulin 
IRS2 
a) b) 
Figure 3.16: Immunoprecipitation of IRS2 with p-Ser573 antibody. a) Flp-In HEK293 cells
were starved for serum and incubated with 50ng/ml IGF-1 for the indicated time points in
min. 400µg of total protein was used for immunoprecipitation with 1.3µg p-Ser573 antibody
and membrane was incubated with GFP antibody. b) Fao cells were starved for serum and
incubated with 10nM insulin for the indicated time points in min. 400µg of total protein were
used for immunoprecipitation with 1.3µg p-Ser573 antibody and membrane was incubated with
IRS2 antibody. Experiments were performed once.
p-Ser573 antibody successfully immunoprecipitated IRS2 from Flp-In HEK293
and Fao cells. In both approaches there was no difference in the band intensities
observable. Of note, in both cell lines did the antibody precipitate IRS2 from
the serum starved condition. This was not unexpected from the serum starved
sample of Flp-In HEK293 cells that stably expressed GFP-IRS2, since this cell
line showed a permanent active Akt/PKB kinase (see Figure 3.12c), that could
have influenced phosphorylation of Ser573 in the serum starved condition. In
addition, it seemed that the antibody precipitated two different IRS2 species in
the Flp-In HEK293 cells as can be seen by the two bands in every lane.
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In Fao cells the band shift from IRS2 caused by insulin stimulation and
subsequent posttranslational modifications that increased its molecular weight
could be nicely seen, but it was unexpected that the antibody precipitated IRS2
from Fao cells deprived of serum. This could indicate a permanent phosphory-
lation of Ser573 and the antibody failed to precipitate increased amounts of
phosphorylated Ser573 upon IGF-1 or insulin stimulation. In conclusion, the
p-Ser573 antibody was specific for phosphorylated Ser573 of mouse IRS2, rec-
ognized Ser577 of human IRS2 and did not recognize its homologue Ser522 of
mouse/rat IRS1.
3.2.9 Time course of Ser573 phosphorylation in Fao cells
upon insulin stimulation
The phosphorylation pattern of Ser573 of endogenous expressed IRS2 was mon-
itored in Fao cells and is shown in Figure 3.17. Cells were starved for serum
and incubated with insulin for several time points.
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Figure 3.17: Ser573 phosphorylation upon insulin stimulation in Fao cells. Cells were starved
for serum and incubated with 10nM insulin for the indicated time points in min. a) 100µg
protein was separated on 7.5 % SDS gel, membrane was incubated with p-Ser573 antibody
diluted 1:2000 in NET-G. Phosphorylation of p-Thr308 of Akt/PKB is shown as stimulation
control. Corresponding protein reblots are shown. b) Densitometric analysis of Ser573 phos-
phorylation. The p-Ser573 signal was normalized for IRS2 protein content (mean ± SEM;
n = 3).
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Ser573 showed a slight basal phosphorylation which modestly increased after
5 and 30 min and peaked at 60, 90 and 120 min of insulin stimulation before
decreasing again. The time course experiment showed that phosphorylation of
Ser573 phosphorylation was a rather late event in insulin signalling.
3.2.10 Inhibition of Akt/PKB leads to a reduced phos-
phorylation of Ser573 and reduced binding of 14-3-3
Comparison of the sequence surrounding Ser573 (RKRTYpS573) with the Akt/
PKB consensus motif (RXRXXpS/T) revealed concordance. A literature search
for publications concerning the homologue position of Ser522 in IRS1 brought
up the publication from Giraud et al. [53]. They described Ser522 of IRS1 as an
inhibitory serine phosphorylation site and a substrate for Akt/PKB kinase or a
kinase downstream of Akt/PKB. It was a matter of course to test if Akt/PKB
was involved in phosphorylation of Ser573. Flp-In HEK293 cells stably express-
ing GFP-IRS2 were incubated with an Akt/PKB inhibitor (Akti) before IGF-1
stimulation and phosphorylation status of Ser573 was investigated. A represen-
tative blot is shown in Figure 3.18.
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Figure 3.18: Phosphorylation of Ser573 after inhibition of Akt/PKB. a) Flp-In HEK293
cells stably expressing GFP-IRS2 were starved for serum and incubated with 50ng/ml IGF-1
for 30min, 1µM Akti for 30min or Akti incubation prior IGF-1 stimulation. 100µg protein
was separated on 7.5 % SDS gel and membranes were incubated with p-Ser573 antibody (di-
luted 1:5000 in NET-G) and reprobed with GFP antibody. To check inhibition of Akt/PKB
phosphorylation of Thr308 of Akt/PKB and its substrate Ser9 of GSK3β were detected. In
addition, corresponding protein reblots are shown. b) Effect of Akt/PKB inhibition on Ser573
phosphorylation was assessed by scanning densitometry of blots and normalization for GFP-
IRS2 protein (mean ± SEM, n = 3, * p < 0.05 IGF-1 vs. Akti/IGF-1).
The compound Akti-1/2 reduced the phosphorylation of Thr308 Akt/PKB, of
its substrate Ser9 GSK3β and the IGF-1-stimulated phosphorylation of Ser573.
Densitometric analysis revealed that the reduction in Ser573 phosphorylation by
pretreating cells with Akti before IGF-1 stimulation was significant compared
to IGF-1 treatment alone. Again, similar to Figure 3.12, Flp-In HEK293 cells
showed phosphorylation of Thr308 Akt/PKB in the serum starved condition,
which may influence phosphorylation of Ser573 as already described in subsec-
tion 3.2.7.
To further test whether Akt/PKB inhibition also influences 14-3-3 binding to
IRS2, a GFP pulldown and subsequent overlay assay to visualize 14-3-3 binding
to IRS2 was performed. See Figure 3.19 for the result of the experiment. Of
note, Flp-In HEK293 cells stably expressing GFP-IRS2 were used.
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Figure 3.19: Akt/PKB kinase is part of IGF-1-mediated 14-3-3 binding to IRS2. Flp-In
HEK293 cells stably expressing GFP-IRS2 were starved for serum and incubated for 30min
with 50ng/ml IGF-1, 1µM Akti-1/2 alone for 30min or Akti-1/2 preincubation followed IGF-
1 stimulation. GFP pulldown was performed with 200µg of total protein and overlay assay
followed reprobing with IRS2 antibody. 100µg of total protein was separated on 7.5 % SDS
gel and membrane was checked for p-Thr308 phosphorylation and reprobed with Akt/PKB
protein antibody. Experiment was performed once.
IGF-1 stimulation resulted in increased binding of 14-3-3 to IRS2, which
was prevented by incubation with Akti-1/2 before IGF-1 stimulation. These
findings led to the conclusion that Akt/PKB activity was necessary for Ser573
phosphorylation and the IGF-1-stimulated 14-3-3 binding to IRS2.
3.2.11 Positive influence of S573A mutant on Akt/PKB
phosphorylation
To investigate if the phosphorylation of Ser573 had an influence on downstream
signalling of the insulin/IGF-1 signalling cascade, the phosphorylation of Thr308
and Ser473 of Akt/PKB in HEK293 cells transfected transiently with GFP-IRS2
or GFP-IRS2-S573A was assessed after incubation with IGF-1 for several time
points.
Figure 3.20 shows the induction of Thr308 and Ser473 phosphorylation of
Akt/PKB after 5min of IGF-1 stimulation in HEK293 cells expressing wild
type IRS2 and this stimulation was decreased after 120min. In contrast, this
downregulation was impaired in the S573A mutant expressing cells. This data
suggest that phosphorylation of Ser573 negatively regulated IGF-1 signalling.
3.2.12 Ser573 is not the only IGF-1-dependent 14-3-3 bind-
ing site
The results of the overlay assay using the S573A mutant did not indicate a sec-
ond site relevant for insulin/IGF-1-dependent 14-3-3 binding to IRS2. However,
with a differential 14-3-3 affinity approach using insulin-stimulated HeLa cells
and the yeast 14-3-3 isoforms BMH1 and BMH2 as capture proteins, Dubois et
al. identified IRS2 as a 14-3-3 interaction protein and also identified an IRS2
derived peptide containing a phosphorylated serine corresponding to Ser556 [35]
by mass spectrometry. Our mass spectrometry experiment also identified a
phosphorylation site that corresponded to Ser556. As shown in Figure 3.11 the
S556A mutant did not show reduced binding of 14-3-3 in the overlay assay. Nev-
ertheless, to study the potential involvement of this site together with Ser573 in
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Figure 3.20: Ser573 influences phosphorylation of Akt/PKB. a) HEK293 cells transiently
expressing GFP-IRS2 or GFP-IRS2-S573A were stimulated with 50ng/ml IGF-1 for the in-
dicated time points. 40µg of total protein was separated on 7.5 % SDS gels and membranes
were incubated with GFP antibody to ensure equal expression levels and with p-Thr308 and
p-Ser473 antibody respectively. Corresponding Akt/PKB reblots are shown. b) Densitomet-
ric analysis of Akt/PKB phosphorylation. Black diamonds represent IRS2 wild type, white
squares IRS2-S573A mutant. Phosphorylation was normalized against total protein and IRS2
wild type protein stimulated with IGF-1 for 5min was set as 1 (mean ± SEM; n = 3; * p <
0.05 IRS2 120min vs. S573A 120min; IRS2 240min vs. S573A 240min).
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14-3-3 binding GST pulldown assays were applied, where cell lysates were mixed
with GST tagged 14-3-3β or 14-3-3. Western blot membranes were incubated
with GST antibody to ensure equal pulldown and with GFP to visualize the
amount of protein that interacted with GST-14-3-3. First, the GST pulldown
was applied for the single Ser573 to alanine mutant of IRS2 to confirm Ser573 as
14-3-3 binding site.
GFP 
GFP 
GST 
GST 
pulldown: 
GST-14-3-3β 
pulldown:  
GST-14-3-3ε 
IGF-1 
wortmannin 
GFP-IRS2-
S556A/S573A 
- + + 
- - + 
GFP-IRS2 GFP-IRS2-
S573A 
- + + - + + 
- - + - - + 
b) a) 
Figure 3.21: Ser573 is not the only IGF-1-dependent 14-3-3 binding site. a) and b) GFP-
IRS2, GFP-IRS2-S573A and GFP-IRS2-S556A/S573A were expressed transiently in HEK293
cells and cells were stimulated with 50ng/ml IGF-1 for 30min or after preincubation with
100nM wortmannin for 30min. Lysates were incubated with 2µg GST-14-3-3β or  for 2h.
Samples were separated on 7.5 % SDS gels and membranes were probed with GFP and GST
antibodies.
Unexpectedly, Figure 3.21a shows that the GST pulldown experiments still
resulted in interaction of IRS2-S573A with 14-3-3 in contrast to the results of
the overlay assays. The interaction was also not reduced using the single S556A
mutant (data not shown) and also the double GFP-IRS2 mutant S556A/S573A
failed to disrupt 14-3-3 binding (Figure 3.21b).
Together, these results may either reflect restrictions of the GST pulldown
in the context of the protein constructs of IRS2 and 14-3-3 or give a hint for
an additional binding site of 14-3-3 in IRS2 that does not influence the binding
detectable in the overlay assay but the binding visualized in the GST pulldown.
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3.3 cAMP-mediated 14-3-3 interaction with IRS2
With the kinase panel assay (Figure 3.1) forskolin and H89 were identified as
modulators of 14-3-3 binding to IRS2. The interaction was induced by the
adenylylcyclase activator forskolin. Increased cAMP levels activate PKA and
compound H89 inhibits PKA. The second aim of this thesis was to identify
the cAMP/PKA-dependent phosphorylation sites on IRS2 and the biological
outcome of this interaction. First, the kinase panel data were reproduced to
verify the cAMP-dependence of 14-3-3 binding to IRS2. Beside forskolin the cell-
permeable cAMP analogue CPT-cAMP (8-(4-chlorophenylthio) adenosine 3’,5’-
cyclic monophosphate) was used to trigger 14-3-3 binding to IRS2. HEK293 cells
transiently expressing GFP-IRS2 were incubated with forskolin or CPT-cAMP
alone or after preincubation with H89.
14-3-3-HRP 
IRS2 
forskolin 
H89 
b) a) 
H89 
CPT-cAMP 
14-3-3-HRP 
IRS2 
- + + - + + 
- - + - - + 
Figure 3.22: 14-3-3 interacts with IRS2 upon elevated cAMP levels. a) and b) HEK293 cells
were transiently transfected with GFP-IRS2, starved for serum and incubated with 20µM
forskolin or 100µM CPT-cAMP for 30min or with 30µM H89 for 30min prior forskolin/CPT-
cAMP stimulation. a) 200µg total protein were pulled down and sample was divided in two
equal volumes and separated by SDS-PAGE. One membrane was used for overlay assay, the
other one was directly incubated with IRS2 antibody as expression and loading control. b)
200µg of total protein were pulled down and after overlay assay membrane was stripped and
reprobed with IRS2 antibody as expression and loading control.
Forskolin as well as CPT-cAMP stimulation led to increased binding of 14-3-3
to IRS2 and this interaction was completely abolished when cells were pretreated
with compound H89. H89 is described as PKA inhibitor, although it inhibits
other kinases like MSK1 (mitogen- and stress-activated protein kinase 1), S6K1
or ROCK-II (Rho-associated protein kinase II) with a similar potency [30]. The
potential additional inhibition of other kinases was of minor relevance in the per-
formed experiments due to the fact that they are not cAMP-dependent. Since
phosphorylation of serine/threonine residues is a prerequisite for 14-3-3 binding
in most cases, further experiments were conducted to confirm that the observed
effect by overlay assay was mediated by phosphorylation of IRS2 on PKA mo-
tifs. For this, an experimental tool to monitor PKA-dependent phosphorylation
of IRS2 was searched.
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3.3.1 The PKA substrate antibody as a convenient tool
for the identification of PKA phosphorylation sites
on IRS2
The PKA substrate antibody from Cell Signalling Technology R© provided the
possibility to monitor PKA-dependent phosphorylation of IRS2. The antibody
is advertised to recognize PKA phosphorylation sites and was tested for its
suitability before the actual experiments.
The PKA substrate antibody
A peptide containing an arginine at position -3 relative to a phosphorylated
serine or threonine was used to generate the PKA substrate antibody. It rec-
ognizes the following motifs: RXXpS or RXXpT (X denotes any amino acid
and pS or pT indicates the phosphorylated serine or threonine). This enables
the antibody to identify substrates of the AGC (arginine-directed) kinase family
that comprises PKA, Akt/PKB, PKC, ROCK-II and CamK (Ca2+/Calmodulin-
dependent kinases). When the recognition motifs of the AGC kinases were com-
pared with 14-3-3 binding motifs it became obvious that the motifs show partial
sequence accordance. The AGC kinases had the probability to phosphorylate
serine or threonine residues which resided in 14-3-3 binding motifs on IRS2. Ta-
ble 3.4 shows the recognition motifs of Akt/PKB and PKA and the two 14-3-3
binding motifs.
Table 3.4: Presentation of the recognition motifs of Akt/PKB, PKA and 14-3-3 (R - arginine;
X - any amino acid; F - phenylalanine; Y - tyrosine; P - proline; φ - bulky, hydrophobic residue)
Akt/PKB R X R X X S/T φ
PKA R X X S/T
14-3-3 mode I R S X S/T X P
14-3-3 mode II R F/Y X S/T X P
The recognition motifs for Akt/PKB and PKA show partial concordance
in the arginine at postion -3 relative to the phosphorylated serine/threonine.
Due to the fact that the PKA substrate antibody was raised to recognize argi-
nine at -3 from a phosphorylated serine or threonine and the knowledge that
insulin/IGF-1 stimulation led to activation of the PI 3-kinase pathway with
subsequent Akt/PKB activation resulting in phosphorylation of Ser573 of IRS2
and possibly other sites as well, the antibody had to be evaluated if it could
distinguish between PKA and IGF-1-mediated phosphorylation of IRS2.
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Forskolin stimulation induces phosphorylation of IRS2 detected by
the PKA substrate antibody
In a first test (Figure 3.23) it was evaluated what the PKA substrate antibody
detected when cells were incubated with forskolin and H89. Therefore HEK293
cells transiently expressing either GFP as control or GFP-IRS2 were starved
for serum and stimulated afterwards with forskolin or after preincubation with
H89.
GFP GFP-IRS2 GFP GFP-IRS2 
PKA substrate antibody GFP 
- 
- - 
+ + 
+ 
- 
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+ + 
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- 
- - 
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- - 
+ + 
+ 
forskolin 
H89 
Figure 3.23: PKA substrate antibody recognizes phosphorylation on IRS2 after forskolin
stimulation. HEK293 cells were transfected transiently with a vector containing either GFP or
GFP-IRS2. 48h later cells were stimulated with 20µM forskolin for 30min or after incubation
with 30µM H89 for 30min. Samples were loaded twice (40µg lysate/lane) on a 7.5 % SDS
gel and after western blot the membrane was cut in halve as indicated by the vertical line.
The left part was incubated with PKA substrate antibody, the right membrane with GFP
antibody. Experiment was performed once.
The left membrane was incubated with the PKA substrate antibody, the
right membrane was incubated directly with the GFP antibody to have a control
where GFP-IRS2 migrated in the SDS gel. It can be clearly seen that the
antibody detected several PKA sites in several proteins of the cell lysates, but
there was only one prominent band at the same height where the corresponding
IRS2 band on the right side of the blot migrated. This band was only seen in
the forskolin-treated sample, indicating that forskolin induced phosphorylation
of one or more serine/threonine sites on the IRS2 molecule and that these sites
did not appear when PKA was inhibited by H89 treatment.
IGF-1-induced phosphorylation of IRS2 is not recognized by the PKA
substrate antibody
To test if the PKA substrate antibody could distinguish between IGF-1 stim-
ulation and PKA-mediated phosphorylation of IRS2, HEK293 cells transiently
expressing GFP-IRS2 were stimulated with IGF-1 or forskolin.
Samples were loaded twice onto a SDS gel and the left membrane was incu-
bated with PKA substrate antibody, whereas the right membrane was incubated
with GFP antibody. The western blot in Figure 3.24 showed the expected signal
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Figure 3.24: IGF-1-induced phosphorylation of IRS2 is not recognized by PKA substrate
antibody. HEK293 cells transiently expressing GFP-IRS2 were incubated for 30min with
20µM forskolin, 50ng/ml IGF-1, 30µM H89 or 100nM wortmannin as indicated. 30µg of
total protein was separated on 7.5 % SDS gel and membrane was cut in halve as indicated by
the vertical line. Left side of the membrane was incubated with PKA substrate antibody, the
right side with GFP antibody. Experiment was performed once.
on IRS2 caused by forskolin and no relevant signals from the samples treated
with IGF-1. Reduced expression of GFP-IRS2 in the H89 pretreated samples
was not only seen in this blot but appeared frequently in the experiments. This
phenomenon will be explained later in subsection 4.3.2. From the experiments
shown in Figure 3.23 and Figure 3.24 it was concluded that the PKA substrate
antibody only detected forskolin-induced serine/threonine phosphorylation on
IRS2 and therefore was suited for the experiments concerning the identification
of PKA phosphorylation sites on IRS2.
3.3.2 PKA-mediated phosphorylation of IRS2 is not influ-
enced by Akt/PKB or kinases of the MAPK path-
way
Akt/PKB and PKA show overlapping recognition motifs and regulation of
Akt/PKB activity by cAMP has been described before [224]. To rule out a pos-
sible influence of Akt/PKB on cAMP-dependent phosphorylation of IRS2, cells
transiently expressing GFP-IRS2 were stimulated with IGF-1 and the Akt/PKB
inhibitor Akti. After GFP pulldown the membrane was incubated with PKA
substrate antibody.
In Figure 3.25 successful IGF-1 stimulation is shown as phosphorylation of
Thr308 of Akt/ PKB, but this did not lead to phosphorylation of sites recognized
by the PKA substrate antibody. As a read-out for stimulation with forskolin
phosphorylation of Ser157 of VASP (vasodilator-stimulated protein) was moni-
tored. Only stimulation with forskolin led to phosphorylation of PKA sites on
IRS2 and pretreatment of cells with the Akt/PKB inhibitor had no influence.
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Figure 3.25: Akt/PKB has no influence on forskolin-stimulated phosphorylation of IRS2.
GFP-IRS2 was transiently expressed in HEK293 cells and cells were incubated for 30min with
20µM forskolin or 50ng/ml IGF-1. Incubation with 1µM Akti was performed 30min prior
IGF-1/forskolin stimulation. GFP-IRS2 was precipitated from 200µg total protein and mem-
brane was incubated with PKA substrate antibody. Phosphorylation of Thr308 of Akt/PKB
was assessed as IGF-1 stimulation control and phosphorylation of Ser157 of VASP as forskolin
stimulation control. Corresponding IRS2 and Akt/PKB reblots are also shown.
ERK has been shown to phosphorylate IRS2 [48] and kinases downstream of
ERK (e.g. p90RSK) could probably also influence cAMP-dependent phosphory-
lation of IRS2. To exclude this, HEK293 cells transiently expressing GFP-IRS2
were pretreated with MEK1 inhibitor PD98059 before forskolin treatment. GFP
pulldown followed incubation of the membrane with the PKA substrate anti-
body. The results of this experiment are depicted in Figure 3.26.
PD98059 
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Figure 3.26: MAPK pathway kinases have no influence on forskolin-stimulated phosphory-
lation of IRS2. GFP-IRS2 was transiently expressed in HEK293 cells and cells were incu-
bated for 30min with 20µM forskolin or 100ng/ml EGF. Cells were incubated with 50µM
PD98059 for 30min prior EGF/forskolin stimulation. GFP-IRS2 was precipitated from 200µg
total protein and membrane was incubated with PKA substrate antibody. Phosphorylation
of Thr202/Tyr204 of ERK was monitored as control for successful EGF stimulation. Corre-
sponding IRS2 and ERK reblots are also shown.
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MEK1 inhibitor PD98059 did not influence cAMP-dependent phosphory-
lation of PKA sites on IRS2. Moreover, stimulation with EGF as an activator
of the MAPK pathway did not lead to phosphorylation of sites recognized by
the PKA substrate antibody. As a positive control for EGF stimulation phos-
phorylation of ERK on Thr202 and Tyr204 was assessed.
To conclude, these results indicated a regulated interaction between IRS2
and 14-3-3 upon elevated cAMP levels and this interaction may be mediated by
phosphorylation of IRS2 on PKA sites.
3.3.3 Investigation of IRS2 and its fragments by overlay
assay and PKA substrate antibody leads to opposing
results
To locate the PKA-dependent 14-3-3 binding region on IRS2 the already de-
scribed fragments of IRS2 were transfected transiently in HEK293 cells and
tested for residual 14-3-3 binding after stimulation with forskolin and H89.
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Figure 3.27: Overlay assay from IRS2 wild type and fragments after forskolin and H89 stim-
ulation. HEK293 cells were transiently transfected with GFP-IRS2 wild type or fragments
GFP-IRS2-1-300, GFP-IRS2-1-600, GFP-IRS2-301-1321 and GFP-IRS2-601-1321. Stimula-
tion with 20µM forskolin for 30min and with 30µM H89 prior forskolin stimulation followed
pulldown of 200µg of total protein and samples were divided in two equal volumes and sepa-
rated on 5-15 % gradient gel. Membranes were incubated either with 14-3-3-HRP for overlay
assay or with GFP as expression and loading control.
Wild type IRS2 showed binding of 14-3-3 in the serum starved condition
and after forskolin stimulation, but was completely blocked by inhibiting PKA
activity with H89. Fragment 1-300 did not show any binding at all, whereas
fragment 1-600 displayed a similar binding pattern compared to wild type IRS2.
For the fragments 301-1321 and 601-1321 a regulated binding of 14-3-3 to IRS2 in
the forskolin-stimulated condition was detected, which was completely abolished
when cells were pretreated with H89. Based on these results it was concluded
that PKA-mediated 14-3-3 binding of IRS2 occurred somewhere after position
300. The different signal intensities from the fragments in the overlay assay
were caused by the unequal expression of GFP-IRS2 and the fragments thereof.
The fragments showed a differential expression pattern on western blot (see
Figure 3.28), although the same amount of plasmid DNA was used to transfect
the cells. This had been observed before, when the IGF-1-mediated 14-3-3
binding to IRS2 had been investigated (Figure 3.9).
To verify the overlay data shown in Figure 3.27 with the PKA substrate
antibody, the experiment was repeated and the membrane was incubated with
the PKA substrate antibody (Figure 3.29).
The PKA substrate antibody gave comparable results concerning GFP-IRS2,
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Figure 3.28: Cell lysates from transiently transfected IRS2 wild type and fragments. Lysates
were prepared as described in Figure 3.27. 20µg of total protein was separated on 5-15 %
gradient gel and membrane was incubated with GFP antibody. The arrow indicates a longer
exposure time.
fragment 1-300, fragment 301-1321 and fragment 601-1321. A clear difference
compared to the overlay data was observed with fragment 1-600 since the PKA
substrate antibody detected no signal in any condition. This opposing result
for the fragments led to the following hypothesis: a serine or threonine between
amino acids 300-600 was probably phosphorylated constitutively or phosphory-
lated by another kinase than PKA, and resided within a 14-3-3 binding motif
which explained the overlay assay data. The residue(s) that can be phosphory-
lated by forskolin stimulation and recognized by the PKA substrate antibody
are located behind amino acid position 601.
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Figure 3.29: Detection of GFP-IRS2 wild type and fragments with PKA substrate antibody.
HEK293 cells were transiently transfected with GFP-IRS2 or GFP-IRS2-1-300, GFP-IRS2-1-
600, GFP-IRS2-301-1321 and GFP-IRS2-601-1321. Cells were incubated with 20µM forskolin
for 30min or after preincubation with 30µM H89 for 30min. 100µg of total protein was
used for GFP pulldown, samples were separated on a 5-15 % SDS gel and membrane was
incubated with PKA substrate antibody. Stripping of the membrane followed reprobing with
GFP antibody as expression and loading control.
3.3.4 GST pulldown experiments to further elucidate 14-
3-3 binding to IRS2
The opposing results from subsection 3.3.3 led to the application of GST pull-
down experiments as another methodic approach than the overlay assay to in-
vestigate which fragments were capable of interacting with a GST-14-3-3 fusion
protein. HEK293 cells were transfected transiently with GFP-IRS2 wild type
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and fragments, stimulated with forskolin and H89 and lysates were incubated
with either GST-14-3-3 isoform β or . Membranes were incubated with GST
antibody to ensure equal pulldown and with GFP antibody to visualize inter-
action between GST-14-3-3 and IRS2 fragments.
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Figure 3.30: GST pulldowns from GFP-IRS2 wild type and fragments. HEK293 cells were
transfected transiently with GFP-IRS2 or fragments GFP-IRS2-1-300, GFP-IRS2-1-600, GFP-
IRS2-301-1321 and GFP-IRS2-601-1321. Cells were stimulated with 20µM forskolin for 30min
or with 30µM H89 for 30min prior forskolin stimulation. 250µg of total protein was incubated
with GST-14-3-3β or  and samples were separated on 5-15 % gradient gels and membranes
were incubated with GFP and GST antibody.
Wild type IRS2 interacted nicely with the GST-14-3-3 fusion proteins upon
stimulation with forskolin and this interaction was completely inhibited when
cells were treated with H89 prior forskolin stimulation. Comparable to the over-
lay assay data did the GST-14-3-3 fusion proteins not at all interact with the
fragment 1-300. Fragment 1-600 showed increased interaction upon forskolin
stimulation and reduced interaction by H89 pretreatment in contrast to the
overlay data, where only an unregulated binding in every condition was ob-
servable. Fragments 301-1321 and 601-1321 showed similar results compared
to the overlay data. The GST pulldowns supported the hypothesis drawn in
subsection 3.3.3 that in the amino acid area 300-600 a serine/threonine residue
resided in a 14-3-3 binding motif. This residue was phosphorylated in the basal
state, forskolin stimulation could increase its phosphorylation and compound
H89 could block this phosphorylation, hence reduce binding of 14-3-3 in the
GST pulldown. In addition did the GST pulldown verify the finding that a
PKA-dependent phosphorylation site on IRS2 resides behind amino acid posi-
tion 601 and the phosphorylation of this serine/threonine residue is important
for 14-3-3 binding.
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3.3.5 Generation of fragment 601-952 to further narrow
down the PKA-dependent 14-3-3 binding region
Due to the fact that the area from amino acids 601-1321 still comprised 720
amino acids another fragment was generated to further narrow down the area
for forskolin-dependent 14-3-3 binding. The additionally generated fragment is
shown together with the already described fragments in Figure 3.31.
PH PTB KRLB N C 
31 140 191 294 591 735 
1-300 GFP 
601-1321 GFP 
1-600 GFP 
301-1321 GFP 
GFP 601-952 
Figure 3.31: Scheme of IRS2 fragments used for identification of the PKA-dependent 14-3-3
binding region. Shown are 5 fragments of IRS2 according to mouse numbering. All fragments
were GFP-tagged at the N-terminus.
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Figure 3.32: Detection of GFP-IRS2 and fragments with PKA substrate antibody after
GFP pulldown. HEK293 cells were transfected transiently with GFP-IRS2, GFP-IRS2-1-300,
GFP-IRS2-1-600, GFP-IRS2-301-1321, GFP-IRS2-601-1321 or GFP-IRS2-601-952. Starva-
tion for serum followed incubation with 20µM forskolin for 30min or after preincubation with
30µM H89 for 30min. After cell lysis 100µg of protein was used for GFP pulldown and af-
ter separation on a 7.5 % SDS gel membrane was incubated with PKA substrate antibody.
Stripping of the membrane followed reprobing with GFP antibody as expression and loading
control.
Again, fragments and wild type IRS2 were expressed transiently in HEK293
cells, stimulated with forskolin and H89, followed by GFP pulldown and incuba-
tion of the membranes with PKA substrate antibody (Figure 3.32). The PKA
substrate antibody did not recognize any signal in the fragment GFP-IRS2-601-
952.
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To test if fragment GFP-IRS2-601-952 also did not interact with 14-3-3 a
GST pulldown assay was performed to test for residual 14-3-3 binding. Frag-
ments were transfected transiently in HEK293 cells and after stimulation with
forskolin and H89 GST pulldowns were performed. A representative blot for
pulldown with GST-14-3-3β is shown in Figure 3.33.
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Figure 3.33: GST pulldown of IRS2 wild type and fragments including fragment 601-952.
HEK293 cells were transfected transiently with GFP-IRS2 wild type or fragments, stimulated
with 20µM forskolin for 30min or after preincubation with 30µM H89 for 30min. Lysates
containing 250µg protein were incubated with 2µg GST-14-3-3β for 2h. After SDS-PAGE and
western blot membrane was incubated with PKA substrate antibody and stripped afterwards
for GFP reblot. Lower part of the membrane was incubated with GST antibody to ensure
equal pulldown.
Incubation with the PKA substrate antibody confirmed the presence of PKA
phosphorylation sites on IRS2. Fragment 601-952 could not interact with GST-
14-3-3β, thus the PKA substrate antibody could not detect a phosphorylation
on this fragment. From this experiment it was concluded that one or more
PKA-dependent phosphorylation site(s) on IRS2 were located behind amino
acid position 952.
3.3.6 Mass Spectrometry for the identification of poten-
tial PKA phosphorylation and 14-3-3 binding sites
In collaboration with the Institute for Experimental Ophtalmology in Tu¨bingen
mass spectrometry was applied to identify candidates for phosphorylation by
PKA. HEK293 cells were transfected transiently with GFP or GFP-IRS2 and
stimulated with forskolin or after preincubation with H89. GFP-IRS2 was puri-
fied from 5mg of total protein with the GFP Trap R© and run on a precast Bis-tris
mini gel. After staining with Coomassie the corresponding IRS2 bands were cut
and processed according to section 2.10 for mass spectrometric analysis.
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Figure 3.34: Coomassie staining of a SDS gel to cut bands for mass spectrometry. HEK293
cells were transfected transiently with GFP or GFP-IRS2, starved for serum and incubated
with 20µM forskolin for 30min or after preincubation with 30µM H89 for 30min. 5mg of total
protein were used for purification with GFP-TrapR©. Samples were run on a 4-12 % Bis-tris
mini gel and protein bands were visualized by staining with Coomassie G-250. The first lane
shows the molecular weight marker and the corresponding molecular weights are depicted on
the left side of the figure in kDa.
The Coomassie staining (Figure 3.34) showed successful purification of GFP-
IRS2 as can be seen by the prominent bands that migrated between 150 and
250kDa in the GFP-IRS2 lanes. Only the bands corresponding to IRS2 were
cut and analyzed by mass spectrometry for phosphorylated residues. Other
bands visible in the GFP and the GFP-IRS2 lanes indicate unspecific interac-
tions, but several bands are unique to the GFP-IRS2 lanes. These bands were
not analyzed by mass spectrometry but may represent interaction partners or
IRS2 degradation products. Three biological replicates were prepared, analyzed
and evaluated. The previous experiments with the different IRS2 fragments re-
vealed the region behind amino acid position 952 to contain one or more PKA
phosphorylation sites. That is why only sites that matched the following crite-
ria were considered for further testing: present in all three replicates, located
behind position 952, not present in the H89 pretreated sample, match the con-
sensus sequence for PKA (RXXpS) and match a 14-3-3 binding motif (mode
I: RSXpS/pTXP; mode II: RX(F/Y)XpS/pTXP). From that evaluation three
candidates emerged that are presented in Table 3.5.
Table 3.5: Sequences surrounding the potential PKA phosphorylation sites Ser1137, Ser1138
and Ser1163 are shown according to mouse IRS2 numbering.
Ser1137 1131GGRRRHSSETFSS1143
Ser1138 1131GGRRRHSSETFSS1143
Ser1163 1157NSKRHNSASVENV1169
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Of note, phosphorylated Ser1137 and Ser1138 could be found in peptides as
single phosphorylated residues but also doubly phosphorylated peptides contain-
ing phosphorylated Ser1137 and Ser1138 were detectable as shown in Figure 3.35.
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Figure 3.35: MS/MS analysis of a tryptic peptide. The peptide with the parent mass
(M+3H) = 951.4145 reveals a mass spectrum consisting of a single- and double-charged frag-
ment mass (preferably ions most relevant to phosphorylation sites are annotated) matching
the doubly phosphorylated IRS2 peptide sequence: RHpSpSETFSSTTTVTPVSPSFAHNSK.
When the surrounding amino acids of Ser1137 and Ser1138 were inspected it
became obvious that Ser1137 (GRRRHS1137SETFSS) and Ser1138 (GRRRHSS1138
ETFSS) could probably compensate for each other, because in the case of sub-
stitution of either residue with an alanine there would still be the same motif
present that could be recognized by PKA as shown in Table 3.6.
Table 3.6: Comparison of the recognition motif of the PKA substrate antibody with the
amino acids surrounding Ser1137 and Ser1138
PKA substrate ab R X X pS/pT
Ser1137 G R R R H Ser1137 Ser1138 E T F S
Ser1138 R R R H Ser1137 Ser1138 E T F S S
To exclude the possibility of compensation not only the single residues were
mutated to alanine, but also an additional double mutant S1137A/S1138A was
generated. Transient expression of GFP, GFP-IRS2, GFP-IRS2-S1137A, GFP-
IRS2-S1138A, GFP-IRS2-S1163A or GFP-IRS2-S1137A/S1138A in HEK293
cells followed stimulation with forskolin and H89, subsequent GFP pulldown
and incubation of the membrane with the PKA substrate antibody.
Figure 3.36 shows that the PKA substrate antibody only detected forskolin-
induced phosphorylation on GFP-IRS2 wild type and the GFP-IRS2-S1163A
mutant. This argued against Ser1163 as a PKA phosphorylation site and for
Ser1137 and Ser1138 as PKA phosphorylation sites. Due to the detection of a
peptide phosphorylated on both Ser1137 and Ser1138 residues and the PKA motif
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Figure 3.36: Mutation of Ser1137 and Ser1138 abolishes recognition by PKA substrate
antibody. HEK293 cells were transfected transiently with GFP, GFP-IRS2, GFP-IRS2-
S1137A, GFP-IRS2-S1138A, GFP-IRS2-S1163A, GFP-IRS2-S1137A/S1138A and incubated
with 20µM forskolin for 30min or after preincubation with 30µM H89 for 30min. 200µg total
protein were used for GFP pulldown, samples were separated on a 7.5 % SDS gel and after
western blotting the membrane was incubated with PKA substrate antibody. Stripping and
reprobing with IRS2 antibody was performed as expression and loading control.
still present in the single mutants GFP-IRS2-S1137A and GFP-IRS2-S1138A
the double mutant GFP-IRS2-S1137A/S1138A was used for further studies.
Sequence alignments, as shown in Table 3.7, of IRS2 protein sequences from
human, rat, mouse and frog revealed sequence conservation.
Table 3.7: Sequence alignment from different species in the area surrounding Ser1137/Ser1138.
Shown are the amino acid areas surrounding Ser1137 and Ser1138 from IRS2 in different
species: Homo sapiens (NP 003740.2), Mus musculus (NP 001074681.1), Rattus norvegicus
(NP 001162104.1), Xenopus laevis (AAH72768.1).
Mus musculus 1131GGRRRHSSETFSST1148
Rattus norvegicus 1133GGRRRHSSETFSST1151
Homo sapiens 1142GGRRRHSSETFSST1155
Xenopus laevis 957G-RRRHSSETFAS-
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3.3.7 Mutation of Ser1137 and Ser1138 on IRS2 reduces in-
teraction with 14-3-3
If Ser1137 and Ser1138 are important for cAMP-mediated interaction with 14-
3-3 proteins, mutation of these sites should reduce interaction. This hypothe-
sis was tested by expressing GFP-IRS2 and GFP-IRS2-S1137A/S1138A tran-
siently in HEK293 cells and subsequent stimulation with forskolin and H89
prior forskolin stimulation. Pulldown experiments were performed with either
GST-14-3-3 or GST-14-3-3β and membranes were incubated with GFP anti-
body to visualize the amount of protein that interacted with GST-14-3-3 (Fig-
ure 3.37a) and in Figure 3.37b the densitometric analysis of IRS2 interaction
with GST-14-3-3 is shown.
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Figure 3.37: Double mutant GFP-IRS2-S1137A/S1138A shows reduced binding to GST-
14-3-3. a) GFP-IRS2 and GFP-IRS2-S1137A/S1138A were expressed transiently in HEK293
cells and cells were either left untreated, stimulated with 20µM forskolin alone for 30min or
after preincubation with 30µM H89 for 30min. Lysates containing 250µg of total protein were
incubated with 2µg GST-14-3-3β or GST-14-3-3 for 2h and afterwards separated by 7.5 %
SDS PAGE. Transfer onto nitrocellulose membranes followed incubation with GFP antibody
to visualize the amount of protein that interacted with GST-14-3-3 and with GST to ensure
equal pulldown and loading. b) Densitometric analysis of pulldown with GST-14-3-3. GFP
signal intensities were normalized to GST and GFP-IRS2 stimulated with forskolin was set
as 1 (mean ± SEM, n = 3, * p < 0.05 GFP-IRS2 forskolin vs. GFP-IRS2-S1137A/S1138A
forskolin).
IRS2 wild type slightly interacted with both GST-14-3-3 and GST-14-3-3β
fusion proteins in the serum starved condition. Forskolin stimulation increased
the interaction and treatment of cells with H89 prior forskolin stimulation com-
pletely abolished it. The double mutant showed no interaction with GST-14-3-3
in the basal condition and minor interaction with GST-14-3-3β. There was also
an interaction detectable in the forskolin-treated samples, but the extent was
significantly reduced compared to IRS2 wild type.
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To further confirm these results co-immunoprecipitation assays were per-
formed where HEK293 cells were transiently transfected with GFP-IRS2 or
GFP-IRS2-S1137A/S1138A in addition with myc-tagged 14-3-3. Cells were sti-
mulated with forskolin and H89 and lysates were incubated with myc antibody.
Western blot membranes were incubated with myc antibody to ensure equal
immunoprecipitation and expression of myc and with GFP antibody to detect
co-precipitated GFP-IRS2 or mutant IRS2.
Figure 3.38a shows the results of the western blot analysis and the signal
intensities of GFP were normalized for myc and analyzed statistically in Fig-
ure 3.38b. The double mutant showed interaction with myc-14-3-3 to a very
much lesser extent compared to GFP-IRS2.
Taken together, it could be concluded that Ser1137/Ser1138 were crucial for
PKA-mediated interaction between IRS2 and 14-3-3.
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Figure 3.38: Co-immunoprecipitation of myc-14-3-3 and IRS2. a) HEK293 cells were tran-
siently co-transfected with GFP-IRS2 and myc-14-3-3γ or GFP-IRS2-S1137A/S1138A and
myc-14-3-3γ and were incubated with 20µM forskolin for 30min or after pretreatment with
30µM H89 for 30min. Lysates containing 200µg protein were incubated with myc antibody
and protein G sepharose for 3h at 4◦C. Samples were separated on 5-15 % SDS gels and after
western blotting membrane was incubated with GFP and myc antibody. b) Densitometric
analysis of co-immunoprecipitated GFP. Band intensities were normalized for myc and GFP-
IRS2 treated with forskolin was set as 1 (mean ± SEM, n = 3, * p < 0.05, GFP-IRS2 forskolin
vs. GFP-IRS2-S1137A/S1138A forskolin).
3.3.8 Forskolin stimulation prevents protein degradation
of IRS2 wild type but not of IRS2-S1137A/S1138A
Based on the strong effects of elevated cAMP levels on IRS2 protein amount [76]
a direct effect on IRS2 protein stability from forskolin-induced 14-3-3 binding
was hypothesized. Therefore, HEK293 cells stably expressing IRS2 were gener-
ated. The advantage of stable transfection is the continuous expression of the
desired protein at considerably lower levels than in transiently transfected cells,
thus preventing an obscuring of IRS2 protein half-life due to permanently high
expression levels.
IRS2 protein degradation in Flp-In HEK293 cells
Figure 3.39 shows the visualization of IRS2 protein degradation. For this, cells
were incubated with either cycloheximide to inhibit protein translation alone or
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in combination with forskolin for 1, 3 and 6h and the IRS2 protein content was
assessed by western blot.
After 3 and 6h of incubation with cycloheximide IRS2 protein content was
reduced by 80 %. Concomitant incubation with forskolin reduced IRS2 protein
content only by 25 %.
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Figure 3.39: IRS2 protein stability is increased upon forskolin stimulation in Flp-In HEK293
cells. a) Flp-In HEK293 cells stably expressing IRS2 were starved 3h for serum and incubated
with 25µg/ml cycloheximide (CHX) alone or in combination with 20µM forskolin (FSK) for 1,
3 and 6h. 10µg of total protein was separated on 7.5 % SDS gel and membrane was incubated
with IRS2 antibody. Detection of p-Ser157 of VASP was performed to ensure successful
stimulation and β-actin was detected as loading control and to enable normalization of IRS2
protein content. b) Densitometric analysis of IRS2 protein, IRS2 content from untreated cells
was set as 100 % (mean ± SEM, n = 8, * p < 0.05 CHX vs. CHX/FSK). White diamonds
represent treatment with CHX, black squares represent treatment with CHX and FSK.
IRS2 protein degradation in primary mouse hepatocytes
To evaluate if the results of the experiment in Figure 3.39 could be verified in a
system that is closer to the in vivo situation, the experiment was also performed
with primary mouse hepatocytes.
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Figure 3.40: Visualization of IRS2 protein degradation in primary hepatocytes. a) Hepato-
cytes were isolated from male C57Bl/6 mice, plated onto 6-well plates and starved for serum
overnight 24h later. Cells were incubated with 25µg/ml cycloheximide (CHX) alone for 1, 3
and 6h or in combination with 20µM forskolin (FSK). 100µg protein was separated by 7.5 %
SDS gel and membranes were incubated with antibodies against IRS2, p-Ser157 VASP and
β-actin. Experiment was performed once.
Similar to the results from the Flp-In HEK293 cells stably expressing IRS2,
IRS2 protein content decreased over time with cycloheximide treatment in pri-
mary hepatocytes. Additional incubation with forskolin prevented the IRS2
protein from degradation.
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Ser1137 and Ser1138 are important for increased IRS2 protein stability
upon PKA activation
Having identified Ser1137 and Ser1138 as important sites on IRS2 for phosphory-
lation by PKA and subsequent 14-3-3 binding the question arised if the IRS2
S1137A/S1138A double mutant is sensitive to PKA-dependent protein stabiliza-
tion. Therefore, Flp-In HEK293 cells were stably transfected with GFP-IRS2
or GFP-IRS2-S1137A/S1138A and incubated with cycloheximide and forskolin
for 1, 3 and 6h.
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Figure 3.41: Ser1137 and Ser1138 are crucial for IRS2 protein stability. a) Flp-In HEK293
cells were stably transfected with GFP-IRS2 or GFP-IRS2-S1137A/S1138A. Cells were starved
for serum and incubated with 25µg/ml cycloheximide (CHX) and 20µM forskolin (FSK) for 1,
3 and 6h. 50µg protein was separated on 7.5 % SDS gels and membranes were incubated with
IRS2 antibody, p-Ser157 VASP antibody as stimulation control and β-actin antibody as loading
control. b) Extent of IRS2 protein degradation was quantified by scanning immunoblots and
normalization of IRS2 signal intensities for β-actin. Untreated cells were set as 100 % (mean
± SEM, n = 4, * p < 0.05 GFP-IRS2 CHX vs. GFP-IRS2 CHX/FSK at 3h and 6h).
GFP-IRS2 wild type protein showed increased protein stability upon stimu-
lation with forskolin compared to the S1137A/S1138A mutant. Thus, the lack
of cAMP-dependent phosphorylation of IRS2 on Ser1137/Ser1138 abolished the
ability of forskolin to increase IRS2 protein stability.
Chapter 4
Discussion
IRS1 and IRS2 as intracellular signalling nodes contain numerous serine and
threonine residues beside tyrosine residues that can be modified by protein ki-
nases and protein phosphatases. Especially for IRS1 this has been shown ex-
tensively [201, 113, 159, 202, 200]. An increasing number of studies revealed the
importance of 14-3-3 proteins in controlling cellular processes like cell cycle, cell
growth, gene transcription and apoptosis as reviewed in [120, 105, 43, 49]. Less
is known about individual serine/threonine phosphorylation sites on IRS2, the
interaction of 14-3-3 with IRS2 and the influence on cellular metabolism. This
thesis aimed to characterize the interaction between 14-3-3 and IRS2.
Interaction of IRS1 and 14-3-3 has been investigated in some studies, but
with partially opposing results. Isotype- and cell line-specific differences may
account for the different results in the different publications. The overall ten-
dency seems to be a rather negative modulation of binding partners and sig-
nalling. Ogihara et al. identified three potential 14-3-3 binding sites on IRS1
[121]. Additional experiments led to the conclusion that 14-3-3 binding to IRS1
is not insulin-dependent since the amount of 14-3-3 bound to IRS1 was similar
with or without insulin stimulation in HepG2 cells, but co-immunoprecipitated
IRS1 was less phosphorylated on serine and tyrosine residues in comparison to
immunoprecipitated IRS1 alone. They suggested that 14-3-3 binding to IRS1
may regulate insulin sensitivity by interrupting IRS1 association with the in-
sulin receptor. On the contrary, Kosaki et al. described that 14-3-3β binds to
IRS1 in 3T3-L1 adipocytes and this interaction could be increased with insulin
stimulation [85]. Since PI 3-kinase isolated from a complex consisting of 14-3-
3β/IRS1/PI 3-kinase showed only half of the activity of PI 3-kinase isolated
from a complex of IRS1/PI 3-kinase by sequential immunoprecipitation, they
concluded an inhibitory function on PI 3-kinase activity. Oriente et al. de-
scribed a regulatory function of 14-3-3 in 3T3-hIR cells [123]. In this study the
authors showed that upon insulin stimulation a multimolecular complex consist-
ing of IRS1, PKCα and 14-3-3 is formed, in which 14-3-3 is not necessary for
the formation of the complex, but for regulating the function of PKCα. Capraro
et al. showed in vitro interaction of 14-3-3 with the IGF-1 receptor and IRS-1,
but not the insulin receptor [26] and Xiang et al. demonstrated a role for 14-3-3
binding to IRS-1 in intracellular trafficking of IRS-1 [211].
A clear role for IRS1 and 14-3-3 interaction cannot be established from these
publications, thus extrapolating a possible outcome for the interaction between
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IRS2 and 14-3-3 can not be made. This stresses the importance of the general
characterization of IRS2 and 14-3-3 interaction. The IRS2/14-3-3 interaction
has been documented in large-scale proteomic studies, but only as one of many
interaction partners without any further characterization [39, 77, 109]. Ogihara
et al. showed interaction of overexpressed IRS2 and 14-3-3 in Sf9 cells [121] and
Dubois et al. showed IRS2 as 14-3-3 interaction partner upon IGF-1 stimulation
involving the PI 3-kinase pathway in HEK293 cells [35].
This thesis aimed to characterize the insulin/IGF-1-dependent 14-3-3 bind-
ing to IRS2 and to discover additional, novel modulating stimuli. Elevated
cAMP levels could be identified as novel modulator of 14-3-3 binding to IRS2. As
in the results section the first part of the discussion is dealing with insulin/IGF-
1-dependent 14-3-3 binding to IRS2 and the second part is concentrating on the
cAMP-dependent 14-3-3 binding to IRS2.
4.1 Application of truncated proteins as a help-
ful tool to track down important binding re-
gions
IRS2 contains > 100 serine/threonine residues and since 14-3-3 binding motifs
do not necessarily conform to the exact consensus sequence described by Yaffe
et al. and Rittinger et al. it was reasonable to narrow down the area of 14-3-3
binding and then search within that area for the exact binding sites [214, 136].
The time consuming generation of random single alanine mutations would have
been unreasonable. Although very artificial, truncated versions of the IRS2
protein transiently transfected in HEK293 cells were expressed quite well and
were folded properly enough that Ser1137/Ser1138 could be recognized by PKA.
Truncated versions of proteins are used regularly to identify binding regions as
shown by [121, 64, 152].
4.2 Insulin and IGF-1-dependent interaction be-
tween 14-3-3 and IRS2
4.2.1 Identification of phosphorylated serine/threonine re-
sidues on IRS2
The mouse IRS2 sequence was used to identify possibly novel and already de-
scribed phosphorylation sites on IRS2. Mass spectrometric analysis revealed 24
phosphorylated serine/threonine residues and a sequence alignment of mouse
and human IRS2 showed that these sites seem to be conserved in human IRS2
as well. Certain sites could also be found in the mouse and human IRS1 sequence
with a high degree of conservation. Due to the high sequence conservation be-
tween IRS2 in different species and with the IRS1 amino acid sequence, the
literature and internet databases were screened for any possible reported phos-
phorylation site that was also identified in the mass spectrometric approach
described in this thesis. The IRS2 protein sequence was scanned for modified
residues by using the online tool PhosphositePlus R©1. This database shows if a
1http://www.phosphosite.org
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modified site or a homologue of it was already reported. It distinguishes between
records where the sites were experimentally determined with site-specific meth-
ods, or if the site was assigned by proteomic discovery-mode mass spectrometry.
Ser66, Ser968, Ser977, Ser999 and Ser1266 were not found in this Scan, whereas
Ser303, Ser305, Thr347, Ser385, Ser388, Thr401, Thr517, Ser556, Ser573, Ser675,
Ser722, Ser727, Ser728, Ser762, Ser907, Ser1089, Ser1151, Ser1165 and Ser1190 were
listed. However, beside Thr347 all sites were identified in big mass spectromet-
ric screens without any further confirmation and some sites were not annotated
themselves but the homologue of human or rat IRS2. Of note, several addi-
tional sites that were not identified in this mass spectrometric approach are
listed on the PhosphositePlus R© website. Reported homologues are described in
the following passage.
Ser303 of mouse IRS2 has a homologue in the human IRS1 sequence – Ser270.
This site has been described as substrate for S6K1 and as part of TNFα-induced
insulin resistance [222]. Thr347 of mouse IRS2 has a homologue in mouse IRS1
that is Thr306. This site has not been experimentally described, but it is located
next to Ser307 which has been shown to be phosphorylated by JNK, S6K1 and
mTOR [59, 28, 202, 201]. One could speculate that since IRS1 Ser307 seems to
play an important role in insulin signalling maybe Thr347 of IRS2 could be an
important residue as well. And indeed, Solinas et al. showed phosphorylation
of the rat IRS2 homologue Thr348 by JNK and suggest that this residue might
be equivalent to Ser307 of mouse/rat IRS1 [172]. Ser573 was identified and char-
acterized as insulin/IGF-1-dependent phosphorylation and 14-3-3 binding site
in this thesis. Ser522 is the mouse IRS1 homologue to Ser573 and was exper-
imentally described and characterized by Giraud et al. [53]. Phosphorylation
of Ser675 and Ser907 after insulin stimulation has already been described by
Fritsche et al. from our lab [48]. The mutation of Ser675 to alanine led to
an increased protein stability of IRS2 and phosphorylation of this site could
be mediated by mTOR. Ser675 has an IRS1 homologue – Ser632 in mouse/rat
IRS1 and Ser636 in human IRS1. Mouse IRS1 Ser632 has been shown to be
phosphorylated by ERK [59, 104], ROCK I [92] and to modulate PI 3-kinase
activity together with Ser612 [113]. Tzatsos et al. showed the phosphorylation
of human IRS1 Ser636 by mTOR [189]. Phosphorylation of human IRS1 Ser636
was increased in myotubes from patients with diabetes [21] and also in muscle
biopsies of insulin-resistant offspring of type II diabetic parents [111]. The IRS2
Ser762 homologue in mouse IRS1 – Ser731 was shown to modulate PI 3-kinase
activity together with Ser662 [113] and was required together with Ser632 and
Ser662 for negative regulation by PDGF (platelet derived growth factor) [94].
Ser907 was shown to be phosphorylated by ERK [48].
For an overview of the just described homologue residues see Table 4.1 and
the complete sequence alignment of mouse and human IRS1 and IRS2 with
indication of the identified modified residues by mass spectrometry can be found
in Figure A.5.
Taken together, with a sequence coverage of 92 % the mass spectrometric
analysis was very successful and suitable to identify several phosphorylated re-
sidues that have already been listed in big mass spectrometric approaches. The
corresponding residues in IRS1 do have an important influence on the intracel-
lular signalling cascade. It is therefore of uttermost importance to investigate
the corresponding IRS2 serine/threonine residues since a biological impact of
these sites is also very likely.
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Table 4.1: Experimentally reported serine/threonine residues of IRS1 and IRS2, that were
also identified in the mass spectrometric approach for identification of IGF-1-dependent phos-
phorylation sites on mouse IRS2.
mouse
IRS2
Corresponding
residue
Description Reference
Ser303 human IRS2 Ser270 S6K1 substrate [222]
Thr347 next to mouse/rat
IRS1 Ser307
JNK/S6K1/mTOR
substrate
[59, 28, 202, 201]
Thr347 rat IRS2 Thr348 JNK substrate [172]
Ser573 mouse/rat IRS1
Ser522
Akt/PKB substrate [53]
Ser675 mouse/rat IRS1
Ser632
ERK/ROCK I substrate [59, 104, 92]
Ser675 mouse/rat IRS1
Ser632 together with
Ser612
modulation of PI 3-kinase
activity
[113]
Ser675 human IRS1 Ser636 mTOR substrate [189]
Ser675 human IRS1 Ser636 MAPK-dependent,
increased in T2D patients
[21]
Ser675 human IRS1 Ser636 increased in muscle from
insulin-resistant offspring
of T2D
[111]
Ser762 mouse/rat IRS1
Ser731 together with
Ser662
modulation of PI 3-kinase
activity
[113]
Ser762 mouse/rat IRS1
Ser731
PDGF-dependent [94]
4.2.2 Regulation and function of insulin/IGF-1-dependent
14-3-3/IRS2 interaction
The kinase panel assay revealed increased binding of 14-3-3 to transiently ex-
pressed IRS2 upon IGF-1 stimulation. Co-immunoprecipitation of endogenous
expressed 14-3-3 also showed an increased interaction with IRS2 after IGF-1
stimulation (Figure 3.3). Overlay assays performed on IRS2 immunoprecipi-
tates from insulin-stimulated Fao rat epatoma cells which expressed IRS2 en-
dogenously (Figure 3.2) and from insulin-treated and refed mice (Figure 3.4
and Figure 3.5) confirmed this data and implicated a physiological occurrence
with potentially important consequences. The dependence on the PI 3-kinase
pathway was demonstrated by two chemically different PI 3-kinase inhibitors
− PI-103 and wortmannin. PI-103 is an ATP-competitive inhibitor targeting
the catalytic subunit p110 of PI 3-kinase. Wortmannin irreversibly inhibits
PI 3-kinase since it covalently binds in the ATP binding site of p110. According
to Bain and co-workers PI-103 and wortmannin are recommended to inhibit PI
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3-kinase in biological processes [14].
From all five tested single alanine mutants only mutation of Ser573 to ala-
nine did abrogate the 14-3-3 interaction with IRS2 in the overlay assay (Fig-
ure 3.11). This result could be confirmed in Flp-In HEK293 cells stably express-
ing the S573A mutant (Figure 3.12). Ser573 and the surrounding amino acids
(RKRTYS573LTT) do not completely conform to a 14-3-3 binding motif with
the lack of proline at position +2 relative to the phosphorylated serine being
the most prominent feature to be different. However, a proline in position +2
is found in only 50 % of the target sites as has been reported by Johnson et
al. [79]. In addition, if the target sequence would match the consensus motif
completely, the strength of binding would not give appropriate regulation of
this protein [6]. The antibody against phosphorylated Ser573 of mouse IRS2 was
indispensable for the characterization of the phosphorylation site. Experiments
with the S573A mutant revealed the specificity of the antibody for the sequence
LRKRTYpS573LTTPAR (Figure 3.13). Although the antibody worked quite
well in transiently and stably transfected HEK293 and Flp-In HEK293 cells it
was not possible to detect increased Ser573 phosphorylation in mouse liver by
western blot (data not shown). Of note, when the antibody was used to im-
munoprecipitate IRS2 phosphorylated on Ser573 from total cell lysates as shown
in Figure 3.16 or from mice liver protein lysates (data not shown), it became
evident that the antibody failed to precipitate increased amounts of phosphory-
lated Ser573 upon insulin or IGF-1 stimulation. This discrepancy cannot be fully
explained since attempts with non-phosphorylated peptides to block unspecific
binding during the immunoprecipitation process in the reaction tube were not
successful (data not shown) and in addition the antibody as polyclonal anti-
body was already purified for the phosphopeptide. To conclude, the Ser573
antibody was specific for phosphorylated Ser573 and when used for western blot
was able to detect increased Ser573 phosphorylation of IRS2 upon stimulation
with insulin or IGF-1, but when the antibody was used for immunoprecipitation
increased amounts of IRS2 protein in insulin- or IGF-1-stimulated samples were
not observable.
The phosphorylation of Ser573 was increased upon insulin/IGF-1 stimulation
in a PI 3-kinase-Akt/PKB-dependent manner, thus under the same conditions
when the 14-3-3/IRS2 interaction occured. Notably, pharmacological inhibi-
tion of PI 3-kinase using wortmannin or PI-103 or inhibition of Akt/PKB using
Akti-1/2 prevented the enhanced phosphorylation of Ser573 (Figure 3.18) and
the increased 14-3-3 binding of IRS2 (Figure 3.19). Phosphorylation of Ser573 of
mouse IRS2 with insulin and IGF-1 stimulation and also phosphorylation of the
corresponding residue Ser577 in human IRS2 could be observed (Figure 3.14). A
time course of Ser573 phosphorylation in Fao cells showed peak phosphorylation
levels after 60, 90 and 120 min of insulin treatment (Figure 3.17). A physiolog-
ical importance of Ser573 is suggested by the fact that sequence alignments of
different mammalian species showed complete sequence accordance, and even
an amphibian sequence showed partial accordance (Table 3.2).
Akt/PKB is one of the key serine/threonine kinases downstream of PI 3-
kinase and is essential for adequate stimulation of glycogen synthesis in skeletal
muscle. Paz et al. described Akt/PKB phosphorylation of IRS1 as a posi-
tive regulatory mechanism, since phosphorylation by Akt/PKB protected IRS1
from rapid dephosphorylation of tyrosine residues, thus maintaining tyrosine-
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phosphorylated conformation of IRS1 [126]. They searched the IRS1 sequence
for potential Akt/PKB recognition motifs and generated a mutant where Ser265,
Ser302, Ser325 and Ser358 of mouse IRS1 were mutated to alanine and phosphory-
lation of this mutant by Akt/PKB was markedly inhibited. A scan of the IRS1
mouse sequence with the online tool Motif Scan2 showed Ser265, Ser302, Ser325
and Ser522 as Akt/PKB site. Ser522 was identified by Giraud et al. a few years
later as potential Akt/PKB target [53]. They showed insulin-dependent phos-
phorylation of Ser522 in L6 myoblasts and myotubes and provided evidence for
a negative role of Ser522 in insulin signalling. Online tools to predict possible
recognition motifs for kinases can be very helpful, but loss-of-function mutants
and inhibitor studies are indispensable to clearly identify a phosphorylation site
and the respective kinase. The quadruple mutant from Paz et al. showed a mea-
surable effect, but since they not applied single mutants it cannot be excluded
that some of the tested sites were not targets for Akt/PKB. Ser573 as homologue
position of Ser522 also resides in an Akt/PKB consensus motif (RXRXXpS/pT).
Treating cells with an Akt/PKB inhibitor resulted in significantly reduced phos-
phorylation of Ser573, thus indicating Akt/PKB as kinase for Ser573 phosphory-
lation (Figure 3.18). The Akt/PKB inhibitor Akti is a specific inhibitor of Akt1
and Akt2 as has been shown by Logie et al. [103]. Interaction of Akti with the
PH domain of Akt/PKB prevents the conformational change that is required
for phosphorylation and activation of Akt/PKB by the upstream kinase. Of
note, downstream kinases of Akt/PKB and other kinases cannot be excluded to
phosphorylate Ser573, due to the fact that Ser573 phosphorylation was markedly
increased when cells were treated with TPA (Figure 3.13). Akt/PKB belongs
to the family of AGC kinases and an arginine at position -3 relative to a serine
or threonine corresponds to a sequence motif which correlates with recognition
motifs of this kinase family. In line with Ser522 as phosphorylation site for
negative regulation of signalling were the results with the alanine mutant of
Ser573 that increased Akt/PKB phosphorylation upon IGF-1 stimulation. IGF-
1 stimulation was carried out over several time points and significantly increased
phosphorylation of Akt/PKB on Thr308 and Ser473 was observable after 120 and
240 min of stimulation (Figure 3.20). In conclusion, the data suggested com-
parable regulation and function of the homologue Ser573 and Ser522 in IRS2
and IRS1, but the implication of Ser522 in 14-3-3 binding of IRS1 has not been
reported yet. It is imaginable that phosphorylation of Ser573 functions as a
negative feedback loop for downregulation of Akt/PKB activity.
The data of the overlay assay indicated that only one phosphorylated residue
on IRS2 was sufficient to trigger insulin/IGF-1-dependent 14-3-3 interaction
with IRS2. This would be in line with several other studies which also identified
single phosphorylated residues as 14-3-3 interaction site [206, 27, 128]. However,
there are also other reports that showed 14-3-3 binding to two simultaneously
phosphorylated serine/threonine residues on the same target protein (see [79]
for a collection of reported binding partners). Ser556 appeared in the study from
Dubois et al. to be phosphorylated after insulin stimulation in HeLa cells and
the same residue was identified in the mass spectrometric approach from this
thesis. This opened the possibility that perhaps Ser556 and Ser573 were 14-3-
3 binding sites. The S556A mutant showed regulated binding of 14-3-3 in the
2www.scansite.mit.edu/motifscan seq.phtml
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overlay assay, hence arguing against Ser556 as a 14-3-3 binding site (Figure 3.11).
To support these findings with another methodical approach GST pulldown ex-
periments were conducted. Unexpectedly, both single mutants S556A (data not
shown) and S573A did interact with GST-14-3-3 and also the double mutant
S556A/S573A failed to disrupt the interaction (Figure 3.21). The cause of this
discrepancy between the overlay assay and GST pulldown cannot be explained
yet, but it can be speculated that the S573A mutant probably failed to dis-
rupt interaction of 14-3-3 with IRS2 in the GST pulldown due to the presence
of other proteins stabilizing 14-3-3 binding or preventing regulated binding of
exogenously added GST-14-3-3 protein. How can the persuasive result of the
overlay assay be explained? The overlay assay was used to monitor interaction
of 14-3-3 with IRS2. This type of assay is regularly used to directly visual-
ize protein/protein interactions on western blot membranes [151, 175, 79, 35].
However, this technique showed binding of 14-3-3 to denaturated IRS2 resolved
on SDS-PAGE which is quite different from the in vivo situation. Usually, for
proteins to interact a native conformation is needed. By SDS treatment the pro-
teins are denaturated, but upon transfer onto the nitrocellulose membrane and
the subsequent procedure for protein detection the SDS is removed and a partial
renaturation of the protein on the membrane can take place. A possibility is
that the partial renaturation of the IRS2 protein on the nitrocellulose membrane
probably was effective enough to enable binding of 14-3-3 to the phospho-Ser573
motif, whereas the second binding site might not have been easily accessible and
full renaturation of the IRS2 protein would have been required. This may have
led to abrogation of 14-3-3 binding in the S573A mutant in the overlay assay,
despite the presence of a second binding site.
Limitations in either of the aforementioned techniques make it necessary
to employ at least two of these methodic approaches to ensure observation of
protein/protein interaction.
4.2.3 Potential relevance of insulin/IGF-1-dependent phos-
phorylation of Ser573 and interaction with 14-3-3 pro-
teins
Experiments performed in this thesis concerning phosphorylation kinetics of
Ser573 and Akt/PKB indicated a potential role of Ser573 phosphorylation in a
negative feedback loop to downregulate insulin/IGF-1 signalling. This is sup-
ported by the fact that Ser573 showed peak phosphorylation levels after 60, 90
and 120 min of insulin stimulation in Fao cells (Figure 3.17) and the S573A
mutant increased Akt/PKB phosphorylation significantly at late time points of
prolonged IGF-1 stimulation (120 and 240 min) (Figure 3.20).
How could the interaction of IRS2 with 14-3-3 proteins influence downstream
insulin signalling? The rigid structure of the 14-3-3 proteins led to the hypoth-
esis that 14-3-3 proteins provide themselves as an anvil whereon the target
protein can be restructured/reshaped [161]. Experimental data from Datta et
al. showed that upon 14-3-3 binding to Ser316 of BAD (Bcl-2-associated death
promoter) the accessibility of Ser155 of BAD for other kinases increased [29].
GlobPlot R© analysis revealed unstructured regions in the IRS2 protein, which
could potentially be restructured/reshaped upon 14-3-3 binding. Since IRS2
functions as a multi-adapter protein, thereby linking the insulin receptor and
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other receptor tyrosine kinases with intracellular effector molecules, 14-3-3 pro-
teins could modulate the interactions with binding partners by binding to IRS2
upon phosphorylation of Ser573 and a possible yet to be discovered second bind-
ing site.
In summary the presented results include the identification of 24 phos-
phorylation sites with not yet described sites on IRS2 and mapping of the
insulin/IGF-1-dependent 14-3-3 binding region. Ser573 as novel phosphory-
lation site was shown to be part of insulin/IGF-1-dependent interaction be-
tween 14-3-3 and IRS2 and its phosphorylation may have an inhibitory role in
insulin/IGF-1 signalling. The evidence of the interaction between 14-3-3 pro-
teins and the signal transducer IRS2 in vivo opens several novel perspectives in
the (patho)physiological regulation of the biological function of IRS2 including
its role in metabolic disorders such as insulin resistance and type 2 diabetes.
4.3 Interaction between 14-3-3 and IRS2 upon
elevated cAMP levels
4.3.1 cAMP and PKA
Glucagon as fasting hormone and physiological antagonist of insulin is secreted
from the α-cells of the pancreas to ensure adequate blood glucose levels dur-
ing fasting. It activates the G-protein-coupled glucagon receptor which in turn
activates adenylylcyclase. Adenylylcyclase catalyzes the formation of cAMP
from ATP. However, elevated cAMP levels can also be generated by the cat-
echolamines adrenaline and noradrenaline. They activate β-adrenergic recep-
tors that are also G-protein-coupled and stimulate the adenylylcyclase. Cate-
cholamines are incrased during exercise and when the body is in a stress situ-
ation for preparation of the so-called fight or flight response. Elevated cAMP
levels lead to activation of PKA which has long been thought to be the most
important cAMP-dependent kinase, but cAMP can also activate protein kinase
G (PKG) [204] and exchange proteins directly activated by cAMP (EPAC) [83,
31]. How can these different pathways that all rely on elevated cAMP levels
be distinguished? Inhibitor studies can help to dissect the different signalling
pathways. H89 as non-selective PKA inhibitor was used in the experiments
of this thesis. Of note a cAMP analogue, 8-(chloro-phenylthio)-2’-O-methyl-
adenosine-3’,5’-cyclic monophosphate (8CPT-2MecAMP) that specifically acti-
vate EPACs [38] could have also been used, but other inhibitor studies were
applied to rule out an influence of EPACs, the PI 3-kinase or Ras/MAPK path-
way on cAMP-dependent effects observed in the experiments. Of note, cAMP
can protect various cell types from apoptosis by synthesis of antiapoptotic pro-
teins, inactivation of proapoptotic proteins and activation of the prosurvival PI
3-kinase/Akt/PKB pathway [107, 199, 144], but it can also exert proapototic
effects in certain cancer cell lines [57, 148].
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4.3.2 Regulation and function of cAMP-dependent 14-3-
3/IRS2 interaction
The kinase panel assay showed reduced binding of 14-3-3 to IRS2 in samples
which were pretreated with the PKA inhibitor H89 before stimulation with
forskolin. PKA as modulator of interaction between 14-3-3 and IRS2 had not
been described before, so the first task concerning this part of the thesis was to
confirm this interaction and its dependence on cAMP/PKA. There are several
indications that the observed effects of increased 14-3-3 binding to IRS2 were
mediated by PKA. Stimulation of HEK293 cells transiently expressing GFP-
IRS2 with the adenylylcyclase stimulating agent forskolin or the cAMP ana-
logue CPT-cAMP caused increased binding of 14-3-3 to IRS2 in overlay assays
what was preventable by pretreating cells with H89 (Figure 3.22). The kinase
inhibitor H89 is not solely inhibiting PKA as has been shown by Davies et al.
[30]. It can inhibit MSK1, S6K1 or ROCK-II with a similar potency, but in the
experiments conducted in this thesis these potential additional inhibitions of the
mentioned kinases should be of minor relevance due to the fact that they are not
cAMP-dependent kinases as PKA is. EPAC proteins as Rap1 GTP exchange
factors are upstream of the prominent serine kinases ERK and Akt/PKB. In-
hibition of these kinases did not reduce the forskolin-induced phosphorylation
of IRS2 on PKA motifs and direct stimulation of ERK and Akt/PKB did not
activate phosphorylation of these sites (Figure 3.25 and Figure 3.26). Together
these are good indications for the involvement of the cAMP-PKA pathway as
mediator of the forskolin-induced IRS2 phosphorylation and binding of 14-3-3
proteins.
Having established that the observed 14-3-3 binding to IRS2 was cAMP-
dependent truncated versions of the IRS2 protein were applied to identify the
amino acid area behind amino acid position 952 as being crucial for 14-3-3
binding. Mass spectrometric analysis led to the identification of IRS2 ser-
ine/threonine residues as potential candidates for phosphorylation by PKA.
Only 3 candidates matched the criteria to reside in a PKA consensus motif, a
14-3-3 binding motif and were present in the forskolin-stimulated sample in all
3 biological replicates. The single alanine mutant of Ser1163 did not alter the
signal detected by the PKA substrate antibody and was therefore excluded to be
a PKA site (Figure 3.36). Single mutation of either Ser1137 (RRHA1137SETF)
or Ser1138 (RRHSA1138ETF) to alanine still resulted in a PKA phosphorylation
motif (RXXpS). Although the PKA substrate antibody only detected a faint sig-
nal in both single S1137A and S1138A mutants, subsequent experiments were
performed with the double GFP-IRS2-S1137A/S1138A mutant to circumvent
any possible compensatory effects that could not be detected with the PKA
substrate antibody and due to the fact that peptides phosphorylated on both
residues 1137 and 1138 at the same time were detected by mass spectrometry
(Figure 3.35). The human IRS1 protein sequence contains homologue positions
to Ser1137 and Ser1138 – Ser1100 and Ser1101. Yi et al. expressed GST-IRS1
fusion proteins (with only certain areas of the human IRS1 protein) and phos-
phorylated them in vitro with PKA or ERK2 followed by HPLC-ESI-MS/MS
to detect phosphorylated residues [218]. Among other residues they could ob-
serve PKA phosphorylation of residues on peptides corresponding to Ser1100 or
Ser1101 of human IRS1. Due to the lack of additional definitive spectra the au-
thors were not able to clearly state if only Ser1100 or Ser1101 was phosphorylated
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Table 4.2: Reported homologue residues of mouse IRS2 Ser1137/Ser1138
mouse IRS2 Corresponding Description Reference
Ser1137 human IRS1 Ser1100 PKA substrate [218]
Ser1138 human IRS1 Ser1101 PKA substrate [218]
Ser1138 human IRS1 Ser1101,
human IRS2 Ser1149
PKCθ substrate [96]
or if maybe a doubly phosphorylated peptide could also have been possible.
According to the data acquired in this thesis Ser1137/Ser1138 seem to be
the only cAMP-dependent phosphorylation sites on the IRS2 molecule that
are located in a PKA motif and can mediate cAMP-induced 14-3-3 binding to
IRS2. However, other stimuli could lead to the phosphorylation of Ser1137 or
Ser1138. The Ser1138 homologues in human IRS1 (Ser1101) and human IRS2
(Ser1149) have been investigated by Li et al., who showed Ser1101 and Ser1149
to be phosphorylated by insulin treatment of C2C12 cells and PKCθ was estab-
lished as kinase for this phosphorylation [96]. They suggest a role for Ser1101
phosphorylation as part of an inhibitory feedback signal. This could implicate
that Ser1138 also probably could be phosphorylated by insulin or IGF-1 stim-
ulation. Insulin/IGF-1-dependent phosphorylation of Ser1138 was not tested in
the experiments of this thesis, but the data from Li et al. should be kept in
mind when further experiments concerning Ser1138 are performed. In Table 4.2
the just described homologue residues are listed again for clarity and a sequence
alignment of mouse and human IRS1 and IRS2 to visualize the sequence con-
servation of Ser1137/Ser1138 can be found in Figure A.5.
The importance of Ser1137/Ser1138 was verified by three different experi-
mental approaches: overlay assay, GST pulldown and co-immunoprecipitation
of transfected myc-14-3-3 protein. In some experiments interaction between
GFP-IRS2 wild type and GST-14-3-3 fusion proteins could also be found at
basal conditions. This could indicate the existence of further 14-3-3 binding
sites on IRS2 that can be phosphorylated at basal conditions. These sites could
be phosphorylated for example by other family members of the AGC kinase
family. The completely abolished binding of 14-3-3 to IRS2 by treating cells
with H89 can be explained with the already mentioned fact that H89 can also
inhibit MSK1, S6K1 or ROCK-II. There was still observable interaction between
GST-14-3-3 and the double mutant S1137A/S1138A in the forskolin-stimulated
condition (Figure 3.37). It is imaginable that PKA phosphorylated a substrate
that itself is a kinase and phosphorylated IRS2 on another 14-3-3 binding motif.
A possible candidate in this case for example would be Ser573, since this site was
shown to be a 14-3-3 binding site and can be phosphorylated by insulin/IGF-1-
dependent pathways as well as TPA stimulation. Forskolin stimulation led to a
phosphorylation of Ser573 and this was blockable with pretreatment of the cells
with H89 (data not shown). A triple GFP-IRS2-S573A/S1137A/S1138A mutant
was generated and also tested in GST pulldown and co-immunoprecipitation
experiments to test this assumption, but failed to further suppress 14-3-3 inter-
action with IRS2 (data not shown).
In summary, forskolin could induce phosphorylation of Ser573 but this site
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seems not to be a relevant second 14-3-3 binding site beside Ser1137/Ser1138 in
cAMP-dependent 14-3-3 binding to IRS2. Sequence alignments of different IRS2
species revealed complete sequence accordance of the amino acids surrounding
Ser1137/Ser1138. A high degree of conservation may implicate an important role
for Ser1137/Ser1138.
The data presented in this thesis show an increased IRS2 protein half-life
upon forskolin stimulation in Flp-In HEK293 cells stably expressing either IRS2
or GFP-IRS2 and also in primary hepatocytes. Crucial for this increased stabil-
ity were Ser1137/Ser1138, because a double GFP-IRS2-S1137A/S1138A mutant
did not show increased protein stability upon forskolin stimulation (Figure 3.41).
This is no direct proof that binding of IRS2 to 14-3-3 proteins was responsible
for the increased half-life of IRS2 protein, but based on the present data it could
be concluded that phosphorylation on Ser1137/Ser1138 is necessary for both, the
cAMP-enhanced binding to 14-3-3 proteins and the stabilization of the protein.
Other groups also reported increased protein stability associated with 14-3-3
binding. Short et al. showed for p27 an AMPK-dependent phosphorylation
of Thr197 which increased 14-3-3 binding and protein half-life [165]. The his-
tone deacetylase HDAC7 associated with 14-3-3 proteins upon phosphorylation
by calcium/calmodulin-dependent kinases, thus preventing ubiquitinylation and
subsequent degradation via the 26S proteasome [95]. Finally, Yang et al. pro-
vided evidence for 14-3-3σ-dependent stabilization of the cell cycle checkpoint
protein p53 [216]. 14-3-3 binding blocked Mdm2-dependent ubiquitinylation and
nuclear export of p53.
The amount of IRS2 protein present in cells is dependent on mRNA expres-
sion and protein stability [87]. The stability of the IRS2 protein is regulated by
posttranslational modifications that designate the molecule for ubiquitinylation
and subsequent proteasomal degradation [139, 140]. To designate a protein for
proteasomal degradation 3 classes of enzymes are needed: ubiquitin-activating
enzyme, ubiquitin-conjugating enzyme and ubiquitin ligase [66]. The presented
data suggest a protection from proteasomal degradation upon cAMP-mediated
14-3-3 binding to IRS2. It is imaginable that this protein/protein interaction
results in a conformational change that obscures the recognition motif for an
E3 ubiquitin ligase, thus protecting IRS2 from proteasomal degradation. This
hypothesis is supported by GlobPlot R© analysis that predicted the C-terminal
part of the IRS2 molecule to be unstructured. Unstructured regions can of-
ten be found in proteins that serve as regulatory and signalling proteins [71],
because these intrinsically unstructured regions are suitable for restructuring
upon interaction with a binding partner. 14-3-3 proteins itself display a very
rigid structure and therefore can provide themselves as an anvil whereupon the
binding partner can be restructured [213]. Conformational change upon 14-3-3
binding has been shown in several examples: the phosphatidylinositol 4-kinase
IIIβ is protected from dephosphorylation in the active site by 14-3-3 binding [63],
14-3-3 binding to BAD (Bcl-2-associated death promoter) enhances accessibility
of Ser155 for phosphorylation by prosurvival kinases [29] and AANAT (serotonin
N-acetyltransferase) shows an increased affinity for its substrates upon 14-3-3
binding [119].
The experimental data indicate an additional mechanism for the upregula-
tion of IRS2 protein levels in physiological conditions with elevated cAMP con-
centrations. During fasting blood glucagon levels are increased and are known to
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induce IRS2 mRNA expression through glucagon-dependent G protein-coupled
increases in cAMP levels, activation of PKA and subsequent activation of the
transcription factor CREB and its coactivator TORC2 [24, 76]. Of note, IRS2
expression in the fasting state is important to negatively regulate glucose out-
put from the liver to avoid hyperglycemia [24]. Increased IRS2 protein levels in
hepatocytes during the fasting state ensure fast and effective signalling upon in-
sulin stimulation in the transition from the fasted to the fed state. In pancreatic
β-cells IRS2 expression is crucial for growth and survival [65]. Increased blood
glucose levels in the refed state are followed by insulin secretion of the β-cell.
Glucose itself can induce IRS2 mRNA and protein expression in β-cells by a
calcium-dependent mechanism [97]. In addition, glucagon like peptide (GLP) 1
is released into the systemic circulation from enteroendocrine cells during feed-
ing and potentiates insulin secretion. GLP1 increases cAMP levels in β-cells,
thus promoting β-cell viability via increased IRS2 expression [76]. The finding
of increased IRS2 protein stability due to elevated cAMP levels could provide an
additional mechanism for the β-cell to protect itself from reduced IRS2 protein
levels. Of note, Van de Velde et al. observed rapid gene expression of CREB
target genes by forskolin stimulation that decreased to baseline levels after 4h,
whereas elevated IRS2 protein expression was measurable by western blot up
to 16 hours [193]. This discrepancy in decreased IRS2 gene activation but ele-
vated IRS2 protein levels could be explained with the finding of increased IRS2
protein stability due to cAMP-induced 14-3-3 binding to IRS2. To conclude,
Ser1137/Ser1138 could be identified as PKA phosphorylation sites on IRS2 that
mediate 14-3-3 binding and regulate IRS2 protein stability. The increased IRS2
protein stability upon elevated cAMP levels provides an additional mechanism
to cAMP-induced IRS2 mRNA and subsequent protein expression to ensure
sufficient amounts of IRS2 protein.
Chapter 5
Conclusion
IRS proteins represent a central signalling node in insulin/IGF-1 signalling and
tyrosine as well as serine/threonine phosphorylation of IRS proteins modulate
downstream signalling with inhibitory or stimulatory consequences.
Serine/threonine phosphorylation of IRS2 was investigated in this thesis.
With mass spectrometry a total of 24 phosphorylated residues were identified,
among them Ser573 was identified within a 14-3-3 binding region. Another
mass spectrometric approach for the identification of cAMP/PKA-dependent
serine/threonine residues revealed at least three candidate residues that were
investigated further, namely Ser1137, Ser1138 and Ser1163.
Insulin/IGF-1-dependent 14-3-3 binding to IRS2 is partially mediated by
Ser573, since the alanine mutant abrogated 14-3-3 binding in overlay assays.
GST pulldown experiments indicated a second 14-3-3 binding site. Of note,
to randomly mutate single serine/threonine residues to alanine for studies on
14-3-3 binding might not be a successful strategy, when the second site has only
a weak affinity for 14-3-3 proteins there might be no differences observable in
overlay assays or GST pulldown and co-immunoprecipitation studies [213]. A
probably reasonable approach would be further sequence alignments with evo-
lutionary old species to find highly conserved residues as candidates for 14-3-3
binding and to perform direct phosphorylation analysis of these sites by apply-
ing phosphorylated peptides and corresponding non-phosphorylated peptides.
In addition, the presented data suggest a negative role for Ser573 phosphory-
lation in insulin/IGF-1 signalling, Ser573 is probably part of a negative feedback
loop for downregulation of Akt/PKB phosphorylation.
cAMP-dependent phosphorylation of IRS2, presumably mediated by PKA,
represents a novel mechanism to upregulate IRS2 protein levels with possible
implications for hepatic metabolism and β-cell survival, where IRS2 expression is
essential for growth, survival and function [154, 65]. Stimulation with forskolin
increased the phosphorylation of Ser1137/Ser1138, 14-3-3 binding and protein
stability of IRS2, whereas the S1137A/S1138A mutant did not show increased
IRS2 protein stability. Whether the cAMP-dependent 14-3-3 binding to IRS2
is responsible for the protein stabilizing effect needs to be proven.
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Figure 5.1 summarizes the serine residues that were identified as phosphory-
lation sites during this thesis. In addition, kinases and stimuli that probably
lead to phosphorylation of Ser573 and Ser1137/Ser1138 of IRS2 and the postulated
biological outcome is shown.
PH PTB N C KRLB 
S573 S1137 S1138 
other AGC kinases? Akt/PKB 
TPA-dependent 
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Figure 5.1: Kinases and stimuli that can phosphorylate Ser573 and Ser1137/Ser1138 of IRS2.
14-3-3 interaction with IRS2 was investigated in this thesis from a mecha-
nistic point of view with further experiments to elucidate the biological function
of insulin/IGF-1-dependent and cAMP-dependent 14-3-3 binding to IRS2. The
next steps would be to confirm the data from this thesis in primary cell cul-
tures and phosphosite-specific knock-out mice. Special attendance should be
paid to the β-cell, since profound effects of the S1137A/S1138A mutant could
be expected. First, experiments should be performed to see if the results of this
thesis in HEK293 cells with transient and stable expression can be confirmed
for example in the rat insulinoma cell line INS1.
The ongoing challenge to develop new strategies and pharmacological treat-
ments for the prevention and treatment of insulin resistance and T2D needs a
full understanding of the cellular pathways and their dysregulation in pathologic
states. Characterization of the 14-3-3 binding to IRS2 is another step in the
understanding of the cellular network and potentially opens new possibilities in
drug development for the treatment of insulin resistance and T2D.
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GLP glucagon-like peptide
GLUT4 glucose transporter 4
Grb2 growth receptor bound 2
GSK glycogen synthase kinase
GTP guanosine triphosphate
H2O water
h hour
HEK human embryonic kidney cells
HPLC high performance liquid chromatography
HRP horseradish peroxidase
IGF-1 insulin like growth factor 1
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IR insulin receptor
IRS insulin receptor substrate
i.p. intraperitoneally
JNK c-Jun N-terminal kinase
kDa kilo Dalton
KRLB kinase regulatory loop binding
MAPK mitogen activated protein kinase
MAPKK mitogen activated protein kinase kinase
MAPKKK mitogen activated protein kinase kinase kinase
MEK MAP kinase ERK kinase
mTOR mammalian target of rapamycin
p phospho
PCR polymerase chain reaction
PDGF platelet derived growth factor
PDK phosphoinositide-dependent kinase
PEG polyethylene glycol
PH pleckstrin homology
PIP2 phosphatidylinositol (4, 5)-bisphosphate
PIP3 phosphatidylinositol (3, 4, 5)-trisphosphate
PI 3-kinase phosphatidylinositol 3-kinase
PKB protein kinase B
PKC protein kinase C
PTB phosphotyrosine binding
S serine
S6K1 S6 ribosomal protein kinase 1
SDS-PAGE sodium dodecylsulfate polyacrylamide gelelectrophoresis
Ser serine
SH2 Src homology domain 2
Shc Src homology s/?-collagen-related protein
SHIP2 SH2-containing inositol phosphatase 2
Sos son of sevenless
SREBP sterol regulatory element-binding protein
T threonine
T1D type I diabetes mellitus
T2D type II diabetes mellitus
TEMED N,N,N’,N’-tetramethylethylenediamine
Thr threonine
TNFα tumor necrosis factor α
TPA 12-O-tetradecanoylphorbol 13-acetate
Y tyrosine
Appendix A
Appendix
A.1 Phosphopeptides detected by mass spectrom-
etry
residue m/z M sequence (ion score > 20) 
66 971,9192 1941,8218 GPGTGGDEASAAGGpSPPQPPR (105) 
303 1010,9786 2019,9375 SKpSQSSGSSATHPISVPGAR (107) 
347 611,7894 1221,5642 TDSLAApTPPAAK (50) 
385/388 1038,1247 3111,3482 TASEGDGGAAGGAGTAGGRPMSVAGpSPLpSPGPVR (98) 
388 1011,4705 3031,3819 TASEGDGGAAGGAGTAGGRPMSVAGSPLpSPGPVR (97) 
401 747,8305 1493,6446 SHpTLSAGCGGRPSK (57) 
517 775,3495 1548,6820 SNpTPESIAETPPAR (55) 
556 684,7994 1367,5830 RVpSGDGAQDLDR (62) 
573 623,3026 1244,5914 RTYpSLTTPAR (38) 
675 904,8615 1807,7045 SDDYMPmpSPTSVSAPK (54) 
722 883,8343 1765,6502 ApSSPAESSPEDSGYmR (73) 
727/728 915,8195 1829,6216 ASSPAEpSpSPEDSGYMR (60) 
762 1522,1939 3041,3841 LLPNGDYLNMpSPSEAGTAGTPPDFSAALR (82) 
907 903,3926 1804,7669 pSPGEYINIDFGEAGTR (72) 
968 898,8778 1795,7375 SPLpSDYmNLDFSSPK (67) 
977 930,8636 1859,7089 SPLpSDYMNLDFSpSPK (75) 
999 1632,7888 4895,3365 SGDTVGSMDGLLpSPEASSPYPPLPPRPSTSPSSLQQPLPPAPGDLYR (50) 
1089 470,2310 938,4474 VApSPTSGLK (61) 
1151 1308,5862 2615,1541 HSSETFSSTTTVTPVpSPSFAHNSK (86) 
1165 696,8173 1391,6194 HNSApSVENVSLR (84) 
1190 1117,5376 3349,5827 SSEGSSTLGGGDEPPTpSPGQAQPLVAVPPVPQAR (101) 
  
Figure A.1: GFP-IRS2 was expressed transiently in HEK293 cells and cells were either left
unstimulated or stimulated with IGF-1 for 30 minutes. Using GFP-TrapR© IRS-2 was purified
from total cell lysate and after SDS-PAGE and Coomassie staining, the bands corresponding
to IRS2 were cut and peptides were digested using trypsin (M = molecular mass of the peptide
in Dalton, m/z = mass to charge). A mass accuracy of 10ppm was used in database searches
and phosphosites were identified by MS/MS analysis and manual inspection of the spectra.
The sequence coverage was 92 %. The phosphorylated residues are indicated in bold with pS
or pT.
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Residue m/z M Sequence (ion score > 20) 
305 903,4133 1804,8105 SQpSSGSSATHPISVPGAR (89) 
1266 779,6802 2336,0182 GEQGSLAQSQPQPGDKNpSWSR (34) 
 
Figure A.2: Phosphopeptides detected by mass spectrometry that are unique to IRS2 iso-
lated from IGF-1-treated cells. Samples were prepared as in Figure A.1. The phosphorylated
residues are indicated in bold with pS or pT.
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Figure A.3: Exemplary MS/MS spectrum and fragmentation table of the peptide
TY(pS)LTTPAR from a tryptic digest of transiently expressed IRS2 in HEK293 cells treated
with IGF-1. Positive-ion MS/MS spectra that enabled identification of Ser573 as phosphory-
lated residue in this peptide (m/z = mass to charge).
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# b b++ b0 b0++ Seq. y y++ y* y*++ y0 y0++ # 
1 102.0550 51.5311 84.0444 42.5258 T             9 
2 265.1183 133.0628 247.1077 124.0575 Y 988.4499 494.7286 971.4234 486.2153 970.4394 485.7233 8 
3 432.1166 216.5620 414.1061 207.5567 S 825.3866 413.1969 808.3601 404.6837 807.3760 404.1917 7 
4 545.2007 273.1040 527.1901 264.0987 L 658.3883 329.6978 641.3617 321.1845 640.3777 320.6925 6 
5 646.2484 323.6278 628.2378 314.6225 T 545.3042 273.1557 528.2776 264.6425 527.2936 264.1504 5 
6 747.2961 374.1517 729.2855 365.1464 T 444.2565 222.6319 427.2300 214.1186 426.2459 213.6266 4 
7 844.3488 422.6781 826.3383 413.6728 P 343.2088 172.1081 326.1823 163.5948     3 
8 915.3859 458.1966 897.3754 449.1913 A 246.1561 123.5817 229.1295 115.0684     2 
9         R 175.1190 88.0631 158.0924 79.5498     1 
 
Figure A.4: b- and y-ion series and fragmentation table of the peptide TY(pS)LTTPAR.
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A.2 Sequence alignment of mouse and human
IRS1 and IRS2
Figure A.5: Complete sequence alignment of mouse and human IRS1 and IRS2 sequence.
Identified phosphosites that are common to IRS2 isolated from serum starved and IGF-1-
treated cells are labeled in red, whereas the phosphosites that were detected by stimulation
of cells with forskolin are labeled in green.
mouse IRS2 1 MASAPLPGPPASAGGDGPNLNNNN-NNNNHSVRKCGYLRKQK  41 
human IRS2 1 MASPPRHGPPGPASGDGPNLNNNN-NNNNHSVRKCGYLRKQK  41 
mouse IRS1 1 -------------------MASPPDTDGFSDVRKVGYLRKPK  23 
human IRS1 1 -------------------MASPPESDGFSDVRKVGYLRKPK  23 
 
mouse IRS2 42 HGHKRFFVLRGPGTGGDEASAAGGSPPQPPRLEYYESEKKWR  83 
human IRS2 42 HGHKRFFVLRGPGAGGDEATAGGGSAPQPPRLEYYESEKKWR  83 
mouse IRS1 24 SMHKRFFVLRAASEAG-----------GPARLEYYENEKKWR  54 
human IRS1 24 SMHKRFFVLRAASEAG-----------GPARLEYYENEKKWR  54 
 
mouse IRS2 84 SKAGAPKRVIALDCCLNINKRADAKHKYLIALYTKDEYFAVA  125 
human IRS2 84 SKAGAPKRVIALDCCLNINKRADAKHKYLIALYTKDEYFAVA  125 
mouse IRS1 55 HKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIA  96 
human IRS1 55 HKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIA  96 
 
mouse IRS2 126 AENEQEQEGWYRALTDLVSEGRSGEGGSG---TTGGSCSASL  164 
human IRS2 126 AENEQEQEGWYRALTDLVSEGRAAAGDAPPAAAPAASCSASL  167 
mouse IRS1 97 ADSEAEQDSWYQALLQLHNRAKAHHDGA------GGGCGGSC  132 
human IRS1 97 ADSEAEQDSWYQALLQLHNRAKGHHDGAA--ALGAGGGGGSC  136 
 
mouse IRS2 165 PGVLGGSAGAAGCDDNYGLVTPATAVYREVWQVNLKPKGLGQ  206 
human IRS2 168 PGALGGSAGAAGAEDSYGLVAPATAAYREVWQVNLKPKGLGQ  209 
mouse IRS1 133 SGSS--GVGEAGEDLSYD-TGP-GPAFKEVWQVILKPKGLGQ  170 
human IRS1 137 SGSS--GLGEAGEDLSYGDVPP-GPAFKEVWQVILKPKGLGQ  175 
 
mouse IRS2 207 SKNLTGVYRLCLSARTIGFVKLNCEQPSVTLQLMNIRRCGHS  248 
human IRS2 210 SKNLTGVYRLCLSARTIGFVKLNCEQPSVTLQLMNIRRCGHS  251 
mouse IRS1 171 TKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHS  212 
human IRS1 176 TKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHS  217 
 
mouse IRS2 249 DSFFFIEVGRSAVTGPGELWMQADDSVVAQNIHETILEAMKA  290 
human IRS2 252 DSFFFIEVGRSAVTGPGELWMQADDSVVAQNIHETILEAMKA  293 
mouse IRS1 213 ENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRA  254 
human IRS1 218 ENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRA  259 
 
mouse IRS2 291 LKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQ  332 
human IRS2 294 LKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQ  335 
mouse IRS1 255 MSDE--FRPRSKSQSSS-SCSNPISVPL--RRHHLNNPPPSQ  291 
human IRS1 260 MSDE--FRPRSKSQSSS-NCSNPISVPL--RRHHLNNPPPSQ  296 
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mouse IRS2 333 TGLVRRSRTDSLAATPPAAKC----TSCRVRTASEGDGGAAG  370 
human IRS2 336 TGLVRRSRTDSLAATPPAAKC----SSCRVRTASEGDGGAAA  373 
mouse IRS1 292 VGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGT---  330 
human IRS1 297 VGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGT---  335 
 
mouse IRS2 371 GAGTAGGRPMSVAGSPLSPGPVRAPLSRSHTLSAGCGGRPSK  412 
human IRS2 374 GAAAAGARPVSVAGSPLSPGPVRAPLSRSHTLSGGCGGRGSK  415 
mouse IRS1 331 -----MSRPASVDGSPVSPSTNRTHAHRHR---------G--  356 
human IRS1 336 -----MSRPASVDGSPVSPSTNRTHAHRHR---------G--  361 
 
mouse IRS2 413 VTLAPAGGALQHSRSMSMPVAHSPPAATSPGSLSSSSGHGSG  454 
human IRS2 416 VALLPAGGALQHSRSMSMPVAHSPPAATSPGSLSSSSGHGSG  457 
mouse IRS1 357 --SSRLHPPLNHSRSIPMPSSRCSPSATSPVSLSSSSTSGHG  396 
human IRS1 362 --SARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHG  401 
 
mouse IRS2 455 SYPLPPGSHPHLPHPLHHPQGQRPSSGSASASGSPSDPGFMS  496 
human IRS2 458 SYPPPPGPHPPLPHPLHHGPGQRPSSGSASASGSPSDPGFMS  499 
mouse IRS1 397 STSDCLFPRRSSASVSGSPSDGGFIS----------------  422 
human IRS1 402 STSDCLFPRRSSASVSGSPSDGGFIS----------------  427 
 
mouse IRS2 497 LDEYGSSPGDLRAFSSHRSNTPESIAETPPARDGS-GGELYG  537 
human IRS2 500 LDEYGSSPGDLRAFCSHRSNTPESIAETPPARDGGGGGEFYG  541 
mouse IRS1 423 SDEYGSSPCDFRS--SFRSVTPDSLGHTPPARGEE---ELSN  459 
human IRS1 428 SDEYGSSPCDFRS--SFRSVTPDSLGHTPPARGEE---ELSN  464 
 
mouse IRS2 538 YMSMDRP-------------LSHCGRPYR-------------  553 
human IRS2 542 YMTMDRP-------------LSHCGRSYR-------------  557 
mouse IRS1 460 YICMGGKGASTLAAPNGHYILSRGGNGHRYIPGANLGTSPAL  501 
human IRS1 465 YICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPAL  506 
 
mouse IRS2 554 -RVSGDGAQDLDRGLRKRTYSLTTPA---RQRQVPQPSSASL  591 
human IRS2 558 -RVSGDAAQDLDRGLRKRTYSLTTPA---RQRPVPQPSSASL  595 
mouse IRS1 502 PGDEAAGAADLDNRFRKRTHSAGTSPTISHQKTPSQSSVASI  543 
human IRS1 507 AGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASI  548 
 
mouse IRS2 592 DEYTLMRATFS----GSSGRLCPSFPASSPKVAYNPYPEDYG  629 
human IRS2 596 DEYTLMRATFS----GSAGRLCPSCPASSPKVAYHPYPEDYG  633 
mouse IRS1 544 EEYTEMMPAAYPPGGGSGGRLP-GYR-HSAFVPTHSYPEEGL  583 
human IRS1 549 EEYTEMMP-AYPPGGGSGGRLP-GHR-HSAFVPTRSYPEEGL  587 
 
mouse IRS2 630 D-----IEIGSHKSSSSNLGADDGYMPMTPGAALRSGGPNSC  666 
human IRS2 634 D-----IEIGSHRSSSSNLGADDGYMPMTPGAALAGSGSGSC  670 
mouse IRS1 584 EMHHLERRGGHHRPDTSNLHTDDGYMPMSPGVAPVPSN--RK  623 
human IRS1 588 EMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSG--RK  627 
 
mouse IRS2 667 KSDDYMPMSPTSVSAPKQILQPRLAA----ALPPSGAAVPAP  704 
human IRS2 671 RSDDYMPMSPASVSAPKQILQPRAAAAAAAAVPSAGPAGPAP  712 
mouse IRS1 624 GNGDYMPMSPKSVSAPQQIINPIRRHPQR--VDPNGYMMM--  661 
human IRS1 628 GSGDYMPMSPKSVSAPQQIINPIRRHPQR--VDPNGYMMM--  665 
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mouse IRS2 705 PSGVGRTFPVNGGG-YKASSPAESSPEDSGYMRMWCGSK---  742 
human IRS2 713 TSAAGRTFPASGGG-YKASSPAESSPEDSGYMRMWCGSK---  750 
mouse IRS1 662 -SPSGSCSPDIGGGSSSSS-SISAAPSGSSYGKPWTNGVGGH  701 
human IRS1 666 -SPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGH  706 
 
mouse IRS2 743 ---------LSMENPDPKLLP-NGDYLNMSPSEAGTAGTPPD  774 
human IRS2 751 ---------LSMEHADGKLLP-NGDYLNVSPSDAVTTGTPPD  782 
mouse IRS1 702 HTHALPHAKPPVESGGGKLLPCTGDYMNMSPVGDSNTSSPSE  743 
human IRS1 707 HSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSD  748 
 
mouse IRS2 775 F-SAALRGGSEGLKGIPGHCYSSLPRSYKAPCSCSG----DN  811 
human IRS2 783 FFSAALHPGGEPLRGVPGCCYSSLPRSYKAPYTCGG----DS  820 
mouse IRS1 744 CYYGPEDPQ-----HKPVLSYYSLPRSFKHTQRPGEPEEGAR  780 
human IRS1 749 CYYGPEDPQ-----HKPVLSYYSLPRSFKHTQRPGEPEEGAR  785 
 
mouse IRS2 812 DQYVLMSSPVGRILEEERLEPQAT------PGAGTFG-AAGG  846 
human IRS2 821 DQYVLMSSPVGRILEEERLEPQAT------PGPSQAASAFGA  856 
mouse IRS1 781 HQHLRLSSSSGRLRYTATAEDSSSSTSSDSLGGGYCGARPES  822 
human IRS1 786 HQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEP  827 
 
mouse IRS2 847 SHTQPHHSAVPSSMRPSAIGGRPEGFLGQRCRAVRPTRLSLE  888 
human IRS2 857 GPTQPPHPVVPSPVRPS--GGRPEGFLGQRGRAVRPTRLSLE  896 
mouse IRS1 823 SLTHPHHHVLQPHL-P----RKVDTAAQTNSRLARPTRLSLG  859 
human IRS1 828 SLPHPHHQVLQPHL-P----RKVDTAAQTNSRLARPTRLSLG  864 
 
mouse IRS2 889 GLQ--TL-----------PSMQEYPLPTEPKSPGEYINIDFG  917 
human IRS2 897 GLP--SL-----------PSMHEYPLPPEPKSPGEYINIDFG  925 
mouse IRS1 860 DPKASTLPRVREQQQ----QQQSSLHPPEPKSPGEYVNIEFG  897 
human IRS1 865 DPKASTLPRAREQQQ----QQQPLLHPPEPKSPGEYVNIEFG  902 
 
mouse IRS2 918 EAGTRLSPPAPPLLASAASSSSLLSASSPASSLGSGTPGTSS  959 
human IRS2 926 EPGARLSPPAPPLLASAASSSSLLSASSPASSLGSGTPGTSS  967 
mouse IRS1 898 SGQPGYLAGPATSR-SS-PSVRCPPQLHP------------A  925 
human IRS1 903 SDQSGYLSGPVAFH-SS-PSVRCPSQLQP------------A  930 
 
mouse IRS2 960 DSRQRSPLSDYMNLDFSSPKSPKPSTRSGDTVGSMDGLLSPE  1001 
human IRS2 968 DSRQRSPLSDYMNLDFSSPKSPKPGAPSGHPVGSLDGLLSPE  1009 
mouse IRS1 926 PRE-ETGSEEYMNMDLGPGRRATWQESGGVELGRIGPA-PPG  965 
human IRS1 931 PREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPA-PPG  971 
 
mouse IRS2 1002 ASSPYPPLPPRPSTSPSSLQQP--LPPAPGDLYRLPPASA-A  1040 
human IRS2 1010 ASSPYPPLPPRPSASPSSSLQPPPPPPAPGELYRLPPASAVA  1051 
mouse IRS1 966 SATVCRP--------------TRSVPNSRGDYMTMQIG----  989 
human IRS1 972 AASICRP--------------TRAVPSSRGDYMTMQMS----  995 
 
mouse IRS2 1041 TSQGPTAGSSMSSEPGDNGDYTEMAFGVAATP----PQPIVA  1078 
human IRS2 1052 TAQGPGAASSLSSDTGDNGDYTEMAFGVAATP----PQPIAA  1089 
mouse IRS1 990 ----CPRQSYVDTSPVAPVSYADMRTGIAAEKASLPRPTGAA  1037 
human IRS1 996 ----CPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAA  1033 
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mouse IRS2 1079 PPKPEGARV---ASPTSGL-------KRLSLMDQVSGVEAFL  1110 
human IRS2 1090 PPKPEAARV---ASPTSGV-------KRLSLMEQVSGVEAFL  1121 
mouse IRS1 1028 PPPSSTASSSASVTPQGATAEQATHSSLLGGPQGPGGMSAFT  1069 
human IRS1 1034 ASSSSAASAS-PTGPQ-GAAELAAHSSLLGGPQGPGGMSAFT  1073 
 
mouse IRS2 1111 QVSQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSP  1152 
human IRS2 1122 QVSQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSP  1163 
mouse IRS1 1070 RVNLSPNHNQSAKVIRADTQGCRRRHSSETFSA---PTRAGN  1108 
human IRS1 1074 RVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGN  1115 
 
mouse IRS2 1153 SFAHNSKRHNSASVENVSLRKSSEGSSTL--GGGDEPPTSPG  1192 
human IRS2 1164 SFAHNPKRHNSASVENVSLRKSSEGGVGVGPGGGDEPPTSPR  1205 
mouse IRS1 1109 TVPFG-------------------AGAAVGGSGGGGGGGSED  1131 
human IRS1 1116 TVPFG-------------------AGAAVGGG-GGSSSSSED  1137 
 
mouse IRS2 1193 QAQPLVAVPPVPQARPWNPGQPGALIGCPGGSSSPMRRETSV  1234 
human IRS2 1206 QLQPA--PPLAPQGRPWTPGQPGGLVGCPGSGGSPMRRETSA  1245 
mouse IRS1 1132 VKR----HSSASFENVWL--RPGDLGGVSKES--APVCGAAG  1165 
human IRS1 1138 VKR----HSSASFENVWL--RPGELGGAPKEP--AKLCGAAG  1171 
 
mouse IRS2 1235 GFQNGLNYIAIDVRGEQGSLAQ-----SQ--------PQPGD  1263 
human IRS2 1246 GFQNGLNYIAIDVREEPGLPPQ-----PQP--PPPPLPQPGD  1280 
mouse IRS1 1166 GLEKSLNYIDLDLAKE---RSQDCPSQQQSLPPPPPHQPLGS  1204 
human IRS1 1172 GLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGS  1213 
 
mouse IRS2 1264 KNSWSRTRSLGGLLGTVGGSGASGVCGGPGTGALPSASTYAS  1305 
human IRS2 1281 KSSWGRTRSLGGLISAVGVGSTGGGCGGPGPGALPPANTYAS  1322 
mouse IRS1 1205 NEGNSPRR------------------------SSEDLSNYAS  1222 
human IRS1 1214 GESSSTRR------------------------SSEDLSAYAS  1231 
 
mouse IRS2 1306 IDFLSHHLKEATVVKE  1321 
human IRS2 1323 IDFLSHHLKEATIVKE  1338 
mouse IRS1 1223 ISFQKQPEDRQ-----  1233 
human IRS1 1232 ISFQKQPEDRQ-----  1242 
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